2-Acylaminothiazole derivative or salt thereof

ABSTRACT

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

TECHNICAL FIELD

The present invention relates to a novel 2-acylaminothiazole derivativeor a salt thereof, which is useful as a medicament particularly in thetreatment of thrombocytopenia, and pharmaceutical composition comprisingthe compound as an active ingredient.

BACKGROUND ART

A platelet is anuclear blood cell playing an important role inphysiological hemostasis and pathological thrombosis, and iscontinuously produced from megakaryocytes in a living organism. Theplatelet originates from pluripotent stem cells like other blood cells.Specifically, the pluripotent stem cell becomes a megakaryocyticprogenitor cell, from which megakaryoblasts, promegakaryocytes, andmegakaryocytes are formed. During the maturation of a megakaryocyte,premature megakaryocytes only carry out DNA synthesis without involvingcell division to become a polyploid. Thereafter, cytoplasm begins tomature to form a platelet separation membrane, and a platelet isreleased by cytoplasm fragmentation.

In addition, since decrease in the number of platelets due to varioushematopoietic dysfunctions in aplastic anemia, myelodysplastic syndrome,or chemotherapy or radiotherapy for malignant tumors and the like causesserious symptoms such as hemorrhagic tendencies, there have been manyattempts at developing various technologies for increasing the number ofplatelets for the purpose of treating such dysfunctions. At present,although platelet transfusion is a powerful means for treatingthrombocytopenia, a sufficient amount of platelets cannot be provided,and it is difficult to sufficiently improve thrombocytepenia because ofa short life span of transfused platelets and the like. Additionally,platelet transfusions involve problems including viral infection,production of alloantibodies, Graft Versus Host Disease (GVHD), and thelike. Thus, there is a demand for the development of a medicament formitigating hematopoietic suppression caused by various conditions ortherapies to thereby promote the recovery of platelet number.

Meanwhile, it has been reported that thrombopoietin (hereinafterreferred to as “TPO”), which is a c-Mpl ligand playing an important rolein differentiation into megakaryocytes, has been cloned, and that itstimulates differentiation and proliferation of megakaryocytes topromote production of platelets (Kaushansky K. et al., Nature, 369,568-571, 1994: Non-patent Document 1). Clinical tests on TPO as an agentfor increasing the number of platelets have been carried out, and itsavailability and admissibility in humans have been confirmed. However,because a neutralizing antibody was confirmed in a clinic test ofPEG-rHuMGDF, a kind of TPO (163 N-terminal amino acids of native TPOmodified with polyethyleneglycol) (Li J. et. al., Blood, 98, 3241-3248,2001: Non-patent Document 2, and Basser R. L. et. al., Blood, 99,2599-2602, 2002: Non-patent Document 3), there is a concern aboutimmunogenicity of TPO. And, because TPO is a protein, it is decomposedin the digestive tract, and thus is not practical as an agent for oraladministration. For the same reason, it is considered that a lowmolecular peptide is also not practical as an agent for oraladministration. Under these circumstances, the development of anonpeptide c-Mpl ligand, which has low immunogenicity and can be orallyadministrated, for the purpose of treatment of thrombocytepenia, isunder progress.

As such compounds, benzazepine derivatives are disclosed in JapaneseLaid-Open Patent Publication No. Hei 11-152276 (Patent Document 1),acylhydrazone derivatives in WO 99/11262 (Patent Document 2),diazonaphthalene derivatives in WO 00/35446 (Patent Document 3),pyrrolocarbazole derivatives in WO 98/09967 (Patent Document 4),pyrrolophenanthridine derivatives in Japanese Laid-Open PatentPublication No. Hei 10-212289, and pyrrolophthalimide derivatives inJapanese Laid-Open Patent Publication No. 2000-44562.

And, it is described in WO 01/07423 (Patent Document 7) that a compoundrepresented by the following general Formula (VII) has an activity ofincreasing the number of platelets:

(wherein symbols are as defined in the above publication).

In addition, the above publication discloses a compound wherein X¹ is anoptionally substituted thiazole, and Y¹ comprises —NHCO—. However, Ar¹or Ar² of the compound of the present invention is not substituted witha substituent group having an A¹ group such as a thiazolyl group as inthe above publication. Also, the above publication does not discloseconcretely in the Examples and the other parts a compound wherein the5-position of thiazole is directly substituted with a nitrogen atom.

It is also described in WO 01/53267 (Patent Document 8) that a compoundrepresented by the following general Formula (VIII) has an activity ofincreasing the number of platelets:X¹—Y¹-Z¹-W¹   (VIII)(wherein symbols are as defined in the publication).

The above publication describes a compound wherein X¹ is an optionallysubstituted thiazole, and Y¹ comprises —NHCO—. However, Ar¹ or Ar² ofthe compound of the present invention is not substituted with asubstituent group having a W¹ group. And, the above publication does notdisclose concretely in the Examples and the other parts a compoundwherein the 5-position of thiazole is directly substituted with anitrogen atom.

In addition to the Patent Documents 7 and 8, it is described in JapanesePatent Publication No. 3199451 (Patent Document 9) that a2-acylaminothiazole compound has the effects of a cholecystokinin andgastrin receptor agonist, and it is described in Chemical andPharmaceutical Bulletin, 25, 9, 2292-2299, 1977 (Non-patent Document 4)that a 2-acylaminothiazole compound has anti-inflammatory effects.However, there is no description about activity for increasing thenumber of platelets.

Under these circumstances, there is a demand for the development of anonpeptide c-Mpl ligand that has low immunogenicity and can be orallyadministrated, for the purpose of treatment of thrombocytepenia.

-   [Patent Document 1] Japanese Laid-Open Patent Publication No. Hei    11-152276-   [Patent Document 2] WO 99/11262 pamphlet-   [Patent Document 3] WO 00/35446 pamphlet-   [Patent Document 4] WO 98/09967 pamphlet-   [Patent Document 5] Japanese Laid-Open Patent Publication No. Hei    10-212289-   [Patent Document 6] Japanese Laid-Open Patent Publication No.    2000-44562-   [Patent Document 7] WO 01/07423 pamphlet-   [Patent Document 8] WO 01/53267 pamphlet-   [Patent Document 9] Japanese Patent Publication No. 3199451-   [Non-patent Document 1] Nature, 1994, 369, p. 568-571-   [Non-patent Document 2] Blood, 2001, Vol. 98, p. 3241-3248-   [Non-patent Document 3] Blood, 2002, Vol. 99, p. 2599-2602-   [Non-patent Document 4] Chemical and Pharmaceutical Bulletin, 1977,    Vol. 25, 9, p. 2292-2299

DISCLOSURE OF THE INVENTION

The present inventors, as a result of assiduous studies on compoundshaving platelet increasing activity, discovered that novel2-acylaminothiazole derivatives have excellent effect of increasing thenumber of platelets, and completed the present invention.

The present invention relates to the following aspects (1)˜(17).

(1) A pharmaceutical composition for increasing the number of plateletscomprising a 2-acylaminothiazole derivative represented by the followinggeneral Formula (I) or a pharmaceutically acceptable salt thereof as anactive ingredient:

wherein symbols have the following meanings:

Ar¹: aryl, moniocyclic aromatic heterocycle, or bicyclic condensedheterocycle, each of which may be substituted (with the proviso thatwhen R¹ is aryl or pyridyl, each of which may be substituted with one ormore groups selected from the group consisting of lower alkyl, —CO-loweralkyl, —COO-lower alkyl, —OH, —O-lower alkyl, —OCO-lower alkyl, andhalogen atom, and R² is a group represented by the following generalFormula (II); Ar¹ is not phenyl or pyridyl, each of which may besubstituted with one or more groups selected from the group consistingof lower alkyl, —CO-lower alky, —COO-lower alkyl, —OH, —O-lower alkyl,—OCO-lower alkyl, and halogen atom.),

R¹: aryl or monocyclic aromatic heterocycle, each of which may besubstituted,

R²: a group represented by the following general Formula (II), (III) or(IV):

wherein symbols have the following meanings:

-   -   n: an integer of 1 to 3,    -   m: an integer of 1 to 3,    -   (when n or m is an integer of 2 or more, CR²⁰R²¹ and CR²²R²³ may        be identical or different.)    -   X: O, S, or a group represented by N—R²⁶ or C(—R²⁷)—R²⁸,    -   E, G, J, L: independently N or a group represented by C—R²⁹,        with the proviso that at least one of them is C—R²⁹,    -   R²⁰, R²¹, R²², R²³, R²⁶, R²⁷, R²⁸, R²⁹: which may be identical        or different —H; —OH; —O-lower alkyl; optionally substituted        lower alkyl; optionally substituted cycloalkyl; optionally        substituted aryl; optionally substituted arylalkyl; optionally        substituted aromatic heterocycle; optionally substituted        aromatic heterocyclic alkyl; optionally substituted nonaromatic        heterocycle; optionally substituted lower alkenyl; optionally        substituted lower alkylidene; —COOH; —COO-lower alkyl;        —COO-lower alkenyl; —COO-lower alkylene-aryl; —COO-lower        alkylene-aromatic heterocycle; carbamoyl or amino, each of which        may be substituted with one or more groups selected from the        group consisting of lower alkyl and cycloalkyl, each of which        may be substituted with halogen, —OH, —O-lower alkyl, or        —O-aryl; —NHCO-lower alkyl; or oxo.    -   R²⁴, R²⁵: which may be identical or different, —H, optionally        substituted lower alkyl, optionally substituted cycloalkyl, or        optionally substituted nonaromatic heterocycle.

Ar¹ in the compound represented by the general Formula (I) is preferablyphenyl or monocyclic aromatic heterocycle, each of which may besubstituted;

-   -   more preferably, phenyl or pyridyl, each of which may be        substituted;    -   still more preferably, phenyl which is unsubstituted at 2- and        6-positions, substituted with —H, —F, —Cl or —Br at 3-position,        substituted with —F, —Cl— or —Br at 5-position, and substituted        at 4-position, or pyridin-3-yl which is unsubstituted at 2- and        4-positions, substituted with —F, —Cl, or —Br at 5 position, and        substituted at 6-position;    -   most preferably, phenyl which is substituted at 4 position with        a group consisting of —O—R^(Y), —NH—R^(Y), optionally        substituted piperidin-1-yl and optionally substituted        piperazin-1-yl, or pyridin-3-yl which is substituted at        6-position with a group consisting of —O—R^(Y), —NH—R^(Y),        optionally substituted piperidin-1-yl, and optionally        substituted piperazin-1-yl.

The “R^(Y)” is lower alkyl which may be substituted with one or moregroups selected from the group consisting of —OH, —O-lower alkyl, aminowhich may be substituted with one or two lower alkyl, —CO₂H, —CO₂-loweralkyl, carbamoyl which may be substituted with one or two lower alkyl,cyano, aryl, aromatic heterocycle, nonaromatic heterocycle, and halogenatom.

R¹ in the compound of the general Formula (I) is preferably phenyl orthienyl, each of which may be substituted; more preferably, phenyl orthienyl, each of which may be substituted with one or more groupsselected from the group consisting of halogen atom and trifluoromethyl;still more preferably, phenyl or thienyl, each of which is substitutedwith 1 to 3 halogen atoms (when substituted with 2 or 3 halogen atoms,the halogen atoms may be identical or different.).

R² in the compound of the general Formula (I) is preferably a grouprepresented by the general Formula (II); more preferably, a grouprepresented by the general Formula (II) wherein n is 2, m is 2, and X isa group represented by N—R²⁶ or C(—R²⁷)—R²⁸; still more preferably,4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl,4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

(2) The pharmaceutical composition according to (1) wherein R¹ is phenylor thienyl, each of which may be substituted with 1 to 3 halogen atoms(when substituted with 2 or 3 halogen atoms, the halogen atoms may beidentical or different); R² is a group represented by the generalFormula (II), (wherein n is 2, m is 2, and X is a group represented byN—R²⁶ or C(—R²⁷)—R²⁸); and Ar¹ is phenyl or pyridyl, each of which maybe substituted.

(3) The pharmaceutical composition according to (1) or (2), wherein thepharmaceutical composition is used as a therapeutic agent forthrombocytopenia.

(4) The pharmaceutical composition according to (1) or (2), wherein thepharmaceutical composition is used as a c-Mpl ligand.

(5) A 2-acylaminothiazole derivative represented by the followinggeneral Formula (V) or a pharmaceutically acceptable salt thereof

wherein symbols have the following meaning,

-   -   Ar²: a group represented by Ar¹ as described in (1), with the        proviso that indol-2-yl is excluded,    -   R³: a group represented by R¹ as described in (1),    -   R⁴: a group represented by R² as described in (1), with the        proviso that a group represented by the general Formula (IV) is        excluded.    -   Ar² in the compound of the general Formula (V) is preferably        phenyl or monocyclic aromatic heterocycle, each of which may be        substituted;    -   more preferably, phenyl or pyridyl, each of which may be        substituted;    -   still more preferably, phenyl which is unsubstituted at 2- and        6-positions, substituted with —H, —F, —Cl, or —Br at 3-position,        substituted with —F, —Cl, or —Br at 5-position, and substituted        at 4-position, or pyridin-3-yl which is unsubstituted at 2- and        4-positions, substituted with —F, —Cl, or —Br at 5-position, and        substituted at 6- position;    -   most preferably, phenyl substituted at 4-position with a        substituent group selected from the group consisting of        —O—R^(Y), —NH—R^(Y), optionally substituted piperidin-1-yl and        optionally substituted piperazin-1-yl, or pyridin-3-yl which is        substituted at 6-position with a substituent group selected from        the group consisting of —O—R^(Y), —NH—R^(Y), optionally        substituted piperidin-1-yl and optionally substituted        piperazin-1-yl.    -   R³ in the compound of the general Formula (V) is preferably        phenyl or thienyl, each of which may be substituted; more        preferably, phenyl or thienyl, each of which may be substituted        with one or more groups selected from the group consisting of        halogen atom and trifluoromethyl; still more preferably, phenyl        or thienyl, each of which is substituted with 1 to 3 halogen        atoms (when substituted with 2 or 3 halogen atoms, the halogen        atom may be identical or different.)    -   R⁴ in the compound of the general Formula (V) is preferably a        group represented by the general Formula (II), more preferably a        group represented by the general Formula (II) wherein n is 2, m        is 2, and X is N—R²⁶ or C—(R²⁷)—R²⁸; still more preferably,        4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl,        4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

(6) The compound according to (5), wherein Ar² is phenyl or monocyclicaromatic heterocycle, each of which may be substituted.

(7) The compound according to (6), wherein R³ is phenyl or thienyl, eachor which may be substituted; R⁴ is a group represented by the generalFormula (II); Ar² is phenyl or pyridyl, each of which may besubstituted.

(8) The compound according to (7), wherein n is 2, m is 2, and X is agroup represented by N—R²⁶ or C(—R²⁷)—R²⁸.

(9) The compound according to (8), wherein R³ is phenyl or thienyl, eachof which is substituted with 1 to 3 halogen atoms (when substituted with2 or 3 halogen atoms, the halogen atoms may be identical or different.).

(10) The compound according to (9), wherein R⁴ is4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl,4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

(11) The compound according to (10), wherein Ar² is phenyl which isunsubstituted at 2- and 6-positions, substituted with —H, —F, —Cl, or—Br at 3 position, substituted with —F, —Cl, or —Br at 5-position, andsubstituted at 4-position; or pyridin-3-yl which is unsubstituted at 2-and 4-positions, substituted with —F, —Cl, or —Br at 5-position, andsubstituted at 6-position.

(12) The compound according to (11), wherein Ar² is phenyl which issubstituted at 4-position with a group selected from the groupconsisting of —O—R^(Y), —NH—R^(Y), optionally substituted piperidin-1-yland optionally substituted piperazin-1-yl; or pyridin-3-yl which issubstituted at 6-position with a group selected from the groupconsisting of —O—R^(Y), —NH—R^(Y), optionally substituted piperidin-1-yland optionally substituted piperazin-1-yl (wherein R^(Y) is lower alkylwhich may be substituted with one or more groups selected from the groupconsisting of —OH, —O-lower alkyl, amino which may be substituted withone or two lower alkyl, —CO₂H, —CO-lower alkyl, carbamoyl which may besubstituted with one or two lower alkyl, cyano, aryl, aromaticheterocycle, nonaromatic heterocycle, and halogen atom.).

(13) The compound according to any one of (5) to (12), which is selectedfrom the group consisting of compound group X, compound group Y, andpharmaceutically acceptable salts thereof, preferably selected fromcompound group X or pharmaceutically acceptable salts thereof.

The “compound group X” includes:

-   -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,    -   N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperidino)thiazol-2-yl]-2-methoxyisonicotinamide,    -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]isoquinoline-6-carboxamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-hydroxypropoxy)nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(3-hydroxypropyl)amino)]nicotinamide,    -   1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic        acid,    -   1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic        acid,    -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-3,5-difluorobenzamide,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxylic        acid,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperidine-4-carboxylic        acid,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxymethylpiperidino)nicotinamide,    -   1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic        acid,    -   1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(3-trifluoromethylphenyl)thiazol-2-yl]carbamoyl}-2-pridyl)piperidine-4-carboxylic        acid,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(2-methoxyethyl)carbamoyl]piperidino}nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(3-methoxypropyl)carbamoyl]piperidino}nicotinamide,        and    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[4-(morpholinocarbonyl)piperidino]nicotinamide.

The “compound group Y” includes:

-   -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-2-methoxyisonicotinamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-methoxyethoxy)benzamide,    -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]quinoline-6-carboxamide,    -   3-chloro-N-[4-(5-chlorothiophen-2-yl)-5-(4-cyclohxylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-5-fluoro-4-(2-hydroxyethoxy)benzamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(3-hydroxypropoxy)benzamide,    -   3,5-dichloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexypiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,    -   3-bromo-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,    -   N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-2-oxo-2,3-dihydrobenzoxazole-6-carboxamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-hydroxybenzamide,    -   (±)-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-hydroxypyrrolidin-1-yl)nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxypiperidino)nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-6-[(2-hydroxyethyl)amino]nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxypiperidino)nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-oxopiperazin-1-yl)nicotinamide,    -   6-(4-carbamoylpiperidino)-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]nicotinamide,    -   (±)-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(2,3-dihydroxypropyl)amino]nicotinamide,    -   (±)-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(tetrahydro-3-furyl)methoxy]nicotinamide,    -   6-(4-carbamoylpiperidino)-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]nicotinamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-hydroxypiperidino)benzamide,    -   1-(2-bromo-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxylic        acid,    -   1-(2-bromo-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxamide,    -   1-(4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl-2,6-difluorophenyl)piperidine-4-carboxylic        acid,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)benzamide,    -   1-(4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2,6-difluorophenyl)piperidine-4-carboxamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-4-(4-hydroxypiperidino)benzamide,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxamide,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidin-4-carboxylic        acid,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-5-fluorobenzamide,    -   1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperidine-4-carboxamide,    -   1-(3-chloro-5-{[4-(3-chlorophenyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic        acid,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(5-oxo-1,4-diazepan-1-yl)nicotinamide,    -   [1-(3-chloro-5-{[4-(4-chlorothiophen2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidin-4-yl]acetic        acid,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(dimethylamino)carbonyl]piperidino}nicotinamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(methylamino)carbonyl]piperidino}nicotinamide,    -   [4-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperazin-1-yl]acetic        acid,    -   6-[4-(acetylamino)piperidino]-5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]nicotinamide,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-5-fluoro-4-[4-(methoxyacetyl)piperazin-1-yl]benzamide,    -   [4-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperazin-1-yl]acetic        acid,    -   3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-5-fluoro-4-(4-sulfamoylpiperazin-1-yl)benzamide,    -   4-[4-(carbamoylmethyl)piperazin-1-yl]-3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-5-fluorobenzamide,    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[4-(propylcarbamoyl)piperidino]nicotinamide,        and    -   5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(2-ethoxyethyl)carbamoyl]piperidino}nicotinamide.

(14) A pharmaceutical composition comprising the compound of any one of(5) to (13) as an active ingredient.

(15) The pharmaceutical composition according (14), wherein thepharmaceutical composition is used as an agent for increasing the numberof platelets.

(16) The pharmaceutical composition according to (14), wherein thepharmaceutical composition is used as a therapeutic agent forthrombocytopenia.

(17) The pharmaceutical composition according to (14), wherein thepharmaceutical composition is used as a c-Mpl ligand.

The compound of the present invention is a 2-acylaminothiazolederivative structurally characterized in that an acylamino group issubstituted at the 2-position thereof and that a nitrogen atom of anitrogen-containing heterocycle is directly bound to the 5-positionthereof. Also, it has pharmacological characteristics of showing theeffects of proliferating human c-mpl Ba/F3 cells and promotingdifferentiation of human CD34+ into megakaryocytes, and good effects inoral administration test for mice, and thus, having the activity ofincreasing the number of platelets.

The present invention will be explained in more detail herein below.

In the definition of the general formula for the compound of the presentinvention, the term “lower” means a straight or branched carbon chainhaving from 1 to 6 carbon atoms, unless otherwise indicated.

Thus, the “lower alkyl” means alkyls having 1 to 6 carbon atoms, and itsexamples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, and the like, of whichthose having 1 to 3 carbon atoms such as methyl, ethyl, propyl, andisopropyl are preferred.

The “lower alkenyl” means alkenyls having 2 to 6 carbon atoms, and itsexamples include ethenyl, propenyl, butenyl, pentenyl, hexenyl and thelike, of which those having 2 to 3 carbon atoms such as ethenyl,1-propenyl, 2-propenyl, and 3-propenyl are preferred.

The “lower alkylidene” means alkylidenes having 1 to 6 carbon atoms, andits examples include methylidene, ethylidene, propylidene, butylidene,pentylidene, hexylidene, and the like, of which those having 1 to 3carbon atoms such as methylidene, ethylidene, 1-propylidene, and2-propylidene are preferred.

The “lower alkylene” means a divalent group of alkyls having 1 to 6carbon atoms, of which those having 1 to 4 carbon atoms such asmethylene, ethylene, trimethylene, methylethylene, tetramethylene,dimethylmethylene, and dimethylethylene are preferred.

The “cycloalkyl” means a carbon ring having 3 to 8 carbon atoms, whichmay have partial unsaturation. Its examples include cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclobutenyl,cyclohexenyl, cyclooctadienyl, and the like.

The “aryl” means a mono- to tri-cyclic aromatic ring having 6 to 14carbon atoms, of which phenyl and naphthyl are preferred, and phenyl ismore preferred.

The “arylalkyl” means the “lower alkyl” substituted with the “aryl”, andits examples include benzyl, 1-phenethyl, 2-phenethyl, naphthylmethyl,1-naphthylethyl, 2-naphthylethyl and the like.

The “monocyclic aromatic heterocycle” means a monovalent group of five-to six-membered aromatic heterocycle or its partially hydrogenated ring,which may comprise a nitrogen, an oxygen, or a sulfur atom, and itsexamples include thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl,imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, thiadiazolyl,oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl,pyridazinyl and the like.

The “bicyclic condensed heterocycle” means a monovalent group of anaromatic heterocycle condensed with an aryl or monocyclic aromaticheterocycle, or its partially hydrogenated ring, which may comprise anitrogen, an oxygen, or a sulfur atom, and its example include indolyl,isoindolyl, indolizinyl, indazolyl, quinolyl, isoquinolyl, quinolidinyl,phthalazinyl, naphthylidinyl, quinoxalinyl, quinazolinyl, cinnolinyl,benzimidazolyl, imidazopyridyl, benzofuranyl, benzoxazolyl,1,2-benzoisoxazolyl, benzothienyl, benzothiazolyl, oxazolopyridyl,thiazolopyridyl, indolinyl, isoindolinyl, 1,2-dihydroquinolinyl,1,2,3,4-tetrahydroquinolinyl, 3,4-dihydro-2H-1,4-benzoxazinyl,1,4-dihydro-2H-3,1-benzoxazinyl, chromanyl, isochromanyl, benzoxolanyl,benzodioxolanyl, benzodioxanyl, and the like.

The “aromatic heterocycle” means the “monocyclic aromatic heterocycle”combined with the “bicyclic condensed heterocycle”.

The “aromatic heterocyclic alkyl” means the “lower alkyl” substitutedwith the “aromatic heterocycle”, and its examples include thienylmethyl,furylmethyl, pyridylmethyl, thiazolylmethyl, oxazolylmethyl,imidazolylmethyl, thienylethyl, furylethyl, pyridylethyl, and the like.

The “non-aromatic heterocycle” means a monovalent group of anon-aromatic heterocycle, which may be condensed with an aryl ormonocyclic aromatic heterocycle, and has one or more hetero atoms, whichare identical or different, selected from the group consisting of anitrogen, an oxygen, and a sulfur, and its examples include azetidinyl,pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl,piperidinyl, azepinyl, piperazinyl, homopiperazinyl, morpholinyl,thiomorpholinyl, indolinyl, isoindolinyl, and the like.

The “halogen” includes fluorine, chlorine, bromine, and iodine atoms.

The “ligand” means a low molecular weight substance binding to anenzyme, receptor, protein, and the like, and includes an agonist andantagonist, of which an agonist is preferred.

As substituent groups that can be used for the term “optionallysubstituted” or “which may be substituted”, those commonly used assubstituent groups for each group can be used, and each group may haveone or more substituent groups.

As the substituent groups that can be used for “aryl or monocyclicaromatic heterocycle, each of which may be substituted” in thedefinition of R¹, “optionally substituted cycloalkyl”, “optionallysubstituted aryl”, “optionally substituted arylalkyl”, “optionallysubstituted aromatic heterocycle”, “optionally substituted aromaticheterocyclic alkyl”, and “optionally substituted nonaromaticheterocycle” in the definitions of R²⁰, R²¹, R²², R²³, R²⁶, R²⁷, R²⁸,and R²⁹, and the “optionally substituted cycloalkyl” and “optionallysubstituted nonaromatic heterocycle” in the definitions of R²⁴ and R²⁵,the following groups (a) to (h) can be exemplified. Wherein, “R^(Z)” isa lower alkyl which may be substituted with one or more groups selectedfrom the group consisting of —OH, —O-lower alkyl, amino which may besubstituted with one or two lower alkyls, carbamoyl which may besubstituted with one or two lower alkyls, aryl, aromatic heterocycle,and halogen.

-   (a) halogen;-   (b) —OH, —O—R^(Z), —O-aryl, —OCO—R^(Z), oxo(═O);-   (c) —SH, —S—R^(Z), —S-aryl, —SO—R^(Z), —SO-aryl, SO₂—R^(Z),    —SO₂-aryl, sulfamoyl which may be substituted with one or two R^(Z);-   (d) amino which may be substituted with one or two R^(Z),    —NHCO—R^(Z), —NHCO-aryl, —NHCO₂—R^(Z), —NHCONH₂, —NHSO₂—R^(Z),    —NHSO₂-aryl, —NHSO₂NH₂, nitro;-   (e) —CHO, —CO—R^(Z), —CO₂H, —CO₂—R^(Z), carbamoyl which may be    optionally substituted with one or two R^(Z), cyano;-   (f) aryl or cycloalkyl, each of which may be substituted with one or    more groups selected from the group consisting of —OH, —O-lower    alkyl, amino which may be substituted with one or two lower alkyl,    halogen and R^(Z);-   (g) aromatic heterocycle or nonaromatic heterocycle, each of which    may be substituted with one or more groups selected from the group    consisting of —OH, —O-lower alkyl, amino which may be substituted    with one or two lower alkyl, halogen and R^(Z);-   (h) lower alkyl which may be substituted with one or more groups    selected from the substituent groups described in (a) to (g).

As the substituent groups that can be used for the “optionallysubstituted lower alkyl”, “optionally substituted lower alkenyl”, and“optionally substituted lower alkylidene” in the definitions of R²⁰,R²¹, R²², R²³, R²⁶, R²⁷, R²⁸, and R²⁹, and the “optionally substitutedlower alkyl” in the definitions of R²⁴ and R²⁵, the group described in(a) to (g) can be exemplified.

As the substituent groups that can be used for the “aryl, monocyclicaromatic heterocycle, or bicyclic condensed heterocycle, each of whichmay be substituted” in the definition of Ar¹, oxo (with the proviso thatoxo can be used only for a bicyclic condensed heterocycle); and a grouprepresented by the general Formula (VI) can be exemplified.-A-B—C-D-E   (IV)Wherein symbols have the following meanings,

-   -   -A-: a single bond, or optionally substituted cyclic aminediyl        (with the proviso that the cyclic aminediyl is bound to Ar¹ with        nitrogen atom of the cyclic amine thereof.),    -   —B—: a single bond, —O—, —NH—, —N(—R^(Z))—, —NHCO—, —CO—,        —CONH—, or —CON(—R^(Z))—,    -   —C—: a single bond; or, lower alkylene or lower alkenylene, each        of which may be substituted with one or more groups selected        from the group consisting of halogen and —OH,    -   -D-: a single bond, —NHCO—, —NHSO₂—, —CO—, or —SO₂—,    -   -E: —H; halogen; —OH; —O—R^(Z); —O—CO—R^(Z); amino which may be        substituted with one or two R^(Z); —R^(Z); cyano; aryl,        cycloalkyl, aromatic heterocycle or nonaromatic heterocycle,        each of which may be substituted,    -   with the proviso that —CH2-nonaromatic heterocycle, and —CH        CH=nonaromatic heterocycle (with the proviso that the carbon        atom of the nonaromatic heterocycle is substituted with methyne)        are excluded from the group represented by the general Formula        (VI); and    -   in case Ar¹ is an aryl or monocyclic aromatic heterocycle, each        of which may be substituted, the following groups are excluded:    -   a group wherein -A- and —B— form a single bond, —C— is a single        bond, or ethylene or vinylene, each of which may be substituted        with one or more groups selected from the group consisting of        halogen and —OH, and -D- is —CO—,    -   a group wherein -A- and —B— form a single bond, —C— is a single        bond, or ethylene or vinylene, each of which may be substituted        with one or more groups selected from the group consisting of        halogen and —OH, -D- is —SO₂—, and -E- is amino which may be        substituted with one or two R^(Z),    -   a group wherein -A- and —B— form a single bond, —C— is a single        bond, or ethylene or vinylene, each of which may be substituted        with one or more groups selected from the group consisting of        halogen and —OH, -D- is a single bond -E- is a monovalent group        of aryl, partially unhydrogenated monocyclic aromatic        heterocycle, or a ring condensed with partially unhydrogenated        monocyclic aromatic heterocycle, each of which may be        substituted,    -   a group wherein -A- is a single bond, and —B— is —CO—,    -   a group wherein -A-, —B—, —C— and -D- form a single bond, and -E        is a monovalent group of aryl, partially unhydrogenated        monocyclic aromatic heterocycle, or a ring condensed with        partially unhydrogenated monocyclic aromatic heterocycle.

And, the “cyclic aminediyl (with the proviso that the cyclic aminediylis bound to Ar¹ with nitrogen atom of the cyclic amine thereof.)” in thedefinition of -A- means a divalent group of three to eight-membered (inthe case of a condensed ring or spiro ring, five- to fifteen-membered)aromatic or nonaromatic cyclic amines, which have at least one nitrogenatom, and may have one or more hetero atoms, identical or different,selected from the group consisting of nitrogen, oxygen, and sulfur,including a condensed ring and spiro ring, and Ar¹ is directlysubstituted with the at least one nitrogen atom. Its examples includedivalent groups of azepine, pyrrolidine, piperidine, piperazine,N-methylpiperazine, azepane, diazepane, N-methyldiazepane, morpholine,thiomorpholine, isoindoline, 1,4-dioxa-8-azaspiro[4,5]decane,1-oxa-8-azaspiro-[4,5]decane, 1-oxa-8-azaspiro[4,5]undecane, and thelike.

As the substituent groups that can be used for the “optionallysubstituted cyclic aminediyl” in the definition of -A- and the “aryl,cycloalkyl, aromatic heterocycle, or nonaromatic heterocycle, each ofwhich may be substituted” in the definition of -E-, the groups describedin (a) to (h), and lower alkylidene which may be substituted with thegroups (a) to (h) can be exemplified.

The compound of the present invention represented by the general Formula(I) or (V) may comprise asymmetric carbon atoms depending on the kindsof substituent groups, and optical isomers based on the asymmetriccarbon atom may exist. The compound of the present invention includes amixture of these optical isomers or isolated ones. And, tautomers mayexist in the compound of the present invention, and the compound of thepresent invention includes these isomers as a mixture or an isolatedone. As the tautomer, 2-hydroxypyridine and 2-pyridone can beexemplified. And, labeled compounds, i.e., compounds wherein one or moreatoms are labeled with radioisotopes or non-radioisotopes, are alsoincluded in the present invention.

In addition, the compound of the present invention may form a salt,which is included in the present invention as long as pharmaceuticallyacceptable. Examples of the salt include addition salts with a mineralacid such as hydrochloric acid, hydrobromic acid, hydroiodic acid,sulfuric acid, nitric acid, phosphoric acid, and the like, or an organicacid such as formic acid, acetic acid, propionic acid, oxalic acid,malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid,malic acid, tartaric acid, citric acid, methanesulfonic acid,ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamicacid, and the like; salts with an inorganic base such as sodium,potassium, magnesium, calcium, and the like, or an organic base such asmethylamine, ethylamine, ethanolamine, lysine, ornithine, and the like;and ammonium salts, and the like. And, a hydrate and a solvate of thecompound and its pharmaceutically acceptable salt of the presentinvention, and those having polymorphism are also included in thepresent invention. In addition, the compound of the present inventionalso includes a compound which is metabolized in a living body to beconverted into the compound of the general Formula (I) or (V) or itssalt, a so-called prodrug. As groups forming the prodrug, thosedescribed in Prog. Med., 5; 2157-2161, 1985; and Hirokawa-Shoten, 1990,“Development of medicine” Vol. 7, Molecular Design, pp 163-198 can beexemplified.

<Production Method>

The compound and its pharmaceutically acceptable salt of the presentinvention can be prepared by various known synthesis methods, usingcharacteristics based on its basic backbone or the kinds of substituentgroups. The following describes representative preparation methods. And,according to the kinds of functional groups, it is advantageous in somecases in terms of preparation technique to substitute a functional groupwith a suitable protection group, i.e., a group that can be easilyconverted into the functional group, in the raw material or intermediatestep. Then, if necessary, the protection group is removed to obtain adesired compound. Examples of the functional group include hydroxyl,carboxy, and amino groups, and examples of the protection group includethose described in “Protective Groups in Organic Synthesis”, thirdedition, edited by Greene and Wuts. It is preferable to suitably usethem depending on reaction conditions.

(wherein R¹, R², Ar¹ are as defined in the foregoing)

In this method, a compound of the general Formula (I) or (V) is preparedby the amidation of a compound (1d) or its salt with a compound (1e) orits reactive derivative by a general method, and then, if necessary,removing a protection group.

As the reactive derivatives of the compound (1e), a common ester such asmethylester, ethylester, tert-butyl ester, and the like; an acid halidesuch as acid chloride, acid bromide, and the like; an acid azide; anactive ester with N-hydroxybenzotriazole, p-nitrophenol, orN-hydroxysuccinimide, or the like; a symmetrical acid anhydride; an acidanhydride mixture with alkyl carbonate, p-toluenesulfonic acid, or thelike can be exemplified.

In case the compound (1e) is reacted in its free acid form, or activeester or acid halide without isolation, and the like, it is preferableto carry out the reaction using a condensing agent such asdicylcohexylcarbodiimide, carbonyldiimidazole, diphenylphosphorylazide,diethylphosphorylcyanide, or1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl),and phosphorous oxychloride in pyridine solvent.

The reaction is, although it varies depending on the reactivederivatives or condensing agent, carried out in an inert organic solventsuch as a halogenated hydrocarbon including dichloromethane,dichloroethane, chloroform and the like; an aromatic hydrocarbonincluding benzene, toluene, xylene and the like; ether including ether,tetrahydrofuran (THF) and the like; an ester including ethyl acetate;N,N-dimethylformamide (DMF) or dimethylsulfoxide (DMSO), and the like,under cooling, cooling to room temperature, or room temperature toheating.

In order to progress the reaction smoothly, it is advantageous in somecases to employ an excess amount of the compound (1e) or carry out thereaction in the presence of a base such as N-methylmorpholine,trimethylamine, triethylamine, N,N-dimethylaniline, pyridine,4-(N,N-dimethylamino)pyridine, picoline, lutidine, and the like. And, asalt consisting of a strong acid and weak base such as pyridinehydrochloride, pyridine p-toluenesulfonate, N,N-dimethylanilinehydrochloride and the like can be used. Pyridine can also be used as asolvent.

Particularly, it is advantageous to carry out the reaction in a solventsuch as acetonitrile or DMF using-a base such as pyridine orN,N-dimethylaniline, or using pyridine as a solvent.

The starting material (1d) used in the reaction can be prepared bysynthesizing a compound (1b) by halogenation of the 5-position of acompound (1a) and then reacting the compound (1b) with a compound (1c).The compound (1b) can also be used in subsequent reaction withoutisolation.

As a halogenation agent, those commonly used for a halogen substitutionreaction of hydrogen on an aromatic ring can be used. A halogen atomsuch as chlorine, bromine and the like, dioxanedibromide,phenyltrimethylammonium tribromide, a pyridine such as pyridiniumhydrobromide perbromide, pyrrolidonehydrotribromide and the like, aperbromide such as α-pyrrolidone, quaternary ammonium, dioxane and thelike are appropriate. An imide-type halogenation agent such asN-bromosuccinimide, N-chlorosuccinimide and the like, a hydrogen halidesuch as hydrochloric acid, hydrobromic acid and the like, a metal agentsuch as copper (II) halide including copper bromide (II), copperchloride (II), and the like can also be used.

In case a halogen or perbromide is used, the compound (1a) can bereacted in an inert organic solvent such as halogenated hydrocarbon;ether; alcohol including methanol (MeOH), ethanol (EtOH), 2-propanol,ethyleneglycol and the like; aromatic hydrocarbon; acetic acid; esterincluding ethyl acetate (EtOAc) and the like. If necessary, the reactionmay be carried out in the presence of a small amount of a catalyst suchas hydrogen halide. It is preferable to carry out the reaction at −30°C. to reflux temperature of the used solvent.

In case a hydrogen halide is used as a halogenation agent, the compound(1a) can be reacted therewith in an acid solution or a base solutionsuch as sodium hydroxide aqueous solution, and the reaction ispreferably carried out at −30° C. to reflux temperature of the usedsolvent. And, in case a metal agent is used as a halogenation agent, thecompound (1a) is generally dissolved in an inert organic solvent such ashalogenated hydrocarbon, ether, alcohol, aromatic hydrocarbon, aceticacid, ester, and the like, or water, or a mixture thereof to react withthe agent, and if necessary, it is advantageous to carry out thereaction in the presence of a small amount of a catalyst such ashydrogen halide, under room temperature to heating.

The thus-obtained compound (1b) is reacted with the compound (1c) in anon-protonic polar solvent such as DMF, N-methyl-2-pyrrolidone, DMSO andthe like, an inert organic solvent such as halogenated hydrocarbon,ether, aromatic hydrocarbon, or water, or a mixture thereof to prepare acompound (1d). The reaction is preferably carried out at roomtemperature to reflux temperature of the used solvent.

In order to progress the reaction smoothly, it is advantageous in somecases to employ an excess amount of the compound (1e) or carry out thereaction in the presence of a base such as N-methylmorpholine,triethylamine, diethylisopropylamine, N,N-dimethylaniline, pyridine,4-(N,N-dimethylamino)pyridine, picoline, lutidine and the like.

In this method, a compound (2a) is synthesized by the amidation of thecompound (1b) synthesized by the first production method with a compound(1e) or its reactive derivative, and then reacted with a compound (1c),and if necessary a protection group is removed to prepare the compound(I) or (V) of the present invention.

Any step can be carried out in accordance with the steps of the firstproduction method.

And, the thus-obtained compounds can be subjected to a process commonlyused in the art such as alkylation, acylation, substitution, oxidation,reduction, hydrolysis, and the like to prepare some of the compounds ofthe general Formula (I) or (V).

The thus-produced compound of the present invention is isolated andpurified as its free form or as a salt thereof. A salt of the compound(I) can be produced by subjecting it to a usual salt formation reaction.The isolation and purification are carried out by usual chemicalmanipulations such as extraction, concentration, evaporation,crystallization, filtration, recrystallization, various types ofchromatography and the like.

Various types of isomers can be separated by usual method using thedifference in physicochemical properties among isomers. For example, aracemic mixture can be separated by a general racemic mixture resolutionmethod, e.g., a method in which racemic mixture is converted intodiastereomer salts with an optically active acid such as tartaric acidand the like and then subjected to optical resolution. And,diastereomers can be separated by fraction crystallization or varioustypes of chromatography or the like. Also, optically active compoundscan be prepared using appropriate optically active starting materials.

Industrial Applicability

The compound and its salt of the present invention have excellenteffects of increasing the number of platelets. Thus, the compound of thepresent invention is useful in the treatment and/or prevention ofthrombocytopenia due to aplastic anemia, myelodysplastic syndrome,chemotherapy or radiotherapy for malignant tumors, idiopathicthrombocytopenic purpura, liver disease, HIV, and the like. In casethrombocytopenia is likely to be caused by chemotherapy or radiotherapy,it is possible to administrate the compound of the present inventionprior to carrying out the therapy.

Pharmaceutical efficacy of the compound of the present invention wasconfirmed by the following tests.

(i) Human c-mpl-Ba/F3 Cell Proliferation Test

In a 96 well microplate, 2×10⁵ cells/ml of human c-mpl-Ba/F3 cells werecultured at 37° C. for 24 hours with 10% fetal bovine serum containing aRPMI1640 medium (100 μl/well) to which varied concentrations of testedcompounds were respectively added. After the culturing, 10 μl /well ofWST-1/1-methoxy PMS (cell counting kit, Dojindo) were added. Immediatelyafter the adding and after 2 hours, absorbance of A450/A650 was measuredwith a microplate reader (Model 3350:Bio-Rad), and the absorbanceincrease after 2 hours was regarded as proliferation activity of eachtested compound. The results are shown in Table 1.

Each term in the Table has the following meaning.

pot.: Concentration of tested compound for promoting cell proliferationof the compound of Example 9 (compound of Example 9 and rhTPO in rhTPO)to 30% of maximum cell proliferation activity value.

Efficacy: Maximum cell proliferation activity value of tested compoundwhen the maximum cell proliferation activity value of the compound ofExample 9 (compound of Example 9 and rhTPO in rhTPO) is set to 100%.TABLE 1 Human c-mpl-Ba/F3 cell proliferation activity of the compound ofthe present invention Tested compound pot. [nM] Efficacy [%] Example 910 87 Example 16 2.4 93 Example 66 14 99 Example 103 18 97 Example 21415 106 Example 250 6.7 87 Example 272 3.3 96 Example 276 8.7 100 Example280 4.9 107 Example 328 9.0 88 Control 1 4.4 101 Control 2 2.1 96Control 3 6.9 96 rhTPO 0.012 100

As Control 1, the compound A-1 of the Patent Document 7 was employed; asthe Control 2, the compound A-14 of the Patent Document 8 was employed;and as Control 3, the compound J-14 of the Patent Document 8 wasemployed. The structures of the control compounds are shown below.

From the above results, it has been verified that the compound of thepresent invention has an activity of proliferating human c-Mpl Ba/F3cells.

(ii) Test for Measuring Effects of Promoting the Formation ofMegakaryocytic Colonies

Human CD34⁺ cells were cultured at 37° C. for 10-14 days in the presenceof tested materials in a 2 well chamber slide, using MegaCult™-C (StemCell Technologies). In accordance with the attached instructions,dehydration, fixing, and staining with antihuman glycoprotein IIb/IIIaantibody were carried out. A group of 3 or more stained megakaryocyteswas regarded as 1 colony, and the number of colonies per well wasmeasured with a microscope. EC₃₀ values of each tested compound werecalculated from a capacity curve.

As results, the compound of Example 9 had an EC₃₀ value of 12 nM, thecompound of Example 66 was 47 nM, and the compound of Example 250 was 26nM.

From these results, it has been confirmed that the compound of thepresent invention has excellent effects of promoting the formation ofmegakaryocytic colonies.

(iii) Oral Administration Test for Mice

To male ICR mice, a tested compound dissolved or suspended in 0.5%methylcellulose aqueous solution was orally administrated in an amountof 100 mg/kg or 10 mg/kg. After 2 hours, blood was drawn from theinferior vena cava of the abdomen using {fraction (1/10)} capacity of3.8% sodium citrate as an anticoagulant. Plasma obtained bycentrifugation at 12,000 rpm for 3 minutes was warmed up at 56° C. for30 minutes, and added to the human c-mpl-Ba/F3 cell proliferation systemdescribed in (i) such that the final plasma concentration became 10%,and then cell proliferation activity was measured. The cellproliferation activity (%) of each plasma batch, when maximum cellproliferation activity of each tested compound was set to 100%, wascalculated. The results are as shown in Table 2. TABLE 2 Humanc-mpl-Ba/F3 cell proliferation activity of plasma after tested compoundis orally administrated Tested compound dose [mg/kg p.o.] Cellproliferation activity [%] Example 16 10 >80% Example 66 10   61%Example 214 10 >80% Example 250 10 >80% Example 272 10 >80% Example 27610 >80% Example 280 10 >80% Example 328 10 >80% Control 1 100 <10%Control 2 100 <10% Control 3 100 <10%

From the above results, it has been verified that the compound of thepresent invention has oral activity in mice. Particularly, it is verysurprising that the control did not show oral activity at 100 mg/kg,while the compound of the present invention showed good oral activityeven at 10mg/kg, which is considered to be achieved by the introductionof a directly bonding nitrogen atom at the 5-position of thiazole. And,controls 2 and 3 showed <10% of cell proliferation activity with thesame dose (10 mg/kg p.o.) as the compounds of Examples. It has also beenconfirmed that, in a mouse in which human platelet production isrecognized after transplanting human hematopoietic stem cells, effectsof increasing the number of platelets are recognized by orallyadministering the compound of the present invention.

A pharmaceutical composition of the present invention can be prepared bygenerally used methods using one or more kinds of the compound of thepresent invention of the general Formula (I) or (V) and pharmaceuticalcarriers, fillers, and other additives generally used in the preparationof medicaments. It may be administrated either by oral administrationthrough tablets, pills, capsules, granules, powders, solutions and thelike, or by parenteral administration through injections such asintravenous injection, intramuscular injection and the like, or throughsuppositories, or pernasal, permucosal, or percutaneous preparations andthe like.

The solid composition for use in the oral administration according tothe present invention is used in the forms of tablets, powders, granulesand the like. In such a solid composition, one or more active substancesare mixed with at least one kind of inert diluent such as lactose,mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose,starch, polyvinyl pyrrolidone, metasilicate, or magnesium aluminate. Inthe usual way, the composition may contain additives other than theinert diluent, which include a lubricant such as magnesium stearate, adisintegrating agent such as calcium cellulose glycolate, a stabilizingagent such as lactose, and a solubilization-assisting agent such asglutamic acid or aspartic acid. As occasion demands, tablets or pillsmay be coated with a sugar coat or a film of gastrosoluble orenterosoluble substance such as sucrose; gelatin,hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, or thelike.

The liquid composition for oral administration includes pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, elixirs and thelike, and contains a generally used inert diluent such as purified wateror ethanol. In addition to the inert diluent, this composition may alsocontain auxiliary agents such as a moistening agent and a suspendingagent, as well as a sweetener, a flavor, an aromatic, and an antiseptic.

The injections for parenteral administration include aseptic aqueous ornon-aqueous solutions, suspensions, and emulsions. Examples of theaqueous solutions and suspensions include distilled water for injectionuse, and physiological saline. Examples of the non-aqueous solutions andsuspensions include plant oil such as propylene glycol, polyethyleneglycol, olive oil or the like; an alcohol such as ethanol, polysorbate80 (trade name) and the like. Such a composition may further containauxiliary agents such as an antiseptic, a moistening agent, anemulsifying agent, a dispersing agent, a stabilizing agent (e.g.,lactose), and a solubilization-assisting agent (e.g., glutamic acid oraspartic acid. These compositions are sterilized for example byfiltration through a bacteria-retaining filter, blending of a germicide,or irradiation. Alternatively, they may be used by firstly making intosterile solid compositions and dissolving them in sterile water or asterile solvent for injection use prior to their use.

In the case of oral administration, a daily dose is approximately0.0001-50 mg/kg of body weight, preferably approximately 0.001-10 mg/kg,and more preferably approximately 0.01-1 mg/kg, and the daily dose isadministered once a day or by dividing it into 2 to 4 doses per day. Inthe case of intravenous administration, a daily dose is approximately0.0001-1 mg/kg of body weight, preferably approximately 0.0001-0.1mg/kg, and the daily dose is administered once a day or by dividing itinto plural doses per day. The dose is appropriately decided by takingsymptoms, age, and sex of the patient to be treated and the like intoconsideration.

BEST MODE FOR CARRYING OUT OF THE INVENTION

The following describes the invention more illustratively with referenceto examples, but the present invention is not limited to these examples.In this connection, novel materials are included in the startingmaterials to be used in the examples, and production methods of thestarting materials from known materials are described as referenceexamples.

REFERENCE EXAMPLE 1

To a solution of 4.18 g of 4-chloro-2-acetylthiophene in 30 ml ofdiethylether, 1.5 ml of bromine was added under ice cooling, and themixture was stirred at room temperature for 2 hours. Water was added tothe reaction solution, and the organic phase was extracted. The obtainedorganic layer was washed with brine and dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure to obtainbrominated compound. To a solution of the brominated compound in 30 mlof EtOH, 2.1 g of thiourea was added at room temperature, and themixture was stirred at 80° C. overnight. The precipitate was filtered,and obtained solution was evaporated under reduced pressure. Chloroformwas added and then an organic layer was washed with aqueous potassiumcarbonate and brine, and dried over sodium sulfate. The residue obtainedby the evaporation of the solvent under reduced pressure was washed withhexane:EtOAc=1:1 to obtain 2.57 g of2-amino-4-(4-chlorothiophen-2-yl)thiazole.

Compounds of Reference Examples 2-8 as shown in Table 3 were synthesizedemploying each corresponding starting material, in the same manner asdescribed in Reference Example 1.

Each symbol in the Table has the following meaning.

Rf: Reference Example number

Data: physical data (MS:FAB-MS(M+H)⁺; MN:FAB-MS(M−H)-; MM: FAB-MS(M)⁺;NMR: δ (ppm) of peaks in ¹H-NMR employing DMSO-d₆ as a measuringsolvent, unless otherwise indicated, and (CH₃)₄Si as an internalstandard)

Structure: Chemical Structure

R¹, R², Ar: substituent group in the general Formula (Me: methyl, Et:ethyl, nPr: normal propyl, nBu: normal butyl, tBu: tert-butyl, cHex:cyclohexyl, cHep: cycloheptyl, allyl: allyl, Ph: phenyl, Bn: benzyl,cyano: cyano, Ac: acetyl, Boc: tert-butyloxycarbonyl, Fur: furanyl, The:thienyl, azet: azetidin-1-yl, pryy: pyrrolidin-1-yl, pipe:piperidin-1-yl, pipa: piperazin-1-yl, mor: morpholin-4-yl,tmor:thiomorpholin-4-yl, imid: imidazol-1-yl, TBS:tert-butyldimethylsilyl, the number before the substituent groupindicates substitution position, and as examples, 5-Cl-3-The indicates5-chlorothiophen-3-yl, and 4-cHex-pipa 4-cylcohexylpiperazin-1-yl.)TABLE 3

Rf R¹ Data 1 4-Cl-2-The MS; 217. 2 5-Cl-3-The MS; 217. 3 5-F-2-The MS;201. 4 3-F-2-The MS; 201. 5 5-Me-2-The MS; 197. 6 4-Me-2-The MS; 197. 74-F-5-Cl-2-The MS; 235. 8 4-F-2-The MS; 201.

REFERENCE EXAMPLE 9

To a solution of 6.0 g of 2-amino-4-(4-fluorophenyl)thiazole in 100 mlof THF, 1.60 ml of bromine was added dropwisely, and the mixture wasstirred at room temperature for 90 minutes. After evaporation of thesolvent, 100 ml of DMF, 10.4 g of 1-cyclohexylpiperazine, and 17.2 ml oftriethylamine were added, and the mixture was stirred at 90° C. for 31hours. The solvent was evaporated under reduced pressure, and theresidue was mixed with saturated aqueous NaHCO₃ and extracted withchloroform. The organic layer was washed with brine, and dried oversodium sulfate. The residue obtained by the evaporation of the solventunder reduced pressure was purified by silica gel column chromatography(elute: chloroform-MeOH=100:1-100:3) to obtain 11.26 g of2-amino-5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazole.

Compounds of Reference Examples 10-40 as shown in Table 4 were eachcorresponding starting material, in the same Reference Example 9.

REFERENCE EXAMPLE 41

To a solution of 0.5 g of the compound of Reference Example 1 in 5 ml ofDMF, 0.45 g of N-bromosuccinimide was added under ice cooling, and themixture was stirred at the same temperature for 50 minutes. To thereaction mixture, 0.6 g of cyclohexylpiperazine and 0.6 ml oftriethylamine were sequentially added, and the mixture was stirred at70° C. for 3 days. The solvent was evaporated under reduced pressure,chloroform was added to the residue, and then the organic layer waswashed with aqueous potassium carbonate and brine, and dried over sodiumsulfate. The residue obtained by the evaporation of the solvent underreduced pressure was purified by silica gel column chromatography(elute: hexane-EtOAc=1:1) to obtain 300 mg of2-amino-4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazole.

Compounds of Reference Examples 42-71 as shown in Table 4 weresynthesized employing each corresponding starting material, in the samemanner as described in Reference Example 41. TABLE 4

Rf R¹ R² Data 9 4-F-Ph 4-cHex-pipa MS; 361. 10 4-F-Ph 4-nPr-pipe MS;320. 11 4-F₃C-Ph 4-cHex-pipa MS; 411. 12 4-O₂N-Ph 4-cHex-pipa MS; 388.13 4-Me₂N-Ph 4-cHex-pipa MS; 386. 14 4-cyano-Ph 4-cHex-pipa MS; 368. 154-EtO₂C-Ph 4-cHex-pipa MS; 415. 16 3-F₃C-Ph 4-cHex-pipa MM; 410. 173-cyano-Ph 4-cHex-pipa MS; 368. 18 4-F-Ph 4-nPrO-pipe MS; 336. 19 4-F-Ph4-mor-pipe MS; 363. 20 5-Cl-2-The

MM; 339. 21 5-Me-2-Fur 4-cHex-pipa MS; 347. 22 3-Cl-2-The 4-cHex-pipaMS; 383. 23 5-Cl-3-The 4-cHex-pipa MS; 383. 24 5-Cl-2-The 4-cHex-pipaMS; 383. 25 5-Br-2-The 4-cHex-pipa MS; 427, 429. 26 5-Me-2-The4-cHex-pipa MS; 363. 27 3-F-2-The 4-cHex-pipa MS; 367. 28 5-Cl-2-The4-nPr-pipe MS; 342. 29 4-F-Ph (MeO(CH₂)₂)(Me)N— MS; 282. 30 4-F-Ph((cHex)(Me)N(CH₂)₂)(Me)N— MS; 363. 31 4-F-Ph (Me₂N(CH₂)₂)(Me)N— MS; 295.32 4-F-Ph (Me₂N(CH₂)₃)(Me)N— MS; 309. 33 4-F-Ph (pipe-(CH₂)₂)(Me)N— MS;335. 34 4-F-Ph 4-AcHN-4-Ph-pipe MS; 411. 35 4-F-Ph imid MS; 261. 364-F-Ph 4-Ph-imid MS; 337. 37 4-F-Ph 4-BnO₂C-pipa MS; 413. 38 4-F-Ph4-nBu-2,5-diMe-pipa MM; 362. 39 4-F-Ph 3-(1-pipe)-azet MS; 333. 403-Cl-Ph 4-cHex-pipa MS; 377. 41 4-Cl-2-The 4-cHex-pipa MS; 383. 425-F-2-The 4-cHex-pipa MS; 367. 43 4-Br-2-The 4-cHex-pipa MS; 427, 429.44 4-Me-2-The 4-cHex-pipa MS; 363. 45 4-Cl-2-The 4-nPr-pipe MS; 342. 464-Cl-2-The (1-nBu-piperidin-4-yl)(Me)N— MS; 385. 47 4-Cl-2-The4-(allylO₂C)-pipa MS; 385. 48 4-Cl-2-The 3-(4-nPr-1-pipe)-azet MS; 397.49 4-Cl-2-The 4-mor-pipe MS; 385. 50 4-Cl-2-The(1-nBu-pyrrolidin-3-yl)(Me)N— MS; 371. 51 4-Cl-2-The(guinuclidin-3-yl)(Me)N— MS; 355. 52 4-F-5-Cl-2-The 4-cHex-pipa MS; 401.53 4-Cl-2-The 4-nPr-pipa MS; 343. 54 4-Cl-2-The mor MS; 302. 554-F-2-The 4-cHex-pipa MS; 367. 56 4-Cl-2-The (mor-(CH₂)₃)(Me)N— MS; 373.57 4-Cl-2-The (mor-(CH₂)₂)(cHex)N— MS; 427. 58 4-Cl-2-The 4-tmor-pipeMS; 401. 59 4-Cl-2-The tmor MS; 318. 60 4-Cl-2-The 3-oxo-pipa MS; 315.61 4-Cl-2-The 4-(cHex)(Me)N-pipe MS; 411. 62 4,5-diCl-2-The 4-cHex-pipaMS; 417. 63 4-Cl-2-The 4-pipe-pipe MS; 383. 64 4-Cl-2-The4-(F₃C—CH₂)(Me)N-pipe MS; 411. 65 4-Cl-2-The (3R* ,5S*)-3,5-diMe-4-nPr-pipa MS; 371. 66 4-Cl-2-The 4-cHep-pipa MS; 397. 674-Cl-2-The 4-(nPr)(Me)N-pipe MS; 371. 68 4-Cl-2-The4-(F₃C—(CH₂)₂)(Me)N-pipe MS; 425. 69 4-Cl-2-The 3-EtO₂C-pipe MS; 372. 704-Cl-2-The 2-EtO₂C-pipe MS; 372. 71 4-Cl-2-The 4-(3-F-pyrr)-pipe MS;387.

REFERENCE EXAMPLE 72

To a solution of 830 mg of the compound of Reference Example 69 in 2 mlof EtOH, 6 ml of 1M NaOH aq. was added, and the mixture was stirred atroom temperature overnight. The solvent was evaporated, and the residuewas mixed with water and extracted with diethylether. 6.5 ml of 1M HClaq. was added to the remaining aqueous layer, and the resultingprecipitate was collected by filtration and dried under reduced pressureto obtain 726 mg of1-[2-amino-4-(4-chlorothiophen-2-yl)thiazol-5-yl]piperidine-3-carboxylicacid.

Compounds of Reference Example 73 as shown in Table 5 were synthesizedemploying each corresponding starting material, in the same manner asdescribed in Reference Example 72. TABLE 5

Rf R¹ R² Data 72 4-Cl-2-The 3-HO₂C-pipe MS; 344. 73 4-Cl-2-The2-HO₂C-pipe MS; 344.

REFERENCE EXAMPLE 74

To a solution of 683 mg of the compound of Reference Example 72 in 20 mlof DMF, 359 mg of 1-hydroxybenzotriazole (HOBt), 506 mg of WSC.HCl, 432mg of dimethylamine hydrochloride, and 1.11 ml of triethylamine wereadded, and the mixture was stirred at room temperature overnight. Thesolvent was evaporated under reduced pressure, and saturated NaHCO₃ aq.was added to the residue. The produced precipitate was collected byfiltration and dissolved in chloroform, and the reaction solution wasmixed with saturated NaHCO₃ aq. and extracted with chloroform. Afterdrying over MgSO₄, the solvent was evaporated, and the thus-obtainedresidue was purified by silica gel column chromatography usingchloroform: MeOH (100:1˜50:1) as an eluent to obtain 628 mg of1-[2-amino-4-(4-chlorothiophen-2-yl)]-N,N-dimethylpiperidine-3-carboxamide.

The compound of Reference Example 75 as shown in Table 6 was synthesizedemploying corresponding starting material, in the same manner asdescribed in Reference Example 74. TABLE 6

Rf R¹ R² Data 74 4-Cl-2-The 3-Me₂NOC-pipe MS; 371. 75 4-Cl-2-The2-Me₂NOC-pipe MS; 371.

REFERENCE EXAMPLE 76

A solution of 608 mg of the compound of Reference Example 74 in 10 ml ofTHF was added to a suspension of 143 mg of LAH in 10 ml of THF, and themixture was heated under reflux overnight. The reaction solution wascooled to room temperature, and 0.14 ml of water, 0.14 ml of 2M NaOHaq., and 0.42 ml of water were added thereto. The thus-producedprecipitate was removed by filtration, the solvent was evaporated underreduced pressure, and the thus-obtained residue was purified by silicagel column chromatography using chloroform:MeOH (20:1) as an eluent toobtain 156 mg of2-amino-4-(4-chlorothiophen-2-yl)-5-{3-[(dimethylamino)methyl]piperidin-1-yl}thiazole.

The compound of Reference Example 77 as shown in Table 7 was synthesizedemploying corresponding starting material, in the same manner asdescribed in Reference Example 76. TABLE 7

Rf R¹ R² Data 76 4-Cl-2-The 3-(Me₂N—CH₂)-pipe MS; 357. 77 4-Cl-2-The2-(Me₂N—CH₂)-pipe MS; 357.

REFERENCE EXAMPLE 78

To a solution of 2.50 g of 3-chloro-4-hydroxybenzoic acid methyl esterin 25 ml of DMF, 2.78 g of potassium carbonate and 4.31 ml of2-(tert-butyldimethylsilyloxy)ethylbromide were added, and the mixturewas stirred at 50° C. for 15 hours. The solvent was evaporated, EtOAcwas added to the residue, and the organic layer was washed with waterand brine and dried over sodium sulfate. After the evaporation of thesolvent, the obtained residue was purified by silica gel columnchromatography (eluent: hexane-EtOAc=10:1˜5:1) to obtain 4.88 g of4-[2-(tert-butyldimethylsilyloxy)ethoxy]-3-chlorobenzoic acid methylester.

Compounds of Reference Examples 79-89 were synthesized employing eachcorresponding starting material, in the same manner as described inReference Example 78.

REFERENCE EXAMPLE 90

To a solution of 1.5 g of 3-chloro-4-hydroxybenzoic acid methyl ester in20 ml of THF, 1.8 ml of 1-tert-butoxy-2-propanol, 3.16 g oftriphenylphosphine, and 1.9 ml of diethylazodicarboxylate were added,and the mixture was stirred at room temperature for 1 hour. Afterevaporation of the solvent under reduced pressure, the obtained residuewas purified by silica gel column chromatography (eluent:hexane-EtOAc=100:1˜5:1) to obtain 2.3 g of4-(1-tert-butoxy-2-propoxy)-3-chlorobenzoic acid methyl ester.

Compounds of Reference Examples 91-93 as shown in Table 8 weresynthesized employing each corresponding starting material in the samemanner as described in Reference Example 90.

REFERENCE EXAMPLE 94

4.0 g of 6-quinolinecarboxylic acid were suspended in 30 ml of MeOH, 2.0ml of conc. sulfate was added under ice cooling, and the mixture wasstirred at 70° C. for 22 hours. The reaction solution was concentratedunder reduced pressure, and the residue was mixed with water andneutralized with potassium carbonate. The thus-precipitated solid wasfiltered and dried to obtain 4.28 g of 6-quinolinecarboxylic acid methylester. 0.5 g of the obtained ester body was dissolved in 5 ml offormamide, 0.15 ml of conc. sulfate, 0.05 g of ferrous sulfatehepta-hydrate, and 0.4 ml of 31% hydrogen peroxide were sequentiallyadded thereto, and the mixture was stirred at 80° C. for 50 minutes. Thereaction solution was mixed with water and alkalinized with potassiumcarbonate. 10% MeOH-chloroform was added, and insoluble matter wasfiltered using celite. The obtained filtrate was separated, the obtainedorganic layer was dried over anhydrous sodium sulfate and concentrated,and the obtained residue was washed with EtOH to obtain 0.15 g of6-methoxycarbonyl-2-quinolinecarboxamide.

REFERENCE EXAMPLE 95

To a solution of 1.96 g of 5-methylpyrazole-3-carboxylic acid ethylester in 40 ml of DMF, 2.64 g of potassium carbonate and 3.53 ml of3-(tert-butyldimethylsilyloxy)propylbromide were added, and the mixturewas stirred at 50° C. for 18 hours. The solvent was evaporated, EtOAcwas added to the residue, and the organic layer was washed with waterand brine and dried over sodium sulfate. After the evaporation of thesolvent, the obtained residue was purified by silica gel columnchromatography (eluent: hexane-EtOAc=15:1˜5:1) to obtain 1.39 g of1-[3-(tert-butyldimethylsilyloxy)propoxyl]-5-methylpyrazole-3-carboxylicacid ethyl ester.

REFERENCE EXAMPLE 96

To a solution of 0.50 g of 3-chloro-4-formylbenzoic acid methylester in10 ml of methylene chloride, 0.5 ml of acetic acid, 0.3 ml of2-methoxyethylamine, and 0.85 g of triacetoxyborohydride were added, andthe mixture was stirred at room temperature for 1 day. The reactionsolution was mixed with water and neutralized with potassium carbonate,and then EtOAc was added thereto. The organic layer was washed withwater and brine, and dried over sodium sulfate. The solvent wasevaporated to obtain a benzyl amine body.

To a solution of the benzyl amine body in 10 ml of THF, 0.70 g ofdi-tert-butyldicarbonate was added, and the mixture was stirred at roomtemperature overnight. After the evaporation of the solvent, theobtained residue was purified by silica gel column chromatography(eluent: hexane-EtOAc=10:1˜8:1) to obtain 0.87 g ofN-(2-chloro-4-methoxycarbonylbenzyl)-N-(2-methoxyethyl)carbamic acidtert-butylester.

The compound of Reference Example 97 as shown in Table 8 was synthesizedemploying corresponding starting material, in the same manner asdescribed in Reference Example 96.

REFERENCE EXAMPLE 98

To a solution of 1.52 g of 3,4,5-trifluorobenzoic acid in 15 ml ofdichloromethane, 0.92 ml of oxalyl chloride was added under ice cooling,and the mixture was stirred at the same temperature for 30 minutes andat room temperature for 80 minutes. After DMF was added dropwise, themixture was stirred at room temperature for 1 hour. To the residueobtained by the evaporation of the solvent under reduced pressure, 20 mlof pyridine, 3.40 ml of 2-tert-butoxyethanol, and 1 fold by spatula ofDMAP were added under ice cooling, and the mixture was stirred at roomtemperature overnight. After the evaporation of the solvent underreduced pressure, the residue was mixed with saturated NaHCO₃ aq.extracted with EtOAc, washed with water and brine, and dried over MgSO₄.The solvent was evaporated under reduced pressure to obtain 2.10 g ofcrude 3,4,5-trifluorobenzoic acid 2-tert-butoxyethyl ester. To asolution of 1.03 g of potassium tert-butoxide in 15 ml of THF, 1.50 mlof 2-tert-butoxyethanol was added, and the mixture was stirred for 40minutes. The reaction solution was cooled to −78° C., a solution of 2.10g of crude 3,4,5-trifluorobenzoic acid 2-tert-butoxyethylester in 5 mlof THF was added thereto, and the mixture was stirred under ice coolingfor 1 hour and at room temperature for 30 minutes. The reaction solutionwas mixed with saturated aqueous ammonium chloride, extracted withEtOAc, and washed with water and brine, and then dried over MgSO₄. Theresidue obtained by the evaporation of the solvent under reducedpressure was purified by silica gel column chromatography (eluent:hexane-EtOAc=100:1˜20:1) to obtain 2.24 g of4-(2-tert-butoxyethoxy)-3,5-difluorobenzoic acid 2-tert-butoxyethylester.

REFERENCE EXAMPLE 99

To a solution of 1.15 g of 3-chloro-4-fluorobenzoic acid in 20 ml ofDMSO, 1.3 g of potassium carbonate and 1.4 g of isonipecotic acid ethylester were added, and the mixture was heated while stirring at 80° C.for 2 days. EtOAc was added to the reaction solution, and the organiclayer was washed with water and brine and then dried over sodiumsulfate. After the evaporation of the solvent, the obtained residue waspurified by silica gel column chromatography (eluent:hexane-EtOAc=20:1˜10:1) to obtain 1.42 g ofN-(4-tert-butoxycarbonyl-2-chloropheyl)isonipecotic acid ethyl ester.

Compounds of Reference Examples 100-108 as shown in Table 8 weresynthesized employing each corresponding starting material, in the samemanner as described in Reference Example 99.

REFERENCE EXAMPLE 109

To a solution of 0.70 g of 3-chloro-4-(4-hydroxypiperidino)benzoic acidin 15 ml of methylene chloride, 1.5 ml of 2,6-lutidine and 2.7 g oftert-butyldimethylsilyltriflate were added, and the mixture was stirredat room temperature for 2 weeks. To the reaction solution, EtOAc wasadded, and the organic layer was washed with water and brine and thendried over sodium sulfate. After the evaporation of the solvent, theobtained residue was purified by silica gel column chromatography(eluent: hexane-EtOAc=5:1˜4:1) to obtain 0.90 g of4-(4-tert-butyldimethylsilyloxypiperidino)-3-chlorobenzoic acid methylester.

REFERENCE EXAMPLE 110

To a solution of 1.50 g of1-(4-ethoxycarbonyl-2-fluorophenyl)piperidine-4-carboxamide in 20 ml ofTHF, 2.0 ml of triethylamine and 0.9 ml of trifluoroacetic acidanhydride were added at −78° C., and the mixture was stirred at roomtemperature for 6 hours. The solvent was evaporated, EtOAc was added,and then the organic layer was washed with water and brine, and driedover sodium sulfate. After the evaporation of the solvent, the residuewas purified by silica gel column chromatography (eluent:hexane-EtOAc=5:1˜4:1) to obtain 1.43 g of4-(4-cyanopiperidino)-3-fluorobenzoic acid ethyl ester.

REFERENCE EXAMPLE 111

To a solution of 0.50 g ofN-(4-tert-butoxycarbonyl-2-fluorophenyl)isonipecotic acid ethyl ester in5 ml of DMF, 0.21 g of N-chlorosuccinimide was added, and the mixturewas stirred at room temperature for 1 day. After the evaporation of thesolvent, the residue was purified by silica gel column chromatography(eluent: hexane-EtOAc=5:1˜1:1) to obtain 0.51 g ofN-(4-tert-butoxycarbonyl-2-chloro-6-fluorophenyl)isonipecotic acid ethylester.

Compounds of Reference Examples 112-113 as shown in Table 8 weresynthesized employing each corresponding starting material, in the samemanner as described in Reference Example 111. TABLE 8 Rf structure Data78

MS; 345. 79

MS; 243 80

MS; 245. 81

MS; 403, 405. 82

NMR(CDCl₃); 0.05-0.13(6H, m), 0.82-0.93(9H, m), 1.40(3H, t, J=7.1 Hz),3.97(2H, t, J=5.1 Hz), 4.28-4.34(2H, m), 4.37(2H, q, J=7.1 Hz), 7.68(1H,dd, J=2.0, 11.6 Hz), 7.87(1H, t, J=2.0 Hz) 83

MS; 393. 84

MS; 359. 85

GC-MS(M)⁺; 214. 86

MS; 231. 87

MS; 343. 88

MS; 339. 89

MS; 339. 90

MS; 301. 91

MS; 285. 92

MS; 271 93

NMR(CDCl₃); 1.38(3H, t, J=6.0 Hz), 1.41(3H, s), 1.47(3H, s),4.00-4.23(4H, m), 4.33(2H, q, J=6.0 Hz), 4.48-4.56(1H, m), 6.96(1H, d,J=8.7 Hz), 7.92(1H, dd, J=2.0, 8.7 Hz), 8.05(1H, d, J=2.0 Hz). 94

MS; 231. 95

MS; 327. 96

MS; 358. 97

MS; 339. 98

MS; 375. 99

MS; 368 100

MS; 318. 101

MS; 312 102

MS; 297 103

MS; 269 104

MS; 352 105

MS; 295 106

MS; 239. 107

MS; 354. 108

MS; 325. 109

MS; 384 110

MS; 277 111

MS; 386 112

MS; 311 113

MS; 373.

REFERENCE EXAMPLE 114

To a solution of 2.16 g of the compound of Reference Example 78 in MeOH20 ml-THF 15 ml, 7.5 ml of 1M NaOH aq was added, and the mixture wasstirred at room temperature for 3 days. The solvent was evaporated, andthe residue was acidified with 5% potassium hydrogen sulfate aq. andextracted with chloroform-2-propanol (3:1). The organic layer was washedwith brine, and dried over sodium sulfate, and then the solvent wasevaporated to obtain 1.17 g of4-[2-(tert-butyldimethylsilyloxy)ethoxy]-3-chlorobenzoic acid.

Compounds of Reference Examples 115-138 as shown in Table 9 weresynthesized employing each corresponding starting material, in the samemanner as described in Reference Example 114.

REFERENCE EXAMPLE 139

To 1.56 g of 3,4,5-trifluorobenzoylchloride, 6.32 ml of 2-methoyethanoland 6.53 g of cesium carbonate were added, and the mixture was stirredat 100° C. for 20 hours. The reaction solution was mixed with 50 ml ofTHF and filtered, and the filtrate was evaporated to obtain 4.36 g ofcolorless solid. The solid was dissolved in 15 ml of THF, 3.16 ml of2-methoxyethanol, and 1.35 g of potassium tert-butoxide were addedthereto, and the mixture was stirred at room temperature for 4 days. Thereaction solution was mixed with 5% potassium hydrogensulfate aq. andextracted with EtOAc. The organic layer was washed with brine and driedover sodium sulfate, and then the solvent was evaporated to obtain 1.76g of 3,5-difluoro-4-(2-methoxyethoxy)benzoic acid.

REFERENCE EXAMPLE 140

0.3 g of the compound of Reference Example 94 was dissolved in 10 ml ofa mixed solvent of THF-MeOH (1:1), 1.5 ml of 1M NaOH aq. was added atroom temperature, and the mixture was stirred at the same temperaturefor 3 days. The reaction solution was concentrated under reducedpressure, mixed with water, and neutralized with 1.5 ml of 1M HCl aq.The thus-obtained solid was filtered and dried to obtain 0.29 g of2-carbamoylquinoline-6-carboxylic acid.

REFERENCE EXAMPLE 141

To a solution of 410 mg of the compound of Reference Example 130 in 10ml of pyridine, 0.24 ml of acetic acid anhydride was added, and themixture was stirred at room temperature for 15 hours. The solvent wasevaporated, EtOAc was added to the residue, and the organic layer waswashed with 1M HCl, water and brine and dried over sodium sulfate. Afterthe evaporation of the solvent, the residue was purified by silica gelcolumn chromatography (eluent: chloroform-MeOH=100:1˜50:1) to obtain 351mg of 4-[2-(acetyloxy)ethoxyl-3-methylbenzoic acid.

The compound of Reference Example 142 as shown in Table 9 wassynthesized employing each corresponding starting material, in the samemanner as described in Reference Example 141.

REFERENCE EXAMPLE 143

To 2.00 g of 2-chloroisonicotic acid, 15 ml of ethyleneglycol and 4.28 gof potassium tert-butoxide were added, and the mixture was stirred at150° C. for 6 days. The reaction solution was poured into 5% potassiumhydrogen sulfate aq. and extracted with EtOAc, and then the organiclayer was washed with brine and dried over MgSO₄. The solvent wasevaporated to obtain 0.54 g of 2-(2-hydroxyethoxy)isonicotic acid.

REFERENCE EXAMPLE 144

To a solution of 4.74 g of1-{4-[(allyloxy)carbonyl]phenyl}piperidine-4-carboxylic acid ethyl esterin 75 ml of THF, 2.10 ml of morpholine and 390 mg oftetrakis(triphenylphosphine)palladium were added, and the mixture wasstirred at 60° C. for 1.5 hours. After the solvent was evaporated underreduced pressure, EtOAc was added to the residue, and the reactionsolution was washed with NaHCO₃ aq. three times. To the collectedsaturated NaHCO₃ aq., conc. HCl was added, and the produced precipitatewas collected by filtration and dried under reduced pressure to obtain2.73 g of 4-[4-(Ethoxycarbonyl)piperidin-1-yl]benzoic acid.

The compound of Reference Example 145 as shown in Table 9 wassynthesized employing corresponding starting material, in the samemanner as described in Reference Example 144.

REFERENCE EXAMPLE 146

1.42 g of the compound of Reference Example 99 were dissolved in 5 ml ofmethylene chloride, 5 ml of trifluoroacetic acid were added under icecooling, and the mixture was stirred at room temperature for 1 day. Thereaction solution was concentrated under reduced pressure, mixed withwater, and neutralized with NaOH aq. The obtained solid was filtered anddried to obtain 1.16 g of 3-chloro-4-(4-ethoxycarbonylpiperidino)benzoicacid.

The compound of Reference Example 147 as shown in Table 9 wassynthesized employing corresponding starting material, in the samemanner as described in Reference Example 146.

REFERENCE EXAMPLE 148

To a solution of 1.12 g of the compound of Reference Example 144 in 20ml of DMF, 775 mg of N-bromosuccinimide were added, and the mixture wasstirred at room temperature for 70 minutes and at 50° C. for 2 hours.After the solvent was evaporated under reduced pressure, water was addedto the residue, and the produced precipitate was collected byfiltration. After adding saturated NaHCO3 aq., EtOAc, and HCl, thereaction solution was extracted with chloroform, and dried over MgSO₄.The residue obtained by the evaporation of the solvent under reducedpressure was purified by silica gel column chromatography (eluent:chloroform-methanol=100:1˜30:1) to obtain 1.29 g of3-bromo-4-[4-(ethoxycarbonyl(piperidin-1-yl)benzoic acid. TABLE 9 Rfstructure Data 114

MN; 329. 115

MN; 213. 116

MN; 229. 117

MN; 373, 375. 118

NMR(CDCl₃); 0.05-0.15(6H, m), 0.85-0.92(9H, m), 3.97(2H, t, J=5.2 Hz),4.32-4.37(2H, m), 7.73(1H, dd, J=2.0, 11.2 Hz), 7.93(1H, t, J=2.0 Hz).119

MN; 363. 120

MN; 343. 121

MS; 287. 122

MN; 199. 123

MS; 217. 124

MN; 297. 125

MS; 257. 126

MN; 241 127

NMR(CDCl₃); 1.41(3H, s), 1.48(3H, s), 4.00-4.25(4H, m), 4.49-4.58(1H,m), 6.99(1H, d, J=8.7 Hz), 7.99(1H, dd, J=2.0, 8.7 Hz), 8.12(1H, d,J=2.0 Hz). 128

MS; 316. 129

MN; 342 130

NMR(CD₃OD); 2.17(3H, s), 3.77-3.85(2H, m), 3.97-4.06(2H, m), 6.86(1H, d,J=8.7 Hz), 7.68-7.78(2H, m). 131

MN; 273. 132

MS; 338. 133

MN; 296 134

MN; 368 135

MN; 281 136

MS; 285. 137

MN; 281 138

MS; 359. 139

MN; 231. 140

MN; 215. 141

MS; 239. 142

MS; 226. 143

NMR; 3.72(2H, t, J=5.0 Hz), 4.31(2H, t, J=5.0 Hz), 4.82(1H, brs),7.18(1H, d, J=1.3 Hz), 7.38(1H, dd, J=5.1, 1.3 Hz), 8.31(1H, d, J=5.1Hz), 13.56(1H, brs). 144

MS; 278. 145

MS; 314. 146

MN; 310. 147

MN; 328 148

MN; 354, 356.

REFERENCE EXAMPLE 149

To a solution of 2.00 g of the compound of Reference Example 9 and 1.14g of 4-formylbenzoic acid in 30 ml of DMF, 992 mg ofN-hydroxybenzotriazole (HOBt) and 1.39 g of WSC.HCl were added, and themixture was stirred at room temperature overnight. After the evaporationof the solvent under reduced pressure, the residue was mixed withsaturated NaHCO₃ aq. and extracted with chloroform, and then the organiclayer was dried over MgSO₄. The residue obtained by the evaporation ofthe solvent was purified by silica gel column chromatography twice usingchloroform: methanol (100:1˜30:1) and hexane: EtOAc (5:1˜1:1) as eluentto obtain 1.32 g ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-formylbenzamide.

The compound of Reference Example 150 as shown in Table 10 wassynthesized employing corresponding starting material, in the samemanner as described in Reference Example 149. TABLE 10 Rf structure Data149

MS; 493. 150

MS; 550.

EXAMPLE 1

To a solution of 300 mg of the compound of Reference Example 9 in 5 mlof pyridine, 280 mg of 4-cyanobenzoylchloride were added under icecooling, the temperature was elevated to room temperature, and then themixture was stirred at the same temperature for 3 days and then at 50°C. for 1 day. The solvent was evaporated under reduced pressure, theresidue was mixed with chloroform, and the organic layer was washed withsaturated aqueous NaHCO₃ and brine and dried over sodium sulfate. Afterthe evaporation of the solvent under reduced pressure, the obtainedresidue was recrystallized from EtOAc to obtain 230 mg ofN-[5-(4-cyclohexypiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-cyanobenzamide.To a solution of 80 mg of the obtained compound in 5 ml of EtOAc, 0.4 mlof a solution of 0.4 M HCl-EtOAc were added, and the mixture was stirredovernight and filtered to obtain 57 mg ofN-[5-(4-cyclohexylpiperzain-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-cyanobenzamidehydrochloride.

EXAMPLE 2

To a solution of 500 mg of the compound of Reference Example 24 in 10 mlof DMF, 300 mg of 2-methoxyisonicotinic acid, 376 mg of WSC.HCl, and 265mg of HOBt were added, and the mixture was stirred at room temperaturefor 4 days. The solvent was evaporated, and the residue was mixed withEtOAc and washed with saturated aqueous NaHCO₃ and brine and then driedover sodium sulfate. After the evaporation of the solvent, the residuewas purified by silica gel column chromatography (hexane-EtOAc=8:1˜2:1)and dissolved in 10 ml of EtOAc, 0.46 ml of 0.4M HCl-EtOAc solution wereadded thereto, and the mixture was stirred for a while, and then theproduced precipitate was collected by filtration to obtain 72 mg ofN-[4-(5-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 3

To a solution of 342 mg of the compound of Reference Example 28 in 10 mlof DMF, 306 mg of 2-methoxyisonicotinic acid, 383 mg of WSC.HCl, 270 mgof HOBt, and 244 mg of 4-(dimethylamino)pyridine were added, and themixture was stirred at 50° C. for 3 days. The solvent was evaporated,and the residue was mixed with EtOAc, washed with saturated aqueousNaHCO₃ and brine, and dried over sodium sulfate. After the evaporationof the solvent, the residue was purified by silica gel columnchromatography (hexane-EtOAc=8:1) and dissolved in 30 ml of EtOAc, 4.1ml of 0.1M HCl-EtOAc solution was added thereto, and the mixture wasstirred for a while, and then the produced precipitate was collected byfiltration to obtain 120 mg ofN-[4-(5-chlorothiophen-2-yl)-5-(4-propylpiperidin-1-yl)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 4

To a solution of 1.72 g of the compound of Reference Example 78 in amixed solvent of MeOH 17 ml-THF 10 ml, 6 ml of 1M NaOH aq. was added,and the mixture was stirred at room temperature for 3 days. To thereaction solution, 5.5 ml of 1M HCl aq. was added, and solvent wasevaporated under reduced pressure to obtain a crude product of4-[2-(tert-butyldimethylsilyloxy)ethoxy]-3-chlorobenzoic acid. To theobtained crude product, 720 mg of the compound of Reference Example 78,20 ml of DMF, 959 mg of WSC.HCl, 676 mg of HOBt, and 611 mg of4-(dimethylamino)pyridine were added, and the mixture was stirred at 50°C. for 22 hours and then at 90° C. for 20 hours. The solvent wasevaporated, the residue was mixed with saturated aqueous NaHCO₃ andextracted with EtOAc, and the organic layer was washed with saturatedaqueous NaHCO₃ and brine and dried over sodium sulfate. After theevaporation of the solvent, the residue was purified by silica gelcolumn chromatography using chloroform-MeOH (100:1˜10:1) as an eluentand silica gel column chromatography using hexane:EtOAc (2:1˜1:1) as aneluent to obtain 38 mg of3-chloro-4-{2-[3-chloro-4-(2-hydroxyethoxy)benzoyloxy]ethoxy}-N-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]benzamide.To the obtained compound, 0.5 ml of MeOH, 1 ml of THF, and 225 μl of 1MNaOH aq. were added, and the mixture was stirred at room temperature for5 days. The reaction solution was mixed with EtOAc, washed withsaturated aqueous NaHCO₃ and brine, and dried over sodium sulfate. Afterthe evaporation of the solvent, the residue was purified by silica gelchromatography (chloroform-MeOH=100:0˜100:2) and the obtained productwas dissolved in 5 ml of EtOAc, 1.0 ml of 0.1 M HCl-EtOAc solution wasadded, the mixture was stirred for a while, and the produced precipitatewas collected by filtration to obtain 18 mg of3-chloro-N-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamidehydrochloride.

EXAMPLE 5

To a solution of 1.0 g of the compound of Reference Example 41 in 30 mlof pyridine, 602 mg of 5,6-dichloronicotinic acid was added, 0.27 ml ofphosphorous oxychloride was added at −25° C., and the temperature waselevated to room temperature, and then the mixture was stirred for 4hours. The solvent was evaporated under reduced pressure, the residuewas mixed with water and potassium carbonate and extracted withchloroform, and the organic layer was washed with brine and dried oversodium sulfate. After the evaporation of the solvent, the obtainedresidue was purified by silica gel column chromatography(hexane-EtOAc=200:1˜100:1) to obtain 1.21 g of5,6-dichloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]nicotinamide.

EXAMPLE 6

To a solution of 100 mg of the compound of Example 246 in 5 ml of EtOH,0.2 ml of 4M HCl-EtOAc solution was added, and the mixture was stirredfor 27 hours. To the reaction solution, chloroform was added, and theorganic layer was washed with saturated aqueous NaHCO₃ and brine anddried over sodium sulfate. After the evaporation of the solvent, theobtained residue was purified by silica gel column chromatography(chloroform-MeOH=100:1˜5:1) and the obtained product was dissolved in 15ml of MeOH, 10 ml of 4M HCl-EtOAc solution was added thereto, and themixture was stirred for a while. Then, the solvent was evaporated underreduced pressure, and the residue was washed with diethylether to obtain28 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-hydroxynicotinamidehydrochloride.

EXAMPLE 7

To 183 mg of the compound of Example 233, 5 ml of trifluoroacetic acidwas added, and the mixture was stirred for 40 hours. Then, the solventwas evaporated under reduced pressure, and the obtained residue waspurified by silica gel column chromatography(chloroform-MeOH=100:1˜20:1) to obtain 50 mg of3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(1-hydroxy-2-propoxy)benzamidetrifluoroacetate.

EXAMPLE 8

0.34 g of the compound of Example 218 was suspended in 5 ml of MeOH, 1ml of conc. HCl was added thereto under ice cooling, and the mixture wasstirred at 50° C. overnight. To the reaction solution, 0.5 ml of conc.HCl was added again, and the mixture was stirred at 50° C. for 5 hoursand 60° C. overnight. The reaction solution was cooled to roomtemperature, and the thus-precipitated solid was filtered and dried toobtain 0.33 g ofN-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamidehydrochloride.

EXAMPLE 9

187 mg of the compound of Example 230 was dissolved in 10 ml of MeOH,3.5 ml of conc. HCl was added, and the mixture was stirred for 18 hours.Then, the thus-produced precipitate was filtered and washed withdiethylether to obtain 90 mg of3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamidehydrochloride.

EXAMPLE 10

To a solution of 5.23 g of the compound of Example 101 in 100 ml of THF,17.0 g of tributyltin hydride was added at 0° C., and the mixture wascooled to −78° C. And, 670 mg of tetrakis(triphenylphosphine)palladiumwas added thereto, the temperature was slowly elevated to roomtemperature, and the mixture was stirred for 1.5 hours. The reactionsolution was mixed with 1.6 ml of acetic acid and stirred at roomtemperature for 15 minutes. Then, the solvent was evaporated underreduced pressure, hexane was added to the obtained residue, and thethus-formed precipitate was collected by filtration and dried underreduced pressure to obtain 4.30 g ofN-[4-(4-chlorothiophen-2-yl)-5-(piperazin-1-yl)thiazol-2-yl]-2-methoxyisonicotinamideacetate.

EXAMPLE 11

0.15 g of the compound of Example 136 was dissolved in 5.0 ml of THF, atotal 1.3 ml of butyl lithium (1.55 M) was added thereto at −78° C., andthe mixture was stirred at the same temperature for 4.5 hours to confirmthe loss of the starting material. 0.5 ml of acetic acid was added tothe reaction solution to stop the reaction, and the temperature waselevated to room temperature. The reaction solution was mixed withwater, alkalinized with potassium carbonate, and extracted withchloroform. The organic layer was dried over anhydrous sodium sulfate,and the solvent was concentrated under reduced pressure. Thethus-obtained residue was purified by silica gel column chromatographyto obtain 0.12 g ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)thiazol-2-yl]-2-methoxyisonicotinamide.The obtained compound was dissolved in 2 ml of EtOAc, 0.25 ml of 1MHCl-EtOAc solution was added thereto under ice cooling, and the mixturewas stirred at room temperature overnight. The thus-precipitated solidwas filtered and dried to obtain 98 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 12

To a solution of 48 mg of 40% sodium hydride in 1 ml of ethyleneglycol,100 mg of the compound of Example 5 was added at room temperature, thetemperature was elevated to 50° C., and the mixture was stirred for 4days. To the reaction solution, chloroform was added, and the organiclayer was washed with saturated aqueous NaHCO₃ and brine and dried oversodium sulfate. After the evaporation of the solvent under reducedpressure, the obtained residue was purified by silica gel columnchromatography (chloroform-MeOH=200:1˜20:1) and the obtained compoundwas dissolved in 5 ml of EtOAc, 0.8 ml of 0.1M HCl-EtOAc solution wasadded thereto, and the mixture was stirred for a while. Then, thesolvent was evaporated under reduced pressure, and the residue waswashed with diethylether to obtain 34 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(2-hydroxyethoxy)nicotinamidehydrochloride.

EXAMPLE 13

To a solution of 750 mg of the compound of Example 5 in 10 ml of THF,2.1 ml of ethyl isonipecotate was added at room temperature, thetemperature was elevated to 50° C., and the mixture was stirred for 5hours. To the reaction solution, chloroform was added, and the organiclayer was washed with saturated aqueous NaHCO₃ and brine and dried oversodium sulfate. After the evaporation of the solvent under reducedpressure, the obtained residue was purified by silica gel columnchromatography (chloroform-MeOH=200:1˜100:1) to obtain 881 mg of1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylicacid ethyl ester.

EXAMPLE 14

231 mg of the compound of Example 10 and 80 μl of benzaldehyde weredissolved in 9 ml of 1,2-dichloroethane-9 ml of acetic acid, 210 mg ofsodium triacetoxyborohydride was added thereto at 0° C., and the mixturewas stirred at 0° C. for 30 minutes and at room temperature for 30minutes. The reaction solution was alkalinized with saturated aqueousNaHCO₃ and 1M aqueous NaOH, and extracted with chloroform. The organiclayer was dried over MgSO₄, and the solvent was evaporated under reducedpressure. Then, to the obtained residue, 5 ml of acetic acid, a total of160 μl of benzaldehyde, and a total of 404 mg of sodiumtriacetoxyborohydride were added, and the mixture was stirred at 50° C.for 4 hours. The solvent was evaporated under reduced pressure,saturated aqueous NaHCO₃ was added to the obtained residue, andinsoluble matter was collected by filtration. Chloroform was addedthereto to dissolve it, and the solution was mixed with saturatedaqueous NaHCO₃ and extracted with chloroform. The organic layer wasdried over MgSO₄, and the solvent was evaporated under reduced pressure.The obtained residue was purified by silica gel column chromatography(hexane-EtOAc=4:1) and the obtained compound was dissolved in EtOAc, andthen a 0.5 M HCl-EtOAc solution was added thereto, and the thus-producedprecipitate was collected by filtration to obtain 64 mg ofN-[5-(4-benzylpiperazin-1-yl)-4-(4-chlorothiophen-2-yl)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 15

To a solution of 0.35 g of the compound of Example 243 in 5 ml of EtOAc,4M HCl-EtOAc was added under ice cooling, and the mixture was stirred atroom temperature for 1 hour. The thus-precipitated solid was filtered toobtain 345 mg of4-aminomethyl-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]benzamidehydrochloride.

EXAMPLE 16

To a solution of 30 mg of the compound of Example 13 in 1 ml of MeOH,0.12 ml of 1M NaOH aq. was added at room temperature, and the mixturewas stirred for 24 hours. After the solvent was evaporated under reducedpressure, the obtained residue was dissolved in 5 ml of EtOAc, 0.2 ml of1M HCl was added thereto, and the mixture was stirred for a while. Then,the solvent was evaporated under reduced pressure and washed withdiethylether to obtain 20 mg of1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperzain-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylicacid hydrochloride.

EXAMPLE 17

To a suspension of 180 mg of the compound of Example 143 in 5 ml of DMF,100 mg of 1,1′-carbonyldimidazole were added, and the mixture wasstirred at room temperature for 4 hours. Then, 1 ml of 28% ammonia waterwas added, and the mixture was stirred at room temperature for 1.5hours. The reaction solution was mixed with water and extracted withchloroform. The organic layer was dried over MgSO₄, and the solvent wasevaporated under reduced pressure. The obtained residue was washed withethanol, and suspended in EtOH. Then, 0.35 ml of 1M HCl-EtOAc solutionwas added thereto, the mixture was stirred overnight, and thethus-produced precipitate was collected by filtration to obtain 151 mgofN-[4-(4-fluorophenyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-carbamoylmethylbenzamidehydrochloride.

EXAMPLE 18

To 138 mg of the compound of Example 147, 3 ml of water and 3 ml ofconc. HCl were added, and the mixture was stirred at 80° C. for 17hours. The reaction solution was cooled to room temperature, and thethus-produced precipitate was collected by filtration and washed withwater. 1M aqueous NaOH, MeOH, and diethylether were added thereto, andinsoluble matter was removed by filtration. The obtained filtrate wasextracted with diethylether, and conc. HCl was added to the aqueouslayer, and the thus-produced precipitate was collected by filtration anddried under reduced pressure to obtain 101 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(3,4-dioxo-2-hydroxycyclobut-1-ene-1-yl)amino]benzamidehydrochloride.

EXAMPLE 19

To 430 mg of the compound of Example 198, 15 ml of water, and 15 ml ofconc. HCl were added, and the mixture was stirred at 80° C. for 3.5hours. The reaction solution was cooled to 0° C., 50 ml of water wasadded thereto, and the thus-produced precipitated was collected byfiltration and dried under reduced pressure to obtain 101 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2,3-dihydroxyquinoxaline-6-carboxamidehydrochloride.

EXAMPLE 20

To a solution of 100 mg of the compound of Reference Example 149 in 5 mlof MeOH, 24 mg of sodium borohydride was added at 0° C., and the mixturewas stirred at room temperature for 1 hour. 2 ml of DMF was addedthereto, and the mixture was stirred for 1 hour, and 36 mg of the sodiumborohydride was added and the mixture was stirred for 1 hour again. Thereaction solution was poured into 1M aqueous HCl, alkalinized withsaturated aqueous NaHCO₃, and extracted with chloroform, and the organiclayer was dried over MgSO₄. The solvent was evaporated under reducedpressure, and the obtained residue was purified by silica gel columnchromatography (chloroform-MeOH=100:1˜20:1) and the obtained compoundwas dissolved in EtOAc, and then 0.5M HCl-EtOAc solution was addedthereto and the thus-produced precipitate was collected by filtration toobtain 73 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-hydroxymethylbenzamidehydrochloride.

EXAMPLE 21

To a suspension of 279 mg of the compound of Example 141 in 10 ml oftoluene, 1.81 g of tributyltin azide was added, and the mixture washeated under reflux for 14 hours. And, diethylether, 1M aqueous NaOH,EtOAc, and conc. HCl were added thereto. The thus-produced precipitatewas collected by filtration and dried under reduced pressure, and thendissolved in 1M aqueous NaOH and MeOH, and washed with diethylether. Tothe aqueous layer, conc. HCl was added at 0° C., and the thus-producedprecipitate was collected by filtration to obtain 138 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(1H-tetrazol-5-ylmethyl)benzamide.

EXAMPLE 22

0.15 g of the compound of Example 149 was dissolved in 10 ml of THF, 0.1ml of triethylamine and a solution of 40 mg of methyl chloroformate in 2ml of THF were sequentially added thereto under ice cooling, and themixture was stirred at room temperature overnight. The reaction solutionwas concentrated, mixed with water, and extracted with EtOAc. Theobtained organic layer was washed with brine, and dried over anhydroussodium sulfate. The solvent was concentrated under reduced pressure, andthe thus-obtained residue was recrystallized from EtOAc to obtain 0.12 gofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(methoxycarbonylaminomethyl)benzamide.The obtained compound was suspended in 5 ml of EtOAc, 0.6 ml of 0.4MHCl-EtOAc solution was added thereto under ice cooling, and the mixturewas stirred overnight. The thus-precipitated solid was filtered anddried to obtain 115 mg ofN-[5-(4-cylcohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(methoxycarbonylaminomethyl)benzamidehydrochloride.

EXAMPLE 23

0.15 g of the compound of Example 149 was suspended in 5 ml of THF, 0.2ml of triethylamine and a solution of 35 mg of methanesulfonyl chloridein 2 ml of THF were sequentially added thereto under ice cooling, andthe mixture was stirred at room temperature for 3 hours. The reactionsolution was concentrated, mixed with water, and extracted with EtOAc.The obtained organic layer was washed with brine, and dried overanhydrous sodium sulfate. The solvent was concentrated under reducedpressure, and the thus-obtained residue was recrystallized fromEtOAc-hexane mixed solvent to obtain 0.12 g ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(methanesulfonylaminomethyl)benzamide.The obtained compound was suspended in 5 ml of EtOAc, 0.2 ml of 1MHCl-EtOAc solution was added under ice cooling, and the mixture wasstirred overnight. The thus-precipitated solid was filtered and dried toobtain 111 mg ofN-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-(methanesulfonylaminomethyl)benzamidehydrochloride.

EXAMPLE 24

To a solution of 57 mg of the compound of Example 168 in 2 ml ofpyridine, 18 μl of methyl chlorooxoacetate were added, and the mixturewas stirred from 0° C. to room temperature for 2 hours. After thesolvent was evaporated under reduced pressure, the residue was mixedwith saturated aqueous NaHCO₃ and extracted with chloroform, and theorganic layer was dried over MgSO₄. Then, the solvent was evaporatedunder reduced pressure, and the obtained residue was purified by silicagel column chromatography (eluent: chloroform-MeOH=100 1). And,diisopropyl ether was added thereto, and the thus-produced precipitatewas collected by filtration to obtain 19 mg of methylN-(4-{[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]carbamoyl}phenyl)oxamate.

EXAMPLE 25

To a suspension of 71 mg of the compound of Example 168 in 5 ml of DMF,71 mg of 3-methoxypropionic acid, 120 mg of HOBt, and 180 mg of WSC.HClwere added, and the mixture was stirred from room temperature to 50° C.for 29 consecutive days. After the solvent was evaporated under reducedpressure, the residue was mixed with saturated aqueous NaHCO₃ andextracted with chloroform, and the organic layer was dried over MgSO₄.Then, the residue obtained by the evaporation of the solvent waspurified by silica gel column chromatography(chloroform-MeOH=100:1˜50:1). And, the obtained compound was dissolvedin MeOH and 1M aqueous HCl, and purified by ODS column chromatography(0.001M HCl aq-MeOH=2:1˜1:1), and then mixed with saturated aqueousNaHCO₃ and extracted with chloroform. After the organic layer was driedover MgSO₄, the solvent was evaporated, diisopropyl ether was addedthereto, and the thus-produced precipitate was collected by filtrationto obtain 20 mg of N-[5-(4-cyclohexypiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-[(3-methoxypropanoyl)amino]benzamide.

EXAMPLE 26

To a solution of 1.00 g of the compound of Example 83 in 15 ml of aceticacid, a total of 886 mg of palladium hydroxide-carbon (20 wt %) wasadded, and the mixture was stirred under a hydrogen atmosphere for 2consecutive days. After celite filtration of the reaction solution,acetic acid was evaporated and saturated aqueous NaHCO₃ was added to theobtained residue. The thus-produced precipitate was collected byfiltration, and dried under reduced pressure to obtain 505 mg ofN-[4-(4-fluorophenyl)-5-(piperazin-1-yl)thiazol-2-yl]-2-methoxyisonicotinamide.

EXAMPLE 27

To a suspension of 202 mg of the compound of Example 26 and 207 mg ofpotassium carbonate in 15 ml of DMF, 46 μl of allyl bromide was added at0° C., the temperature was slowly elevated, and the mixture was stirredat room temperature overnight. After the evaporation of the solventunder reduced pressure, the reaction solution was mixed with water,extracted with chloroform, and the organic layer was dried over MgSO₄.Then, the residue obtained by the evaporation of the solvent underreduced pressure was purified by silica gel column chromatography(chloroform-MeOH=300:0˜100:1) and the obtained compound was dissolved inEtOAc, a 0.5 M HCl-EtOAc solution was added thereto, and thethus-produced precipitate was collected by filtration to obtain 165 mgofN-[5-(4-allylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 28

To a solution of 178 mg of the compound of Example 56 in 4 ml ofchloroform, 90 mg of m-chloroperbenzoic acid (mCPBA) was added under icecooling, and the mixture was stirred at room temperature overnight. And,MeOH, saturated aqueous NaHCO₃, and chloroform were added thereto, andinsoluble matter was removed by filtration, and then the reactionsolution was extracted with chloroform. After drying over MgSO₄, thesolvent was evaporated under reduced pressure. The thus-obtained residuewas purified by silica gel column chromatography(chloroform-MeOH=300:1˜100:1) and the obtained compound was suspended inEtOAc, and 0.5M HCl-EtOAc solution was added thereto, and thethus-produced precipitate was collected by filtration to obtain 39 mg ofN-[4-(4-chloro-2-thienyl)-5-(1-oxidothiomorpholino)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 29

To a solution of 185 mg of the compound of Example 75 in 4 ml of aceticacid, 100 μl of hydrogen peroxide (30%) was added, and the mixture wasstirred at room temperature overnight. And, saturated aqueous NaHCO3, 1Maqueous NaOH, and 1M aqueous HCl were added thereto, and thethus-produced precipitate was collected by filtration. Chloroform andMeOH were added thereto to dissolve it, and the solution was mixed withsaturated aqueous NaHCO₃ and extracted with chloroform. After dryingover MgSO₄, the solvent was evaporated under reduced pressure. Thethus-obtained residue was purified by silica gel column chromatography(chloroform-MeOH=300:1˜100:1) and the obtained compound was suspended inEtOAc, a 0.5M HCl-EtOAc solution was added thereto, and thethus-produced precipitate was collected by filtration to obtain 47 mg ofN-{4-(4-chlorothiophen-2-yl)-5-[4-(1-oxidothiomorpholino)piperidino]thiazol-2-yl}-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 30

To a solution of 268 mg of the compound of Reference Example 41 in 8 mlof pyridine, 241 mg of the compound of Reference Example 127 were added,72 μl of phosphorous oxychloride were added at −25° C., the temperaturewas elevated to room temperature, and the mixture was stirred for 1.5hours. After evaporation of the solvent under reduced pressure, theresidue was mixed with water and potassium carbonate and extracted withchloroform. The organic layer was washed with brine and dried oversodium sulfate. The residue obtained by the evaporation of the solventunder reduced pressure was purified by silica gel column chromatography(chloroform-MeOH=200:1˜100:1) and the obtained compound was dissolved inEtOAc, a 0.1M HCl-EtOAc solution was added-thereto, and thethus-produced precipitate was collected by filtration to obtain 137 mgof3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cycohexylpiperazin-1-yl)thiazol-2-yl]-4-(2,3-dihydroxypropoxy)benzamidehydrochloride.

EXAMPLE 31

To a solution of 132 mg of the compound of Example 244 in 5 ml of MeOH,61 mg of potassium carbonate were added, and the mixture was stirred atroom temperature for 1.5 hours. The solvent was evaporated under reducedpressure, and the residue was mixed with water and extracted withchloroform. The organic layer was washed with brine and dried oversodium sulfate. The residue obtained by the evaporation of the solventunder reduced pressure was purified by silica gel column chromatography(chloroform-MeOH=200:1˜50:1) and the obtained compound was dissolved inEtOAc, a 0.1 M HCl-EtOAc solution was added thereto, and thethus-produced precipitate was collected by filtration to obtain 77 mg ofN-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)-3-methylbenzamidehydrochloride.

EXAMPLE 32

To a solution of 255 mg of the compound of Example 56 in 10 ml ofchloroform, 303 mg of mCPBA were added, and the mixture was stirred atroom temperature for 3 days. And, MeOH, saturated aqueous NaHCO₃, andchloroform were added thereto, insoluble matter was removed byfiltration, and then the reaction solution was extracted withchloroform. The organic layer was dried over MgSO₄, and the solvent wasevaporated under reduced pressure. The obtained residue was purified bysilica gel column chromatography (chloroform-MeOH=300:1) and theobtained compound was suspended in EtOAc, a 0.5M HCl-EtOAc solution wasadded thereto, and the thus-produced precipitate was collected byfiltration to obtain 130 mg of N-[4-(4-chloro-2-thienyl)-5-(1,1-dioxidothiomorpholino)thiazol-2-yl]-2-methoxyisonicotinamidehydrochloride.

EXAMPLE 33

To a solution of 0.35 g of the compound of Example 210 in 15 ml of DMF,0.2 ml of triethylamine, 32 mg of diphenylphosphinoferrocene, and 13 mgof palladium acetate were added at room temperature, and the mixture wasstirred under a carbon monoxide atmosphere at 70° C. for 1 day. Afterthe solvent was evaporated under reduced pressure, the residue was mixedwith water and extracted with chloroform, and the organic layer wasdried over MgSO₄. The residue obtained by the evaporation of the solventunder reduced pressure was purified by silica gel column chromatography(chloroform-MeOH=100:0˜98:2) and the obtained compound was dissolved in5 ml of MeOH, 0.1 ml of 4M HCl-EtOAc solution was added thereto, and thethus-produced precipitate was collected by filtration to obtain 102 mgofN-[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-2-methoxycarbonylquinoline-6-carboxamidehydrochloride.

EXAMPLE 34

To a solution of 0.27 g of the compound of Example 213 in 10 ml oftrifluoroacetic acid, 0.36 g of pentamethylbenzene was added at roomtemperature, and the mixture was stirred at room temperature for 6 days.After the solvent was evaporated under reduced pressure, the residue wasmixed with water, neutralized with potassium carbonate, and extractedwith chloroform, and the organic layer was dried over MgSO₄. The residueobtained by the evaporation of the solvent under reduced pressure waspurified by silica gel column chromatography(chloroform-MeOH=100:0˜97:3) and the obtained compound was dissolved in5 ml of EtOAc, 0.47 ml of a 1M HCl-EtOAc solution was added thereto, andthe thus-produced precipitate was collected by filtration to obtain 148mg ofN-[4-(4-chloro-2-thienyl)-5-(4-cycohexylpiperazin-1-yl)thiazol-2-yl]-7-hydroxyquinoline-3-carboxamide hydrochloride.

EXAMPLE 35

To a solution of 0.30 g of the compound of Example 217 in 5 ml of MeOH,2.0 ml of conc. HCl were added at room temperature, and the mixture wasstirred at 70° C. for 3 days. The reaction solution was cooled to roomtemperature, and the thus-produced precipitated was collected byfiltration to obtain 122 mg of4-amino-3-chloro-N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]benzamidehydrochloride.

EXAMPLE 36

To 350 mg of the compound of Example 5, 5 ml of DMF, 0.5 ml ofpiperidin-4-ylacetic acid ethyl ester, and 1.0 ml of triethylamine wereadded, and the mixture was stirred at 80° C. for 8.5 hours. The solventwas evaporated, and the residue was mixed with 40 ml of water andextracted with chloroform. The organic layer was washed with brine anddried over sodium sulfate to evaporate the solvent. 10 ml of EtOH wasadded thereto to dissolve it, 0.5 ml of a 1M aqueous NaOH was added atroom temperature, and the mixture was stirred at room temperature for 2days, and then 0.5 ml of 1M aqueous NaOH was added thereto and themixture was stirred at room temperature for 5 hours. To the reactionsolution, 3 ml of 1M aqueous HCl were added at room temperature, themixture was stirred for a while, and the thus-precipitated solid wasfiltered and dried to obtain 58 mg of[1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperidin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)-4-piperidyl]aceticacid hydrochloride.

EXAMPLE 37

To 272 mg of the compound of Example 356, 10 ml of THF, 10 ml of1,4-dioxane, 50.5 mg of potassium cyanate, and 0.5 ml of 1M HCl wereadded, and the mixture was stirred at 40° C. for 5 hours and at 80° C.for 13 hours. Then, 2 ml of 1M HCl were added thereto at roomtemperature, and the mixture was stirred at 80° C. for 10 minutes. Thesolvent was evaporated under reduced pressure. The obtained residue wasmixed with 40 ml of saturated aqueous NaHCO₃, and extracted withchloroform. The organic layer was washed with brine and dried oversodium sulfate to evaporate the solvent. The obtained residue waspurified by silica gel column chromatography (chloroform-MeOH =5:1˜1:1)and the obtained compound was dissolved in 60 ml of MeOH, 80 ml ofchloroform, and 10 ml of 1,4-dioxane. And, 4 ml of 4M HCl was addedthereto, and the mixture was stirred for a while, and then the solventwas evaporated under reduced pressure, and the residue was washed withdiethylether to obtain 102 mg of4-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperazin-1-carboxamidehydrochloride.

EXAMPLE 38

To a solution of 1.20 g of the compound of Example 331 in 40 ml of THF,1.29 ml of triethylamine were added, 0.57 ml of trifluoroacetic acidanhydride was added under ice cooling, the temperature was elevated toroom temperature, and the mixture was stirred for 3 days. The solventwas evaporated under reduced pressure, the residue was mixed withsaturated aqueous NaHCO₃, and extracted with chloroform-MeOH (7:3). Theorganic layer was washed with brine and dried over sodium sulfate. Theresidue obtained by the evaporation of the solvent under reducedpressure was purified by silica gel column chromatography(hexane-EtOAc=6:1˜1:1, hexane-THF=1:1˜0:1) and the obtained compound waswashed with chloroform to obtain 882 mg of5-choro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-cyanopiperidin-1-yl)nicotinamide.

120 mg of the obtained compound were suspended in THF-MeOH, 0.1MHCl-EtOAc solution was added thereto, and the solvent was evaporatedunder reduced pressure. Then, EtOH-diethylether was added to theresidue, and the thus-produced precipitate was collected by filtrationto obtain 106 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-cyanopiperidin-1-yl)nicotinamidehydrochloride.

EXAMPLE 39

To a solution of 300 mg of the compound of Example 16 in 6 ml of THF, 56μl of N-methylmorpholine was added, 60 μl of isobutyl chloroformate wasadded at −15° C., and the mixture was stirred for 2 hours. To a solutionof 219 mg of methanesulfonamide in 4 ml of THF, 74 mg of sodium hydridewas added, and the mixture was stirred at room temperature for 2 hoursto prepare a suspension. The prepared suspension was added to thereaction solution, and the mixture was stirred at room temperature for 2hours and at 50° C. for 20 hours. The reaction solution was cooled toroom temperature, and the thus-precipitated solid was collected byfiltration, washed with THF, purified by silica gel columnchromatography (chloroform-MeOH=100:0˜5:1) and the obtained compound wassuspended in EtOH. Then, a 0.4 M HCl-EtOAc solution was added thereto,and the thus-produced precipitate was collected by filtration to obtain119 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexypiperazin-1-yl)thiazol-2-yl]-6-[4-(N-methanesulfonylcarbamoyl)piperidin-1-yl]nicotinamidehydrochloride.

EXAMPLE 40

To a solution of 300 mg of the compound of Example 16 in 6 ml of THF, 56μl of N-methylmorpholine were added, 60 μl of isobutyl chloroformate wasadded at −15° C., and the mixture was stirred for 1.5 hours. And, to asolution of 96 mg of methanesulfonamide in 4 ml of THF, 348 μl of1,8-diazabicyclo[5,4,0]-7-undecene was added, and the mixture wasstirred at room temperature for 19 hours and at 50° C. for 2 days. Thereaction solution was mixed with saturated aqueous NaHCO₃ and extractedwith EtOAc. The organic layer was washed with brine and dried oversodium sulfate. The residue obtained by the evaporation of the solventunder reduced pressure was purified by silica gel column chromatography(hexane-THF=2:1˜0:1) and then by silica gel column chromatography(chloroform-MeOH=100:0˜100:3), and the obtained compound was dissolvedin chloroform-EtOH. A 0.1M HCl-EtOAc solution was added thereto, thesolvent was evaporated under reduced pressure, EtOH-diethylether wasadded thereto, and the thus-produced precipitate was collected byfiltration to obtain 30 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-(3-[2-(methanesulfonylimino)azepin-1-yl]propylaminocarbonyl)piperidin-1-yl)nicotinamidehydrochloride.

EXAMPLE 41

To 1.8 ml of a solution of the compound of Example 16 in THF (0.0856mM), 70 mg of sarcosine ethyl ester hydrochloride, 342 mg of PS-DCC(1.35 mmol/g), 0.2 ml of a solution of HOBt in THF (0.77 mM), and 60 μlof triethylamine were added, and the mixture was stirred at roomtemperature overnight. To the reaction solution, 2 ml of THF, 370 mg ofPS-isocyanate (1.25 mmol/g), and 205 mg of PS-trisamine (3.75 mmol/g)were added, and the mixture was stirred at room temperature for 1 hour.The reaction solution was filtered, and the obtained residue waspurified by silica gel column chromatography (chloroform-MeOH=99:1-97:3)and the obtained compound was dissolved in 2 ml of EtOAc. And, 1 ml of4M HCl-AcOEt was added thereto at room temperature, and the mixture wasstirred for 15 minutes. The thus-precipitated solid was collected byfiltration and dissolved in 2 ml of EtOH, 0.2 ml of 1M aqueous NaOH wasadded thereto, and the mixture was stirred at 50° C. for 160 minutes,and then 0.6 ml of 1M aqueous HCl was added thereto at room temperature,and the mixture was stirred overnight. The thus-precipitated solid wascollected by filtration to obtain 49 mg of[{[1-(3-chloro-5-{[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thizaol-2-yl]carbamoyl}-2-pyridyl)-4-piperazyl]carbonyl}(methyl)amino]aceticacid hydrochloride.

EXAMPLE 42

To a solution of the compound of Example 16 in 1.8 ml of THF (0.0856mM), 39 mg of morpholine, 342 mg of PS-DCC (1.35 mmol/g), and 0.2 ml ofa solution of HOBt in THF (0.77 mM) were added, and the mixture wasstirred at room temperature overnight. To the reaction solution, 2 ml ofTHF, 370 mg of PS-isocyanate (1.25 mmol/g), and 205 mg of PS-trisamine(3.75 mmol/g) were added, and the mixture was stirred at roomtemperature for 1 hour. The reaction solution was filtered, and theobtained residue was purified by silica gel column chromatography(chloroform-MeOH=99:1˜97:3) and the obtained compound was dissolved in 2ml of EtOAc. And, 1 ml of 4M HCl-EtOAc was added thereto at roomtemperature, and the mixture was stirred for 15 minutes. Thethus-precipitated solid was collected by filtration to obtain 84 mg of5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[4-(morpholinocarbonyl)piperidino]nicotinamidehydrochloride.

The structures and physical properties of the compounds of Examples areshown in Tables 11-21. Symbols in the Tables have the following meaning.

-   Ex: Example number (In case only Example number is described in Ex.    column, the compound is hydrochloride, and in case a slant line (/)    and symbol are described after Example number, /AcOH: indicates    acetate; /TFA indicates trifluoroacetate; and /free indicates a free    body.)-   Syn: Synthesis method (The number indicates the Example number used    for is)

R^(A), R^(B), R^(C), R^(D), R^(E), R^(F), R^(G), R^(H), R^(I):substituent groups in the general Formula (nPen: normal pentyl, cPen:cyclopentyl, vinyl: vinyl, naph: naphthyl, Ms: methanesulfonyl, oxo:oxo, Py: pyridyl, pra: pyrazol-3-yl, ttrz: tetrazol-5-yl, bimid:benzoimidazol-1-yl, oxido: oxido, di and tri: respectively di and tri(indicating that 2 or 3 substituent groups substitute) TABLE 11

Ex R^(A); R^(B); R^(C) Data  1 R^(A): 4-cyano-Ph; R^(B): 4-F-Ph; R^(C):4-cHex-pipa 490.  2 R^(A): 2-MeO-4-py; R^(B): 5-Cl-2-The; R^(C):4-cHex-pipa 518.  3 R^(A): 2-MeO-4-py; R^(B): 5-Cl-2-The; R^(C):4-nPr-pipe 477.  4 R^(A): 3-Cl-4-HO(CH₂)₂O-Ph; R^(B): 4-F-Ph; R^(C):4-cHex-pipa 559.  5/free R^(A): 5,6-diCl-3-py; R^(B): 4-Cl-2-The; R^(C):4-cHex-pipa 556.  6 R^(A): 5-Cl-6-HO-3-py; R^(B): 4-Cl-2-The; R^(C):4-cHex-pipa 538. 7/TFA R^(A): 3-Cl-4-HOCH₂CH(Me)O-Ph; R^(B): 4-Cl-2-The;R^(C): 4-cHex-pipa 595.  8 R^(A): 3-F-4-HO-Ph; R^(B): 4-Cl-2-The; R^(C):4-cHex-pipa 521.  9 R^(A): 3-Cl-4-HO(CH₂)₂O-Ph; R^(B): 4-Cl-2-The;R^(C): 4-cHex-pipa 581. 10/AcOH R^(A): 2-MeO-4-py; R^(B): 4-Cl-2-The;R^(C): pipa 436. 11 R^(A): 2-MeO-4-py; R^(B): 2-The; R^(C): 4-cHex-pipa484. 12 R^(A): 5-Cl-6-HO(CH₂)₂O-3-py; R^(B): 4-Cl-2-The; R^(C):4-cHex-pipa 582. 13/free R^(A): 5-Cl-6-(4-(EtO₂C)-pipe)-3-py; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 677. 14 R^(A): 2-MeO-4-py; R^(B):4-Cl-2-The; R^(C): 4-Bn-pipa 526. 15 R^(A): 4-H₂NCH₂-Ph; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 516. 16 R^(A):5-Cl-6-(4-(HO₂C)-pipe)-3-py; R^(B): 4-Cl-2-The; R^(C): 4-cHex-pipa 649.17 R^(A): 4-((H₂NOC)-CH₂)-Ph; R^(B): 4-F-Ph; R^(C): 4-cHex-pipa 522. 18

576. 19 R^(A): 2,3-diHO-guinoxalin-6-yl; R^(B): 4-F-Ph; R^(C):4-cHex-pipa 549. 20 R^(A): 4-HOCH₂-Ph; R^(B): 4-F-Ph; R^(C): 4-cHex-pipa495. 21/free R^(A): 4-(ttrz-CH₂)-Ph; R^(B): 4-F-Ph; R^(C): 4-cHex-pipa547. 22 R^(A): 4-((MeO₂C)-HNCH₂)-Ph; R^(B): 4-F-Ph; R^(C): 4-cHex-pipa552. 23 R^(A): 4-MsHNCH₂-Ph; R^(B): 4-F-Ph; R^(C): 4-cHex-pipa 572.24/free R^(A): 4-((MeO₂C)—OCHN)-Ph; R^(B):4-F-Ph; R^(C): 4-cHex-pipa566. 25/free R^(A): 4-(MeO(CH₂)₂—(OCHN))-Ph; R^(B): 4-F-Ph; R^(C):4-cHex-pipa 566. 26 R^(A): 2-MeO-4-py; R^(B): 4-F-Ph; R^(C): pipa 414.27 R^(A): 2-MeO-4-py; R^(B): 4-F-Ph; R^(C): 4-allyl-pipa 454. 28 R^(A):2-MeO-4-py; R^(B): 4-Cl-2-The; R^(C): 1-oxido-tmor 469. 29 R^(A):2-MeO-4-py; R^(B): 4-Cl-2-The; R^(C): 4-(1-oxido-tmor)-pipe 552. 30R^(A): 3-Cl-4-(HOCH₂CH(OH)CH₂O)-Ph; R^(B): 4-Cl-2-The; 611. R^(C):4-cHex-pipa 31 R^(A): 3-Me-4-HO(CH₂)₂O-Ph; R^(B): 4-Cl-2-The; R^(C):4-cHex-pipa 561. 32 R^(A): 2-MeO-4-py; R^(B): 4-Cl-2-The; R^(C):1,1-dioxido-tmor 485. 33 R^(A): 2-MeO₂C-quinolin-6-yl; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 595. 34 R^(A): 7-HO-quinolin-3-yl; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 554. 35 R^(A): 3-Cl-4-H₂N-Ph; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 536. 36 R^(A):5-Cl-6-(4-((HO₂C)—CH₂)-pipe)-3-py; R^(B): 4-Cl-2-The; 663. R^(C):4-cHex-pipa 37 R^(A): 5-Cl-6-(4-(H₂NOC)-pipa)-3-py; R^(B): 4-Cl-2-The;R^(C): 4-cHex-pipa 649. 38 R^(A): 5-Cl-6-(4-cyano-pipe)-3-py; R^(B):4-Cl-2-The; R^(C): 4-cHex-pipa 630. 39 R^(A):5-Cl-6-(4-(MsHN-OC)-pipe)-3-py; R^(B): 4-Cl-2-The; 726. R^(C):4-cHex-pipa 40

878. 41 R^(A): 5-Cl-6-(4-((HO₂C)—CH₂-(Me)NOC)-pipe)-3-py; R^(B):4-Cl-2-The; 720. R^(C): 4-cHex-pipa 42 R^(A):5-Cl-6-(4-(mor-OC)-pipe)-3-py; R^(B): 4-Cl-2-The; R^(C): 4-cHex-pipa718.

TABLE 12

Ex R^(A) R^(B) R^(C) MS Syn 43 3,5-diMeO-Ph 4-F-Ph —N(Me)((CH₂)₂OMe)446. 2 44 3,5-diMeO-Ph 4-F-Ph —N(Me)((CH₂)₂NMe₂) 459. 2 45 3,5-diMeO-Ph4-F-Ph —N(Me)((CH₂)₃NMe₂) 473. 2 46 3,5-diMeO-Ph 4-F-Ph—N(Me)((CH₂)₂N(Me)(cHex)) 527. 2 47 3,5-diMeO-Ph 4-F-Ph—N(Me)((CH₂)₂-pipe) 499. 2 48 2-MeO-4-py 4-Cl-2-The —N(Me)((CH₂)₃-mor)508. 5 49 2-MeO-4-py 4-Cl-2-The —N(Me)(1-nBu-pyrrolidin-3-yl) 506. 5 502-MeO-4-py 4-Cl-2-The —N(Me)(1-nBu-piperidin-4-yl) 520. 5 51 2-MeO-4-py4-Cl-2-The —N(Me)(quinuclidin-3-yl) 490. 5 52 2-MeO-4-py 4-Cl-2-The—N(cHex)((CH₂)₂-mor) 562. 5

TABLE 13

Ex R^(A) R^(B) R^(C) MS Syn 53 2-MeO-4-py 4-F-Ph imid 396. 2 542-MeO-4-py 4-F-Ph 4-Ph-imid 472. 2 55 2-MeO-4-py 4-F-Ph 3-pipe-azet 468.2 56 2-MeO-4-py 4-Cl-2-The tmor 453. 5 57 2-MeO-4-py 4-Cl-2-The3-(4-nPr-pipe)-azet 532. 5 58 quinolin-6-yl 4-Cl-2-The mor 457. 5

TABLE 14

Ex R^(A) R^(B) R^(D) MS Syn 59 2-MeO-4-py 4-F-Ph 4-nPr 455. 3 602-MeO-4-py 4-F-Ph 4-nPrO 471. 3 61 2-MeO-4-py 4-F-Ph 4-mor 498. 2 622-MeO-4-py 4-F-Ph 4-Ph-4-AcHN MM; 545. 3 63 guinolin-6-yl 4-F-Ph 4-nPr475. 2 64 3-F-4-HO-Ph 4-Cl-2-The 4-nPr 480. 8 65/free 3-F-4-MeOCH₂O-4-Cl-2-The 4-nPr 524. 5 Ph 66 2-MeO-4-py 4-Cl-2-The 4-nPr 477. 5 67guinolin-6-yl 4-Cl-2-The 4-nPr 497. 5 68 2-MeO-4-py 4-Cl-2-The2-((Me₂N)—CH₂) 492. 5 69 2-MeO-4-py 4-Cl-2-The 3-((Me₂N)—CH₂) 492. 5 702-MeO-4-py 4-Cl-2-The 4-(Me)(nPr)N 506. 5 71 2-MeO-4-py 4-Cl-2-The4-(Me)(cHex)N 546. 5 72 2-MeO-4-py 4-Cl-2-The 4-(Me)((F₃C)—CH2)N 546. 573 2-MeO-4-py 4-Cl-2-The 4-(Me)((F₃C)—(CH₂)₂)N 560. 5 74 2-MeO-4-py4-Cl-2-The 4-mor 520. 5 75 2-MeO-4-py 4-Cl-2-The 4-tmor 536. 5 762-MeO-4-py 4-Cl-2-The 4-pipe 518. 5 77/free 5,6-diCl-3-py 4-Cl-2-The4-pipe 556, 558. 5 78/free 5,6-diCl-3-py 4-Cl-2-The 4-(3-F-pyrr) 560. 579 guinolin-6-yl 5-Cl-2-The 4-nPr 497. 3 80 quinolin-6-yl 5-Cl-2-The

495. 3

TABLE 15

Ex R^(A) R^(B) R^(E) MS Syn 81/free 2-MeO-4-py 4-F-Ph 4-((HO₂C)—CH₂)472. 16 82/free 2-MeO-4-py 4-F-Ph 4-((EtO₂C)—CH₂) 500. 27 83 2-MeO-4-py4-F-Ph 4-BnO₂C 547. 2 84 2-MeO-4-py 4-F-Ph 4-(cyano-CH₂) MM; 452. 27 852-MeO-4-py 4-F-Ph 4-((Me₂N)—(CH₂)₂) 485. 27 86 2-MeO-4-py 4-F-Ph(trans)-2,5-diMe-4-nBu 498. 3 87 2-MeO-4-py 4-Cl-2-The 3-oxo 450. 5 882-MeO-4-py 4-Cl-2-The 4-nPr 478. 5 89 2-MeO-4-py 4-Cl-2-The 4-nBu 492.14 90 2-MeO-4-py 4-Cl-2-The (3R*,5S*)-3,5-diMe-4-nPr 506. 5 91/free2-MeO-4-py 4-Cl-2-The 4-((HO₂C)—CH₂) 494. 16 92 2-MeO-4-py 4-Cl-2-The4-((EtO₂C)—CH₂) 522. 14 93 2-MeO-4-py 4-Cl-2-The 4-((Me₂NOC)—CH₂) 521.25 94 2-MeO-4-py 4-Cl-2-The 4-((pipe-OC)—CH₂) 561. 25 95 2-MeO-4-py4-Cl-2-The 4-((2-py)-CH₂) 527. 14 96 2-MeO-4-py 4-Cl-2-The4-((2-The)-CH₂) 532. 14 97 2-MeO-4-py 4-Cl-2-The 4-((2-oxo-pyrr)-(CH₂)₂)547. 27 98 2-MeO-4-py 4-Cl-2-The 4-cPen 504. 14 99 2-MeO-4-py 4-Cl-2-The4-(4-Et-cHex) 546. 14 100  2-MeO-4-py 4-Cl-2-The 4-cHept 532. 5 101 2-MeO-4-py 4-Cl-2-The 4-(allyl-O₂C) 519. 5 102  2-MeO-4-py 4-Cl-2-The4-(tetrahydro-2H-pyran-4-yl) 520. 14 103  3-Cl-4- 4-Cl-2-The 4-nPr 541.9 HO(CH₂)₂O- Ph 104/free 5,6-diCl-3-py 4-Cl-2-The 4-nPr 516. 5 105 5-Cl-6- 4-Cl-2-The 4-nPr 541. 13 HO(CH₂)₂H N-3-py

TABLE 16

Ex R^(A) R^(B) MS Syn 106 2-MeO-4-py 3-F₃C-Ph 546. 5 107 2-MeO-4-py4-F₃C-Ph 546. 2 108 2-MeO-4-py 4-HO₂C-Ph 522. 16 109 2-MeO-4-py4-H₂NOC-Ph 521. 17 110 2-MeO-4-py 3-cyano-Ph 503. 5 111 2-MeO-4-py4-cyano-Ph 503. 2 112 2-MeO-4-py 4-Me₂N-Ph 521. 2 113 2-MeO-4-py4-O₂N-Ph 523. 2 114/free 5,6-diCl-3-py 3-Cl-Ph 550. 5 115/free5,6-diCl-3-py 3-F₃C-Ph 584. 5 116 2-MeO-4-py 5-Me-2-Fur 482. 2 1172-MeO-4-py 3-F-2-The 502. 5 118 2-MeO-4-py 4-F-2-The 502. 5 1192-MeO-4-py 5-F-2-The 502. 5 120 2-MeO-4-py 3-Cl-2-The 518. 5 1213-F-4-HO-Ph 5-Cl-2-The 521. 8 122/free 3-F-4-MeOCH₂O-Ph 5-Cl-2-The 5 1233-F-4-MeO(CH₂)₂O-Ph 5-Cl-2-The 579. 3 124 3,5-diF-4-MeO(CH₂)₂O-5-Cl-2-The 597. 3 Ph 125 3-Cl-4-HO(CH₂)₂O-Ph 5-Cl-2-The 581. 9 1263-Cl-4-MeO(CH₂)₂O-Ph 5-Cl-2-The 595. 3 127/free 3-Cl-4-TBSO(CH₂)₂O-Ph5-Cl-2-The 695. 5 128 2-Cl-6-Me-4-py 5-Cl-2-The 536. 3 1292-Cl-6-MeO-4-py 5-Cl-2-The 552. 3 130 5-MeO-3-py 5-Cl-2-The 518. 3 1312-MeO-6-Me-4-py 5-Cl-2-The 532. 3 132/free 2,6-diMeO-pyrimidin-4-yl5-Cl-2-The 549. 3 133 quinolin-6-yl 5-Cl-2-The 538. 3 134 2-MeO-4-py5-Cl-3-The 518. 5 135 2-MeO-4-py 4-Br-2-The 562, 564. 5 136 2-MeO-4-py5-Br-2-The 562, 564. 2 137 2-MeO-4-py 4-F-5-Cl-2-The 536. 5 1382-MeO-4-py 4,5-diCl-2-The 552. 5 139 2-MeO-4-py 4-Me-2-The 498. 5 1402-MeO-4-py 5-Me-2-The 498. 2

TABLE 17

Ex R^(A) MS Syn 141 4-(cyano-CH₂)-Ph 504. 2 142 3-((HO₂C)—CH₂)-Ph 523.16 143 4-((HO₂C)—CH₂)-Ph 523. 16 144 3-((MeO₂C)—CH₂)-Ph 537. 5 1454-((MeO₂C)—CH₂)-Ph 537. 5 146 3-((H₂NOC)—CH₂)-Ph 522. 17 147

604. 2 148/free 4-AcOCH₂-Ph 537. 2 149 4-H2NCH₂-Ph 494. 15 1504-AcHNCH₂-Ph 536. 2 151/free 4-BocHNCH₂-Ph 594. 2 1524-((H₂NOC)—HNCH₂)-Ph 537. 2 153 4-((H₂NO₂S)—HNCH₂)-Ph 573. 2 1544-HO-3-(mor-CH₂)-Ph 580. 2 155 4-((2-oxo-pyrr)-CH₂)-Ph 562. 2 1564-(cyano-(CH₂)₂)-Ph 518. 5 157 4-((E)-2-cyanovinyl)-Ph 516. 5 1583-F-4-F₃C-Ph 551. 1 159 3-F-4-((Me₂N)—CH₂)-Ph 540. 2 160 3-cyano-Ph 490.1 161 3-Cl-4-((HO₂C)—CH₂O)-Ph 573. 16 162 3-Cl-4-((MeO₂C)—CH₂O)-Ph 587.2 163 3-Cl-4-MeO(CH₂)₂O-Ph 573. 2 164 3-F-4-((Me₂N)—(CH₂)₂O)-Ph 540. 2165 4-PhO-Ph 557. 2 166 4-(4-HO—PhO)-Ph 573. 8 167/free4-(4-MeOCH₂O—PhO)-Ph 617. 5 168/free 4-H₂N-Ph 480. 9 169/free 4-BocHN-Ph580. 2 170 4-MsHN-Ph 558. 2 171 4-((HO₂C)—CH₂HN)-Ph 538. 16 172/free4-((EtO₂C)—CH₂HN)-Ph 566. 14 173/free 4-(MeOCH₂—(OCHN))-Ph 552. 24 1744-((HO₂C)—(OCHN))-Ph 552. 16 175 4-mor-Ph 550. 5 176 4-pipa-Ph 549. 15177 4-(4-Me-pipa)-Ph 563. 14 178 4-(4-Ac-pipa)-Ph 591. 5 179/free4-(4-Boc-pipa)-Ph 649. 5 180/free 4-HO₃S-Ph 545. 2 181 2-naph 515. 1 1826-HO-2-naph 531. 2 183/free 5,6-diCl-3-py 534. 5 1841,3-benzodioxolan-5-yl 509. 1 1853-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl 536. 5 186/free 1H-indol-5-ylMM; 503. 2 187 2-Me-isoindolin-5-yl 520. 2 188 5-bimid 505. 2 189quinolin-2-yl 516. 2 190 quinolin-3-yl 516. 2 191 quinolin-4-yl 516. 5192 quinolin-6-yl 516. 2 193 quinolin-7-yl 516. 5 194 2-HO-quinolin-6-yl532. 2 195 2-MeO-quinolin-6-yl 546. 5 196 isoquinolin-3-yl 516. 2 197isoquinolin-7-yl 516. 5 198/free 2,3-diBnO-quinoxalin-6-yl 729. 5 199imidazo[1,2-a]pyridin-6-yl 505. 2

TABLE 18

Ex R^(A) MS Syn 200 5-Me-1-HO(CH₂)₃-pra 549. 9 201/free5-Me-1-TBSO(CH₂)₃-pra 663. 5 2023-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl 558. 5 2032-oxo-2,3-dihydrobenzoxazol-5-yl 544. 5 2042-oxo-2,3-dihydrobenzoxazol-6-yl 544. 5 2052-oxo-3-HO(CH₂)₂-2,3-dihydrobenzoxazol- 588. 9 6-yl 206/free2-oxo-3-TBSO(CH₂)₂-2,3- 702. 5 dihydrobenzoxazol-6-yl 207 quinolin-3-yl538. 5 208 quinolin-6-yl 538. 5 209 quinolin-7-yl 538. 5 210/free2-Br-quinolin-6-yl 615, 617. 5 211 2-HO₂C-quinolin-6-yl MN; 580. 16 2122-H₂NOC-quinolin-6-yl 581. 5 213/free 7-BnO-quinolin-3-yl 644. 5 214isoquinolin-6-yl 538. 5 215 isoquinolin-7-yl 538. 5 216imidazo[1,2-a]pyridin-7-yl 527. 5 2173-Cl-4-((1,4-dioxa-8-azaspiro[4.5]dec-8-yl)- 662. 5 Ph) 218/free3-F-4-MeOCH₂O-Ph 565. 5 219 3,5-diF-4-HO(CH₂)₂O-Ph 583. 7 2203,5-diF-4-tBuO(CH₂)₂O-Ph 639. 5 221 3,4,5-triF-Ph 541. 5 2223-Cl-5-F-4-HO(CH₂)₂O-Ph 599. 9 223/free 3-Cl-5-F-4-TBSO(CH₂)₂O-Ph 713. 5224 3-Cl-4-MeO(CH₂)₂HNCH₂-Ph 608. 15 225/free3-Cl-4-MeO(CH₂)₂N(Boc)CH₂-Ph 708. 5 226 3-Cl-4-HO-Ph 537. 8 227/free3-Cl-4-MeOCH₂O-Ph 581. 5 228 3-Cl-4-((tetrahydro-2-fur)-CH₂O)-Ph 621. 5229 3-Cl-4-MeO(CH₂)₂O-Ph 595. 5 230/free 3-Cl-4-TBSO(CH₂)₂O-Ph 695. 5231 3-Cl-4-H₂N(CH₂)₂-Ph 580. 15 232/free 3-Cl-4-BocHN(CH₂)₂O-Ph 680. 5233 3-Cl-4-tBuOCH₂CH(Me)O-Ph 651. 5 234 3-Cl-4-HO(CH₂)₃O-Ph 595. 9235/free 3-Cl-4-TBSO(CH₂)₃O-Ph 709. 5 236 3-Cl-4-(tetrahydro-3-fur-O)-Ph607. 5 237 3,5-diCl-4-HO-Ph 571 5 238 3,5-diCl-4-HO(CH₂)₂O-Ph 615. 9239/free 3,5-diCl-4-TBSO(CH₂)₂O-Ph 729. 5 240 3-Br-4-HO(CH₂)₂O-Ph 625,627. 9 241/free 3-Br-4-TBSO(CH₂)₂O-Ph 739, 741. 5 242 4-((Me₂N)—CH₂)-Ph544. 14 243/free 4-BocHNCH₂-Ph 616. 5 244 3-Me-4-AcO(CH₂)₂O-Ph 603. 5245 2-MeO-4-py 518. 5 246 5-Cl-6-MeO-3-py 552. 5 247 2-EtO-4-py 532. 5248 5-Cl-6-(HO(CH₂)₂)(Me)N-3-py 595. 13 249 5-Cl-6-HO(CH₂)₂HN-3-py 581.13 250 5-Cl-6-HO(CH₂)₃O-3-py 596. 12 251 2-AcO(CH₂)₂O-4-py 590. 5 2522-HO(CH₂)₂O-4-py 548. 31 253 5-Cl-6-HO(CH₂)₃HN-3-py 595. 13 2545-Cl-6-MeO(CH₂)₃HN-3-py 609. 13 2555-Cl-6-(1-Me-pyrrolidin-2-yl-(CH₂)₂O)-3-py 649. 12 2565-Cl-6-(HO(CH₂)₂)₂N-3-py 625. 13 257 5-Cl-6-HOCH(Me)CH₂HN-3-py 595. 13258 5-Cl-6-((4-(4-F-Bn)-morpholin-2- 744. 13 yl)CH₂HN)-3-py 2595-Cl-6-((MeO₂C)—CH₂HN)-3-py 609. 13 260 5-Cl-6-H2N(CH₂)₃HN-3-py 594. 13261 5-Cl-6-(4-HO-cHex)HN-3-py 635. 13 262 5-Cl-6-H₂NCH₂CH(OH)CH₂HN-3-py610. 13 263 5-Cl-6-(2-HO-cHex)HN-3-py 635. 13 2645-Cl-6-HOCH₂CH(OH)CH₂HN-3-py 611. 13 265 5-Cl-6-((HO₂C)—CH₂HN)-3-py 595.16 266 5-Cl-6-(3-Me-oxetan-3-yl-CH₂O)-3-py 622. 12 2675-Cl-6-(tetrahydro-3-Fur-CH₂O)-3-py 622. 12 268 5-Cl-6-MeO(CH₂)₂HN-3-py595. 13

TABLE 19

Ex X R^(F) R^(B) R^(C) MS Syn 269 CH 4-cyano-pipe 4-Cl-2-The 4-nPr-pipa589. 5 270 CH 4-HO₂C-pipe 4-Cl-2-The 4-nPr-pipa 608. 16 271 CH4-EtO₂C-pipe 4-Cl-2-The 4-nPr-pipa 636. 5 272 CH 4-H₂NOC-pipe 4-Cl-2-The4-nPr-pipa 607. 7 273/free CH 4-(PhC(Me)₂— 4-Cl-2-The 4-nPr-pipa 725. 25(HNOC))-pipe 274 CH 4-HO-pipe 4-Cl-2-The 4-nPr-pipa 580. 9 275/free CH4-TBSO-pipe 4-Cl-2-The 4-nPr-pipa 694. 5 276 N 4-HO₂C-pipe 4-F-Ph4-cHex-pipa 627. 16 277/free N 4-EtO₂C-pipe 4-F-Ph 4-cHex-pipa 655. 13278 N 4-HO₂C-pipe 3-Cl-Ph 4-cHex-pipa 643 16 279 N 4-EtO₂C-pipe 3-Cl-Ph4-cHex-pipa 671. 13 280 N 4-HO₂C-pipe 3-F₃C-Ph 4-cHex-pipa 677. 16 281 N4-EtO₂C-pipe 3-F₃C-Ph 4-cHex-pipa 705. 13 282 N 4-HO₂C-pipe 4-Cl-2-The4-nPr-pipa 609. 16 283/free N 4-EtO₂C-pipe 4-Cl-2-The 4-nPr-pipa 637. 13284 N 4-H₂NOC-pipe 4-Cl-2-The 4-nPr-pipa 608. 13 285 N 4-HO-pipe4-Cl-2-The 4-nPr-pipa 581. 13 286 N 4-HO₂C-pipe 4-Cl-2-The 4-(3-F-pyrr)-653. 16 pipe 287/free N 4-EtO₂C-pipe 4-Cl-2-The 4-(3-F-pyrr)- 681. 13pipe 288 N 4-H₂NOC-pipe 4-Cl-2-The 4-pipe-pipe 648. 13

TABLE 20

Ex R^(G) R^(H) Y MS Syn 289 Cl H CH-cyano 629. 5 290 Cl H CH—CO₂H 648.16 291 Cl H CH—CO₂Et 676. 5 292 Cl H CH—CONH₂ 647. 17 293 Cl H CH—OH620. 9 294/free Cl H CH—OTBS 734. 5 295 Br H CH—CO₂H 694. 16 296/free BrH CH—CO₂Et 722: 5 297 Br H CH—CONH₂ 693. 25 298 F F CH-cyano 631. 5 299F F CH—CO₂H 650. 16 300/free F F CH—CO₂Et 678. 5 301 F F CH—CONH₂ 649.25 302 F Cl CH-cyano 647. 5 303 F Cl CH—CO₂H 666. 16 304 F Cl CH—CO₂Et694. 5 305 F Cl CH—CONH₂ 664. 7 306/free F Cl CH—CONH—C(Me)₂Ph 783. 25307/free F Cl NH 623. 15 308 F Cl N-(2-HO—Bn) 729. 14 309 F ClN—CH₂—CO₂H 681. 16 310/free F Cl N—CH₂—CO₂Et 709. 14 311 F ClN—CH₂—CONH₂ 680. 25 312/free F Cl N-Boc 723. 5 313 F Cl N—CO—CH₂OMe 695.24 314 F Cl N—CO—CO₂H 695. 16 315/free F Cl N—CO—CO₂Et 723. 24 316 F ClN—SO₂NH₂ 702. 15 317/free F Cl N—SO₂NHBoc 802. 23

TABLE 21

Ex R^(I) MS Syn 318 3-HO-azet 593. 13 319 3-F-pyrr 609. 13 320(S)-2-HOCH₂-pyrr 621. 13 321 (R)-2-HOCH₂-pyrr 621. 13 322 3-HO-pyrr 607.13 323 (R)-3-HO-pyrr 607. 13 324 3-Me₂N-pyrr 634. 13 325 4-ttrz-pipe673. 21 326 4-F-pipe 623. 13 327 3-HOCH₂-pipe 635. 13 328 4-HOCH₂-pipe635. 13 329 2-HO(CH₂)₂-pipe 649. 13 330

689. 13 331 4-H₂NOC-pipe 648. 13 332 4-(MeHNOC)-pipe 662. 25 3334-(nPrHNOC)-pipe 690. 42 334 4-(nPenHNOC)-pipe 718. 42 3354-(cHexHNOC)-pipe 730. 42 336 4-(BnHNOC)-pipe 738. 42 3374-((cHex-CH₂)—(HNOC))-pipe 744. 42 338 4-(MeO(CH₂)₂—(HNOC))-pipe 706. 42339 4-(EtO(CH₂)₂—(HNOC))-pipe 720. 42 340 4-(MeO(CH₂)₃—(HNOC))-pipe 720.42 341 4-(Me₂N(CH₂)₃—(HNOC))-pipe 733. 42 342 4-(Me₂N(CH₂)₄—(HNOC))-pipe747. 42 343 4-(Me₂N(CH₂)₆—(HNOC))-pipe 775. 42 344 4-Me₂NOC-pipe 676. 25345 4-((Me)(nPr)N—OC)-pipe 704. 42 346 4-(MeO(CH₂)₂—((Me)NOC))-pipe 720.42 347 4-(pipe-OC)-pipe 716. 42 348 4-(tmor-OC)-pipe 734. 42 3493-HO-pipe 621. 13 350 4-HO-pipe 621. 13 351 4-H₂N-pipe 620. 15 3524-BnHN-pipe 710. 13 353 4-AcEN-pipe 662. 24 354/free 4-BocHN-pipe 720.13 355 4-MsHN-pipe 698. 23 356 pipa 606. 13 357 3-HOCH₂-4-Me-pipa 650.13 358 4-((HO₂C)—CH₂)-pipa 664 16 359/free 4-((EtO₂C)—CH₂)-pipa 692 13360 4-HO(CH₂)₂-pipa 650. 13 361 4-MeO(CH₂)₂-pipa 664. 13 362 3-oxo-pipa620. 13 363 3,5-dioxo-pipa 634. 13 364 4-Ac-pipa 648. 13 365/free4-EtO₂C-pipa 678. 13 366 4-((4-Me-pipa)-OC)-pipe 731. 25 367 4-Ms-pipa684. 23 368 mor 607. 13 369 tmor 623. 13 370 1,4-diazepan-1-yl 620. 13371 4-Ac-1,4-diazepan-1-yl 662. 13 372 5-oxo-1,4-diazepan-1-yl 634. 13373 5-HO₂C-isoindolin-2-yl 683. 16 374 5-MeO₂C-isoindolin-2-yl 697. 13

NMR data of some of the compounds of Examples are shown in the followingTable 22. TABLE 22 Ex NMR 8 1.05-1.20(1H, m), 1.21-1.36(2H, m),1.38-1.55(2H, m), 1.58-1.68(1H, m), 1.82-1.91(2H, m), 2.14-2.25(2H, m),3.20-3.40(7H, m), 3.55-3.65(2H, m), 7.11(1H, dd, J=8.3, 8.8Hz), 7.49(1H,s), 7.56(1H, s), 7.83(1H, dd, J=1.4, 8.3Hz), 8.21(1H, dd, J=1.4,12.6Hz), 10.95(1H, brs), 12.50(1H, brs). 9 1.06-1.20(1H, m),1.22-1.36(2H, m), 1.43-1.56(2H, m), 1.59-1.68(1H, m), 1.80-1.92(2H, m),2.17-2.27(2H, m), 3.20-3.44(7H, m), 3.54-3.63(2H, m), 3.78(2H, t,J=4.9Hz), 4.21(2H, t, J=4.9Hz), 7.33(1H, d, J=8.8Hz), 7.50(1H, d,J=1.5Hz), 7.57(1H, d, J=1.5Hz), 8.08(1H, dd, J=2.0, 8.8Hz), 8.24(1H, d,J=2.0Hz), 10.89(1H, brs), 12.61(1H, brs). 16 1.06-1.20(1H, m),1.22-1.36(2H, m), 1.40-1.55(2H, m), 1.58-1.70(3H, m), 1.78-2.00(4H, m),2.15-2.25(2H, m), 2.50-2.58(1H, m), 2.98-3.09(2H, m), 3.23-3.40(7H, m),3.54-3.66(2H, m), 3.93-4.02(2H, m), 7.48(1H, d, J=1.5Hz), 7.57(1H, d,J=1.5Hz), 8.40(1H, d, J=1.9Hz), 8.83(1H, d, J=1.9Hz), 10.98(1H, brs),12.28(1H, brs), 12.68(1H, s). 36 1.08-1.20(1H, m), 1.21-1.38(4H, m),1.38-1.55(2H, m), 1.60-1.68(1H, m), 1.74-2.00(4H, m), 2.16-2.22(5H, m),2.87(2H, t, J=12.2Hz), 3.20-3.34(9H, m), 4.04(2H, d, J=13.2Hz), 7.50(1H,s), 7.57(1H, s), 8.39(1H, d, J=2.0Hz), 8.83(1H, d, J=2.0Hz), 10.34(1H,brs), 12.09(1H, brs), 12.66(1H, brs). 42 1.14-1.20(1H, m), 1.21-1.32(2H,m), 1.38-1.53(2H, m), 1.60-1.77(5H, m), 1.81-1.92(2H, m), 2.14-2.25(2H,m), 2.88-3.08(3H, m), 3.30-3.37(2H, m), 3.42-3.50(2H, m), 3.52-3.64(4H,m), 3.76-3.88(9H, m), 4.05-4.12(2H, m), 7.49(1H, d, J=1.5Hz), 7.58(1H,d, J=1.5Hz), 8.40(1H, d, J=1.9Hz), 8.83(1H, d, J=1.9Hz), 10.77(1H, brs),12.67(1H, brs). 66 0.90(3H, t, J=6.8Hz), 1.22-1.49(7H, m), 1.75-1.85(2H,m), 2.63-2.71(2H, m), 3.06-3.16(2H, m), 3.92(3H, s), 7.42(1H, d,J=2.0Hz), 7.43(1H, s), 7.51(1H, d, J=2.0Hz), 7.54(1H, d, J=5.4Hz),8.36(1H, d, J=5.4Hz), 12.80(1H, brs). 103 0.95(3H, t, J=7.3Hz),1.71-1.82(2H, m), 3.11-3.36(8H, m), 3.60(2H, d, J=10.3Hz), 3.78(2H, t,J=5.2Hz), 4.21(2H, t, J=4.9Hz), 7.33(1H, d, J=8.8Hz), 7.50(1H, d,J=1.9Hz), 7.58(1H, d, J=2.0Hz), 8.08(1H, dd, J=2.0Hz, J=8.8Hz), 8.24(1H,d, J=2.0Hz), 10.73(1H, brs), 12.62(1H, s). 105 0.90(3H, t, J=7.3Hz),1.72-1.82(2H, m), 3.11-3.33(8H, m), 3.55-3.61(6H, m), 7.22(1H, brs),7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz), 8.28(1H, d, J=1.9Hz),8.74(1H, d, J=2.0Hz), 10.88(1H, brs), 12.48(1H, s). 125 1.07-1.20(1H,m), 1.22-1.36(2H, m), 1.42-1.55(2H, m), 1.60-1.68(1H, m), 1.81-1.91(2H,m), 2.16-2.26(2H, m), 3.20-3.29(7H, m), 3.56-3.65(2H, m), 3.78(2H, t,J=4.9Hz), 4.21(2H, t, J=4.9Hz), 7.12(1H, d, J=3.9Hz), 7.33(1H, d,J=8.8Hz), 7.47(1H, d, J=3.9Hz), 8.08(1H, dd, J=8.8, 2.0Hz), 8.23(1H, d,J=2.0Hz), 10.93(1H,brs), 12.63(1H, brs). 204 1.07-1.20(1H, m),1.22-1.36(2H, m), 1.41-1.55(2H, m), 1.59-1.68(1H, m), 1.82-1.92(2H, m),2.14-2.24(2H, m), 3.27-3.35(7H, m), 3.55-3.65(2H, m), 7.24(1H, d,J=8.3Hz), 7.50(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz), 7.97(1H, dd,J=1.5, 8.3Hz), 8.06(1H, s), 10.74(1H, brs), 12.13(1H, s), 12.63(1H,brs). 208 1.03-1.20(1H, m), 1.21-1.36(2H, m), 1.38-1.55(2H, m),1.60-1.68(1H, m), 1.82-1.91(2H, m), 2.18-2.25(2H, m), 3.22-3.40(7H, m),3.55-3.65(2H, m), 7.52(1H, s), 7.58(1H, s), 7.76(1H, dd, J=4.2, 8.3Hz),8.21(1H, d, J=8.8Hz), 8.40(1H, dd, J=1.5, 8.8Hz) 8.67(1H, d, J=8.3Hz),8.89(1H, d, J=1.5Hz), 9.11(1H, d, J=4.2Hz), 11.05(1H, brs),12.96(1H,brs). 214 1.03-1.20(1H, m), 1.21-1.36(2H, m), 1.40-1.55(2H, m),1.60-1.68(1H, m), 1.82-1.91(2H, m), 2.18-2.28(2H, m), 3.20-3.43(7H, m),3.52-3.65(2H, m), 7.52(1H, s), 7.59(1H, s), 8.33-8.40(2H, m), 8.50(1H,d, J=8.8Hz), 8.73(1H, d, J=5.8Hz), 8.90(1H, s), 9.78(1H, s), 11.20(1H,brs), 13.12(1H, brs). 222 1.07-1.20(1H, m), 1.21-1.36(2H, m),1.41-1.54(2H, m), 1.58-1.68(1H, m), 1.80-1.92(2H, m), 2.14-2.25(2H, m),3.25-3.37(7H, m), 3.56-3.64(2H, m), 3.73(2H, t, J=4.9Hz), 4.24(2H, t,J=4.9Hz), 7.50(1H, d, J=1.0Hz), 7.58(1H, d, J=1.0Hz), 8.01(1H, dd,J=2.0, 11.7Hz), 8.11(1H, brs), 10.77(1H, brs), 12.77(1H, brs). 2261.06-1.20(1H, m), 1.21-1.36(2H, m), 1.42-1.56(2H, m), 1.59-1.68(1H, m),1.81-1.91(2H, m), 2.16-2.26(2H, m), 3.20-3.45(7H, m), 3.54-3.63(2H, m),7.17(1H, d, J=8.8Hz), 7.49(1H, d, J=1.4Hz), 7.56(1H, d, J=1.4Hz),7.94(1H, dd, J=2.4, 8.8Hz), 8.19(1H, d, J=2.4Hz), 11.26(1H, brs),12.51(1H, brs). 229 1.06-1.20(1H, m), 1.22-1.36(2H, m), 1.44-1.56(2H,m), 1.58-1.68(1H, m), 1.80-1.92(2H, m), 2.15-2.26(2H, m), 3.17-3.47(7H,m), 3.35(3H, s), 3.56-3.63(2H, m), 3.73(2H, t, J=3.9Hz), 4.31(2H, t,J=3.9Hz), 7.33(1H, d, J=8.8Hz), 7.49(1H, d, J=0.9Hz), 7.56(1H, d,J=0.9Hz), 8.08(1H, dd, J=1.9, 8.8Hz), 8.24(1H, d, J=1.9Hz), 11.31(1H,brs), 12.61(1H, brs). 234 1.08-1.20(1H, m), 1.22-1.36(2H, m),1.41-1.55(2H, m), 1.58-1.68(1H, m), 1.82-1.90(2H, m), 1.92(2H, t,J=6.3Hz), 2.19-2.22(2H, m), 3.21-3.37(7H, m), 3.55-3.63(4H, m), 4.25(2H,t, J=6.3Hz), 7.32(1H, d, J=8.8Hz), 7.50(1H, s), 7.57(1H, s), 8.09(1H dd,J=2.0, 8.8Hz), 8.24(1H, d, J=2.0Hz), 10.83(1H, brs), 12.62(1H, brs). 2381.07-1.20(1H, m), 1.22-1.36(2H, m), 1.44-1.56(2H, m), 1.60-1.68(1H, m),1.83-1.91(2H, m), 2.17-2.26(2H, m), 3.20-3.42(7H, m), 3.56-3.63(2H, m),3.78(2H, t, J=4.9Hz), 4.13(2H, t, J=4.9Hz), 7.49(1H, s), 7.57(1H, s),8.21(2H, s), 11.18(1H, brs), 12.79(1H, brs). 240 1.07-1.20(1H, m),1.22-1.36(2H, m), 1.42-1.56(2H, m), 1.60-1.67(1H, m), 1.81-1.90(2H, m),2.18-2.25(2H, m), 3.17-3.43(7H, m), 3.55-3.65(2H, m), 3.78(2H, t,J=4.9Hz), 4.20(2H, t, J=4.9Hz), 7.29(1H, d, J=8.8Hz), 7.49(1H, d,J=1.5Hz), 7.56(1H, d, J=1.5Hz), 8.12(1H, dd, J=2.4, 8.8Hz), 8.39(1H, d,J=2.4Hz), 11.19(1H, brs), 12.61(1H, brs). 245 1.08-1.20(1H, m),1.21-1.34(2H, m), 1.40-1.53(2H, m), 1.60-1.68(1H, m), 1.82-1.89(2H, m),2.14-2.24(2H, m), 3.22-3.45(7H, m), 3.55-3.65(2H, m), 3.95(3H, s),7.44(1H, s), 7.50(1H, s), 7.54(1H, d, J=4.9Hz), 7.56(1H, s), 8.37(1H, d,J=4.9Hz), 10.61(1H, brs), 12.95(1H, brs). 250 1.06-1.20(1H, m),1.22-1.36(2H, m), 1.41-1.54(2H, m), 1.60-1.68(1H, m), 1.82-1.95(2H, m),1.92(2H, t, J=6.4Hz), 2.15-2.24(2H, m), 3.22-3.36(7H, m), 3.55-3.63(2H,m), 3.58(2H, t, J=6.4Hz), 4.51(2H, t, J=6.4Hz), 7.49(1H, d, J=1.5Hz),7.57(1H, d, J=1.5Hz), 8.53(1H, d, J=2.0Hz), 8.82(1H, d, J=2.0Hz),10.83(1H, brs), 12.78(1H, s). 253 1.05-1.20(1H, m), 1.22-1.36(2H, m),1.42-1.54(2H, m), 1.60-1.68(1H, m), 1.70-1.77(2H, m), 1.82-1.92(2H, m),2.15-2.25(2H, m), 3.20-3.40(7H, m), 3.45-3.65(4H, m), 3.49(2H, t,J=6.3Hz), 7.39(1H, brs), 7.48(1H, d, J=1.5Hz), 7.56(1H, d, J=1.5Hz),8.27(1H, d, J=2.0Hz), 8.74(1H, d, J=2.0Hz), 10.98(1H, brs), 12.45(1H,s). 264 1.06-1.20(1H, m), 1.22-1.36(2H, m), 1.40-1.54(2H, m),1.59-1.68(1H, m), 1.80-1.91(2H, m), 2.13-2.24(2H, m), 3.24-3.33(9H, m),3.55-3.45(2H, m), 3.54-3.65(2H, m), 3.68-3.75(1H, m), 7.01-7.07(1H, m),7.49(1H, d, J=1.5Hz), 7.56(1H, d, J=1.5Hz), 8.29(1H, d, J=1.9Hz),8.74(1H, d J=1.9Hz), 10.68(1H, brs), 12.48(1H, s). 267 1.07-1.20(1H, m),1.22-1.36(2H, m), 1.39-1.54(2H, m), 1.60-1.75(2H, m), 1.82-1.92(2H, m),1.98-2.08(1H, m), 2.13-2.24(2H, m), 2.68-2.78(1H, m), 3.22-3.37(4H, m),3.41-3.51(4H, m), 3.54-3.71(3H, m), 3.76-3.82(2H, m), 4.32-4.45(2H, m),7.50(1H, d, J=1.5Hz), 7.58(1H, d, J=1.5Hz), 8.55(1H, d, J=2.0Hz),8.82(1H, d, J=2.0Hz), 10.60(1H, brs), 12.80(1H, s). 270 0.93(3H, t,J=7.3Hz), 1.42-1.81(4H, m), 1.90-2.00(2H, m), 2.40-2.48(1H, m),2.72-2.86(2H, m), 2.80-3.70(12H, m), 7.24(1H, d, J=8.8Hz), 7.48(1H,brs), 7.55(1H, brs), 8.03(1H, dd, J=1.9, 8.8Hz), 8.18(1H, d, J=1.9Hz),10.68(1H, brs), 12.25(1H, brs), 12.58(1H, s). 272 0.95(3H, t, J=7.8Hz),1.68-1.88(6H, m), 2.23-2.34(1H, m), 2.70-2.79(2H, m), 3.10-3.19(2H, m),3.20-3.35(5H, m), 3.40-3.53(3H, m), 3.56-3.64(2H, m), 6.80(1H, brs),7.24(1H, d, J=8.3Hz), 7.33(1H, brs)7.50(1H, d, J=1.5Hz), 7.58(1H, d,J=1.5Hz), 8.03(1H, dd, J=2.0, 8.3Hz), 8.18(1H, d, J=2.0Hz), 10.86(1H,brs), 12.61(1H,s). 274 0.94(3H, t, J=7.3Hz), 1.51-1.63(2H, m),1.71-1.82(2H, m), 1.83-1.92(2H, m), 2.81-2.90(2H, m), 3.10-3.17(2H, m),3.17-3.37(8H, m), 3.55-3.63(2H, m), 3.63-3.72(1H, m), 7.24(1H, d,J=8.3Hz), 7.50(1H, d, J=1.5Hz), 7.58(1H, d, J=1.5Hz), 8.03(1H, dd,J=1.9, 8.3Hz), 8.18(1H, d, J=1.9Hz), 10.92(1H, brs), 12.61(1H, s). 2761.05-1.20(1H, m), 1.22-1.37(2H, m), 1.40-1.52(2H, m), 1.60-1.75(3H, m),1.80-1.97(4H, m), 2.15-2.24(2H, m), 2.50-2.52(1H, m), 3.04(2H, t,J=10.8Hz), 3.17-3.38(7H, m), 3.47-3.60(2H, m), 3.98(2H, d, J=13.2Hz),7.27(2H, t, J=8.8Hz), 8.15(2H, dd, J=5.8, 8.8Hz), 8.40(1H, d, J=2.0Hz),8.84(1H, d, J=2.0Hz), 10.85(1H, brs), 12.28(1H, brs), 12.59(1H, brs).278 1.08-1.20(1H, m), 1.22-1.36(2H, m), 1.38-1.52(2H, m), 1.58-1.75(3H,m), 1.81-1.99(4H, m), 2.11-2.22(2H, m), 2.50-2.52(1H, m), 2.98-3.08(2H,m), 3.19-3.35(7H, m), 3.48-3.64(2H, m), 3.92-4.22(2H, m), 7.34-7.41(1H,m), 7.49(1H, d, J=7.8Hz), 8.09-8.11(1H, m), 8.12-8.17(1H, m), 8.41(1H,d, J=2.0Hz), 8.84(1H, d, J=2.0Hz), 10.55(1H, brs), 12.28(1H, brs),12.59(1H, brs). 280 1.08-1.20(1H, m), 1.21-1.38(2H, m), 1.39-1.51(2H,m), 1.60-1.73(3H, m), 1.80-2.00(4H, m), 2.10-2.22(2H, m), 2.50-2.52(1H,m), 2.99-3.10(2H, m), 3.22-3.40(7H, m), 3.52-3.62(2H, m), 3.94-4.03(2H,m), 7.67-7.74(2H, m), 8.40(2H, d, J=2.0Hz), 8.48-8.50(1H, m), 8.85(1H,d, J=2.0Hz), 10.49(1H, brs), 12.28(1H, brs), 12.63(1H, brs). 2820.90(3H, t, J=7.3Hz), 1.51(2H, brs), 1.64-1.73(2H, m), 1.91-1.99(2H, m),2.33-3.38(13H, m), 3.97(2H, d, J=13.2Hz), 7.45(1H, d, J=1.5Hz), 7.53(1H,d, J=1.0Hz), 8.40(1H, d, J=1.9Hz), 8.83(1H, d, J=2.0Hz), 12.00-12.50(1H,br), 12.58(1H, brs). 284 0.95(3H, t, J=7.3Hz), 1.63-1.83(6H, m),2.33-2.41(1H, m), 2.95(2H, t, J=11.5Hz), 3.13-3.42(8H, m), 3.60(2H, d,J=10.8Hz), 4.07(2H, d, J=13.2Hz), 6.80(1H, s)7.32(1H, s), 7.50(1H, d,J=1.5Hz), 7.58(1H, d, J=1.5Hz), 8.40(1H, d, J=1.9Hz), 8.84(1H, d,J=1.9Hz), 10.65(1H,brs), 12.68(1H, s). 285 0.95(3H, t, J=7.3Hz),1.47-1.55(2H, m), 1.72-1.91 (4H, m), 3.12-3.34(10H, m), 3.59-3.86(5H,m), 7.50(1H, d, J=1.5Hz), 7.58(1H, d, J=1.5Hz), 8.39(1H, d, J=1.9Hz),8.82(1H, d, J=1.9Hz), 10.80(1H, brs), 12.66(1H, s). 289 1.10-1.20(1H,m), 1.22-1.36(2H, m)1.40-1.55(2H, m), 1.59-1.68(1H, m), 1.81-1.94(4H,m), 2.00-2.09(2H, m), 2.15-2.24(2H, m), 2.98-3.07(2H, m), 3.07-3.16(1H,m), 3.18-3.35(4H, m), 3.55-3.74(7H, m), 7.28(1H, d, J=8.3Hz), 7.49(1H,d, J=1.5Hz), 7.57(1H, d, J=1.5Hz), 8.04(1H, dd, J=1.9, 8.3Hz), 8.18(1H,d, J=1.9Hz), 10.82(1H, brs), 12.63(1H, s). 290 1.06-1.20(1H, m),1.22-1.50(4H, m), 1.56-2.30(9H, m), 2.39-2.48(1H, m), 2.75-2.86(2H, m),2.80-3.80(11H, m), 7.23(1H, d, J=8.3Hz), 7.48(1H, brs), 7.56(1H, brs),8.03(1H, dd, J=1.9, 8.3Hz), 8.18(1H, d, J=1.9Hz), 10.50(1H, brs),12.28(1H, brs), 12.68(1H, s). 292 1.08-1.20(1H, m), 1.21-1.35(2H, m),1.38-1.55(2H, m), 1.58-1.90(7H, m), 2.10-2.25(2H, m), 2.22-2.36(1H, m),2.68-2.79(2H, m), 3.20-3.37(7H, m), 3.42-3.49(2H, m), 3.50-3.70(2H, m),6.82(1H, brs), 7.25(1H, d, J=8.8Hz), 7.33(1H, brs), 7.49(1H, brs),7.56(1H, brs), 8.03(1H, dd, J=1.9, 8.8Hz), 8.18(1H, d, J=1.9Hz),10.62(1H, brs), 12.61(1H, s). 293 1.08-1.20(1H, m), 1.20-1.36(2H,m)1.36-1.53(2H, m), 1.53-1.68(3H, m), 1.80-1.93(4H, m), 2.15-2.25(2H,m), 2.80-2.91(2H, m), 3.20-3.40(9H, m), 3.55-3.63(2H, m), 3.63-3.71(1H,m), 7.24(1H, d, J=8.3Hz), 7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz),8.02(1H, dd, J=1.9, 8.3Hz), 8.18(1H, d, J=1.9Hz), 10.98(1H, brs),12.60(1H, s). 295 1.11-1.20(1H, m), 1.22-1.36(2H, m), 1.38-1.50(2H, m),1.64(1H, d, J=12.2Hz), 1.69-1.80(2H, m), 1.87(2H, d, J=12.2Hz),1.91-2.00(2H, m), 2.17(2H, d, J=10.3Hz), 2.42-3.42(12H, m), 3.62(2H, d,J=9.7Hz), 7.24(1H, d, J=8.3Hz), 7.50(1H, d, J=1.9Hz), 7.58(1H, d,J=1.4Hz), 8.08(1H, dd, J=1.9, 8.3Hz), 8.36(1H, d, J=1.9Hz), 9.99(1H,brs), 12.27(1H, brs), 12.65(1H, s). 297 1.06-1.19(1H, m), 1.29(2H, q,J=13.2Hz), 1.48(2H, q, J=11.2Hz), 1.64(1H, d, J=12.7Hz), 1.71-1.91(6H,m), 2.19-2.33(3H, m), 2.67-2.83(2H, m), 3.22-3.46(9H, m), 3.60(2H, d,J=7.4Hz), 6.81(1H, s), 7.25(1H, d, J=8.3Hz), 7.34(1H, s), 7.50(1H, d,J=1.5Hz), 7.57(1H, d, J=1.5Hz), 8.08(1H, dd, J=2.2, 8.6Hz), 8.36(1H, d,J=1.9Hz), 10.86(1H, brs), 12.64(1H, s). 298 1.14-1.19(1H, m), 1.29(2H,q, J=11.7Hz), 1.48(2H, q, J=11.2Hz), 1.64(1H, d, J=12.7Hz), 1.78-1.91(4H, m), 1.96-2.01 (2H, m), 2.20(2H, d, J=10.2Hz), 3.09-3.35(12H, m),3.60(2H, d, J=8.8Hz), 7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz),7.80-7.86(2H, m), 10.96(1H, brs), 12.68(1H, s). 299 1.07-1.18(1H, m),1.29(2H, q, J=12.8Hz), 1.47(2H, q, J=11.2Hz), 1.59-1.72(3H, m),1.82-1.94(4H, m), 2.19(2H, d, J=10.2Hz), 2.42-2.46(1H, m), 3.13(2H, d,J=11.3Hz), 3.26-3.41(9H, m), 3.60(2H, brs), 7.49(1H, d, J=1.5Hz),7.57(1H, d, J=1.5Hz), 7.77-7.86(2H, m), 10.72(1H, brs), 12.27(1H, brs),12.65(1H, s). 301 1.07-1.19(1H, m), 1.29(2H, q, J=12.9Hz), 1.47(2H, q,J=11.0Hz), 1.57-1.72(3H, m), 1.72-1.81(2H, m), 1.86(2H, d, J=13.1Hz),2.18-2.33(3H, m), 3.09(2H, t, J=11.7Hz), 3.22-3.44(9H, m), 3.59(2H,brs), 6.81(1H, s), 7.31(1H, s), 7.50(1H, d, J=1.5Hz), 7.57(1H, d,J=1.4Hz), 7.77-7.86(2H, m), 10.70(1H, brs), 12.66(1H, s). 3021.08-1.20(1H, m), 1.21-1.36(2H, m), 1.40-1.55(2H, m), 1.59-1.68(1H, m),1.78-1.91(4H, m), 1.95-2.05(2H, m), 2.14-2.25(2H, m), 3.09-3.21 (3H, m),3.21-3.45(9H, m), 3.55-3.65(2H, m), 7.50(1H, d, J=1.5Hz), 7.57(1H, d,J=1.5Hz), 7.93 (1H, dd, J=2.0, 12.7Hz), 8.07(1H, brs), 10.81(1H, brs),12.73(1H, s). 303 1.08-1.20(1H, m), 1.22-1.37(2H, m), 1.42-1.55(2H, m),1.59-1.76(3H, m), 1.81-1.95(4H, m), 2.16-2.25(2H, m), 2.40-2.48(1H, m),3.08-3.17(2H, m), 3.24-3.36(7H, m), 3.46-3.65(4H, m), 7.49(1H, d,J=1.4Hz), 7.57(1H, d, J=1.4Hz), 7.89(1H, dd, J=2.0, 13.2Hz), 8.06(1H, d,J=2.0Hz), 10.90(1H, brs), 12.25(1H, brs), 12.72(1H, s). 3051.08-1.20(1H, m), 1.20-1.35(2H, m), 1.38-1.52(2H, m), 1.58-1.90(7H, m),2.10-2.24(2H, m), 2.25-2.36(1H, m), 3.03-3.14(2H, m), 3.15-3.35(9H, m),3.50-3.70(2H, m), 6.80(1H, brs), 7.30(1H, brs), 7.48(1H, brs), 7.56(1H,brs), 7.90(1H, dd, J=2.0, 13.8Hz), 8.06(1H, brs), 10.80(1H, brs),12.69(1H, s). 309 1.07-1.20(1H, m), 1.21-1.35(2H, m), 1.38-1.53(2H, m),1.58-1.67(1H, m), 1.80-1.92(2H, m), 2.08-2.24(2H, m), 2.75-2.88(4H, m),3.16-3.92(15H, m), 7.49(1H, d, J=1.4Hz), 7.53(1H, d, J=1.4Hz), 7.92(1H,dd, J=2.0, 13.2Hz), 8.06(1H, s), 12.7(1H, s). 311 1.08-1.18(1H, m),1.22-1.35(2H, m), 1.42-1.56(2H, m), 1.58-1.68(1H, m), 1.82-1.92(2H, m),2.18-2.26(2H, m), 3.24-3.50(9H, m), 3.51-3.68(8H, m), 4.04(2H, s),7.50(1H, d, J=1.5Hz), 7.58(1H, d, J=1.5Hz), 7.72(1H, s), 7.95(1H, dd,J=1.9, 12.7Hz), 8.05(1H, s), 8.10(1H, s), 8.32(1H, s), 10.33(1H, brs),11.10(1H, brs), 12.8(1H, s). 313 1.05-1.08(1H, m), 1.24-1.35(2H,m)1.43-1.52(2H, m), 1.60-1.69(1H, m), 1.82-1.92(2H, m), 2.12-2.22(2H,m), 3.13-3.24(4H, m), 3.31(3H, s), 3.26-3.35(3H, m), 3.46-3.64(10H, m),4.14(2H, s), 7.50(1H, d, J=1.4Hz), 7.58(1H, d, J=1.4Hz), 7.94(1H, dd,J=2.2, 12.9Hz), 8.09(1H, s), 1011(1H, brs), 12.76(1H, brs). 3161.01-1.20(1H, m), 1.21-1.37(2H, m), 1.41-1.57(2H, m), 1.58-1.67(1H, m),1.75-1.92(2H, m), 2.14-2.28(2H, m), 3.03-3.15(4H, m), 3.21-3.44(11H, m),3.55-3.64(2H, m), 6.88(2H, m), 7.49(1H, d, J=1.4Hz), 7.57(1H, d,J=1.4Hz), 7.95(1H, dd, J=2.0, 12.7Hz), 8.08(1H, brs), 11.2(1H, brs),12.7(1H, brs). 322 1.06-1.20(1H, m), 1.22-1.36(2H, m), 1.40-1.54(2H, m),1.58-1.68(1H, m), 1.81-2.00(4H, m), 2.14-2.24(2H, m), 3.20-3.38(7H, m),3.54-3.64(3H, m), 3.73-3.81(1H, m), 3.82-3.91(2H, m), 4.33-4.39(1H, m),7.49(1H, d, J=1.5Hz), 7.56(1H, d, J=1.5Hz), 8.29(1H, d, J=2.0Hz),8.74(1H, d, J=2.0Hz), 10.70(1H, brs), 12.51(1H, s). 328 1.05-1.20(1H,m), 1.22-1.36(4H, m), 1.41-1.55(2H, m), 1.58-1.70(2H, m), 1.73-1.81(2H,m), 1.82-1.91(2H, m), 2.17-2.26(2H, m), 2.90(2H, t, J=11.2Hz),3.23-3.36(9H, m), 3.60(2H, d, J=9.8Hz), 4.08(2H, d, J=12.7Hz), 7.49(1H,d, J=1.4Hz), 7.56(1H, d, J=1.4Hz), 8.38(1H, d, J=2.0Hz), 8.82(1H, d,J=2.0Hz), 11.03(1H, brs), 12.65(1H, brs). 331 1.05-1.20(1H, m),1.22-1.36(2H, m), 1.41-1.54(2H, m), 1.58-1.74(3H, m), 1.77-1.92(4H, m),2.16-2.24(2H, m), 2.34-2.42(1H, m), 2.95(2H, t, J=12.2Hz), 3.25-3.36(7H,m), 3.52-3.64(2H, m), 4.07(2H, d, J=12.2Hz), 6.80(1H, s), 7.32(1H, s),7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz), 8.40(1H, d, J=2.4Hz),8.83(1H, d, J=2.4Hz), 10.73(1H, brs), 12.67(1H, s). 332 1.08-1.19(1H,m), 1.29(2H, q, J=13.0Hz), 1.47(2H, q, J=11.2Hz), 1.60-1.82(5H, m),1.87(2H, d, J=13.2Hz), 2.19(2H, d, J=10.7Hz), 2.32-2.41(1H, m), 2.58(3H,d, J=4.4Hz), 2.94(2H, t, J=11.5Hz), 3.24-3.66(9H, m), 4.08(2H, d,J=12.7Hz), 7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz), 7.79(1H, g,J=4.6Hz), 8.40(1H, d, J=1.9Hz), 8.83(1H, d, J=1.9Hz), 10.68(1H, brs),12.67(1H, s). 333 0.84(3H, t, J=7.3Hz), 1.08-1.21(1H, m), 1.22-1.34(2H,m), 1.35-1.54(4H, m), 1.59-1.82(5H, m), 1.83-1.92(2H, m), 2.14-2.23(2H,m), 2.34-2.43(1H, m), 2.90-2.99(2H, m), 3.01(2H, q, J=6.9Hz),3.20-3.60(7H, m), 3.55-3.65(2H, m), 4.04-4.12(2H, m), 7.50(1H, d,J=1.5Hz), 7.58(1H, d, J=1.5Hz), 7.83(1H, t, J=5.8Hz), 8.40(1H, d,J=2.4Hz), 8.83(1H, d, J=2.4Hz), 10.53(1H, brs), 12.68(1H, brs). 3381.13-1.20(1H, m), 1.21-1.35(2H, m), 1.42-1.55(2H, m), 1.58-1.74(7H, m),2.16-2.23(2H, m), 2.38-2.46(1H, m)2.88-3.00(2H, m), 3.18-3.36(7H, m),3.25(3H, s), 3.48-3.68(6H, m), 4.08-4.13(2H, m), 7.49(1H, d, J=1.4Hz),7.56(1H, d, J=1.4Hz), 7.94(1H, t, J=5.8Hz), 8.39(1H, d, J=2.0Hz),8.83(1H, d, J=2.0Hz), 10.81(1H, brs), 12.66(1H, brs). 339 1.11(3H, t,J=6.9Hz), 1.07-1.21(1H, m), 1.23-1.36(2H, m), 1.42-1.52(2H, m),1.60-1.91(7H, m), 2.14-2.27(2H, m)2.35-2.48(1H, m), 2.87-3.00(2H, m),3.20(2H, q, J=5.8Hz), 3.20-3.42(9H, m), 3.43(2H, q, J=6.9Hz),3.54-3.66(2H, m), 4.00-4.14(2H, m), 7.49(1H, d, J=1.4Hz), 7.58(1H, d,J=1.4Hz), 7.92(1H, t, J=5.8Hz), 8.40(1H, d, J=1.9Hz), 8.82(1H, d,J=1.9Hz), 11.00(1H, brs), 12.67(1H, brs). 340 1.04-1.20(1H, m),1.23-1.36(2H, m), 1.46-1.56(2H, m), 1.57-1.92(7H, m), 1.63(2H, t,J=6.9Hz), 2.16-2.28(2H, m)2.32-2.42(1H, m), 2.85-2.98(2H, m),3.06-3.13(2H, m), 3.22(3H, s), 3.21-3.45(9H, m), 3.54-3.67(2H, m),4.02-4.20(2H, m), 7.49(1H, d, J=1.5Hz), 7.56(1H, d, J=1.5Hz), 7.88(1H,t, J=5.5Hz), 8.39(1H, d, J=2.0Hz), 8.82(1H, d, J=2.0Hz), 11.27(1H, brs),12.65(1H, brs). 344 1.07-1.19(1H, m), 1.29(2H, q, J=12.1Hz), 1.48(2H, q,J=11.2Hz), 1.60-1.78(5H, m), 1.86(2H, d, J=12.7Hz), 2.20(2H, d,J=10.2Hz), 2.83(3H, s), 2.89-3.06(3H, m), 3.07(3H, s), 3.22-3.38(7H, m),3.60(2H, d, J=7.8Hz), 4.09(2H, d, J=13.2Hz), 7.49(1H, d, J=1.4Hz),7.57(1H, d, J=1.4Hz), 8.39(1H, d, J=2.5Hz), 8.83(1H, d, J=2.4Hz),10.88(1H, brs), 12.66(1H, s). 350 1.07-1.20(1H, m), 1.22-1.36(2H, m),1.41-1.56(4H, m), 1.60-1.67(1H, m), 1.80-1.92(4H, m), 2.15-2.24(2H, m),3.13-3.37(9H, m), 3.55-3.63(2H, m), 3.68-3.76(1H, m), 3.79-3.87(2H, m),7.49(1H, d, J=1.4Hz), 7.57(1H, d, J=1.4Hz), 8.38(1H, d, J=2.4Hz),8.82(1H, d, J=2.4Hz), 10.92(1H, brs), 12.66(1H, s). 353 1.06-1.20(1H,m), 1.22-1.37(2H, m), 1.42-1.57(4H, m), 1.59-1.68(1H, m), 1.81(3H, s),1.82-1.90(4H, m), 2.16-2.26(2H, m), 3.07(2H, t, J=11.2Hz), 3.21-3.41(7H,m), 3.54-3.64(2H, m), 3.82-4.08(3H, m), 7.49(1H, d, J=1.4Hz), 7.57(1H,d, J=1.4Hz), 7.90(1H, d, J=7.8Hz), 8.40(1H, d, J=1.9Hz), 8.84(1H, d,J=1.9Hz), 11.06(1H, brs), 12.67(1H, s). 358 1.05-1.20(1H, m),1.21-1.36(2H, m), 1.42-1.55(2H, m), 1.57-1.67(1H, m), 1.81-1.92(2H, m),2.18-2.24(2H, m), 2.94-3.03(4H, m), 3.18-3.80(15H, m), 7.49(1H, d,J=1.4Hz), 7.57(1H, d, J=1.4Hz), 8.42(1H, d, J=2.2Hz), 8.88(1H, d,J=2.2Hz), 11.16(1H, brs), 12.71(1H, brs). 362 1.06-1.20(1H, m),1.22-1.36(2H, m), 1.40-1.54(2H, m), 1.58-1.69(1H, m), 1.81-1.92(2H, m),2.13-2.24(2H, m), 3.23-3.38(9H, m), 3.57-3.63(2H, m), 3.77(2H, t,J=5.4Hz), 4.05(2H, brs), 7.49(1H, d, J=1.5Hz), 7.57(1H, d, J=1.5Hz),8.05(1H, brs), 8.45(1H, d, J=1.9Hz), 8.86(1H, d, J=1.9Hz), 10.62(1H,brs), 12.73(1H, s). 372 1.07-1.21(1H, m), 1.20-1.37(2H, m),1.37-1.52(2H, m), 1.60-1.77(1H, m), 1.83-1.92(2H, m), 2.10-2.23(2H, m),2.53-2.54(2H, m), 3.15-3.37(9H, m), 3.57-3.68(6H, m), 7.50(1H, s),7.57(1H, s), 7.63-7.70(1H, m), 8.43(1H, s)8.82(1H, s), 10.26(1H, brs),12.68(1H, brs).

The structures of the compounds of the invention are shown in thefollowing Tables 23-33. These compounds can be easily prepared by theabove production methods, methods described in Examples, or methods thatare self-evident to an ordinary skilled person, or its variations.

In the Tables, No indicates the number of compound, and R^(J), R^(K),R^(L), R^(M), R^(N), R^(O), R^(P), R^(Q), R^(R), R^(S), R^(T), R^(AA),R^(BB), R^(CC), R^(DD), R^(EE), R^(FF), R^(GG) indicate substituentgroups in the general Formula. Thus, for examples, in Table 23, “(No:R^(J))=(A0001:HO—CH₂—O)” indicates that “the compound of A0001 has ahydroxymethoxy group as a substituent group R^(J) in the generalFormula”. TABLE 23

(No: R^(J)) =(A0001:HO—CH₂—O),(A0002:MeO-CH₂—O),(A0003:EtO₂C-CH₂—O),(A0004:HO₂C—CH₂—O),(A0005:H₂NOC—CH₂—O),(A0006:cyano-CH₂—O),(A0007:MeHNOC-CH₂—O),(A0008:Me₂NOC-CH₂—O),(A0009:F₃C—CH₂—O),(A0010:HO—(CH₂)₂—O),(A0011:MeO-(CH₂)₂—O),(A0012:EtO₂C-(CH₂)₂—O),(A0013:HO₂C—(CH₂)₂—O),(A0014:H₂NOC—(CH₂)₂—O),(A0015:cyano-(CH₂)₂—O),(A0016:MeHNOC-(CH₂)₂—O),(A0017:Me₂NOC-(CH₂)₂—O),(A0018:F₃C—(CH₂)₂—O),(A0019:HO—(CH₂)₃—O),(A0020:MeO-(CH₂)₃—O),(A0021:EtO₂C-(CH₂)₃—O),(A0022:HO₂C—(CH₂)₃—O),(A0023:H₂NOC—(CH₂)₃—O),(A0024:cyano-(CH₂)₃—O),(A0025:MeHNOC-(CH₂)₃—O),(A0026:Me₂NOC-(CH₂)₃—O),(A0027:F₃C—(CH₂)₃—O),(A0028:1-HO-cHex-O),(A0029:1-MeO-cHex-O),(A0030:1-EtO₂C-cHex-O),(A0031:1-HO₂C-cHex-O),(A0032:1-H₂NOC-cHex-O),(A0033:1-cyano-cHex-O),(A0034:1-MeHNOC-cHex-O),(A0035:1-Me₂NOC-cHex-O),(A0036:1-F₃C-cHex-O),(A0037:2-HO-cHex-O),(A0038:2-MeO-cHex-O),(A0039:2-EtO₂C-cHex-O),(A0040:2-HO₂C-cHex-O),(A0041:2-H₂NOC-cHex-O),(A0042:2-cyano-cHex-O),(A0043:2-MeHNOC-cHex-O),(A0044:2-Me₂NOC-cHex-O),(A0045:2-F₃C-cHex-O),(A0046:3-HO-cHex-O),(A0047:3-MeO-cHex-O),(A0048:3-EtO₂C-cHex-O),(A0049:3-HO₂C-cHex-O),(A0050:3-H₂NOC-cHex-O),(A0051:3-cyano-cHex-O),(A0052:3-MeHNOC-cHex-O),(A0053:3-Me₂NOC-cHex-O),(A0054:3-F₃C-cHex-O),(A0055:4-HO-cHex-O),(A0056:4-MeO-cHex-O),(A0057:4-EtO₂C-cHex-O),(A0058:4-HO₂C-cHex-O),(A0059:4-H₂NOC-cHex-O),(A0060:4-cyano-cHex-O),(A0061:4-MeHNOC-cHex-O),(A0062:4-Me₂NOC-cHex-O),(A0063:4-F₃C-cHex-O),(A0064:3-HO-cPen-O),(A0065:3-MeO-cPen-O),(A0066:3-EtO₂C-cPen-O),(A0067:3-HO₂C-cPen-O),(A0068:3-H₂NOC-cPen-O),(A0069:3-cyano-cPen-O),(A0070:3-MeHNOC-cPen-O),(A0071:3-Me₂NOC-cPen-O),(A0072:3-F₃C-cPen-O),(A0073:3-HO-cBu-O),(A0074:3-MeO-cBu-O),(A0075:3-EtO₂C-cBu-O),(A0076:3-HO₂C-cBu-O),(A0077:3-H₂NOC-cBu-O),(A0078:3-cyano-cBu-O),(A0079:3-MeHNOC-cBu-O),(A0080:3-Me₂NOC-cBu-O),(A0081:3-F₃C-cBu-O),(A0082:2-HO-cPr-O),(A0083:2-MeO-cPr-O),(A0084:2-EtO₂C-cPr-O),(A0085:2-HO₂C-cPr-O),(A0086:2-H₂NOC-cPr-O),(A0087:2-cyano-cPr-O),(A0088:2-MeHNOC-cPr-O),(A0089:2-Me₂NOC-cPr-O),(A0090:2-F₃C-cPr-O),(A0091:HO—CH₂—HN),(A0092:MeO-CH₂—HN),(A0093:EtO₂C-CH₂—HN),(A0094:HO₂C—CH₂—HN),(A0095:H₂NOC—CH₂—HN),(A0096:cyano-CH₂—HN),(A0097:MeHNOC-CH₂—HN),(A0098:Me₂NOC-CH₂—HN),(A0099:F₃C—CH₂—HN),(A0100:HO—(CH₂)₂—HN),(A0101:MeO-(CH₂)₂—HN),(A0102:EtO₂C-(CH₂)₂—HN),(A0103:HO2C—(CH₂)₂—HN),(A0104:H₂NOC—(CH₂)₂—HN),(A0105:cyano-(CH₂)₂—HN),(A0106:MeHNOC—(CH₂)₂—HN),(A0107:Me₂NOC—(CH₂)₂—HN),(A0108:F₃C—(CH₂)₂—HN),(A0109:HO—(CH₂)₃—HN),(A0110:MeO—(CH₂)₃—HN),(A0111:EtO2C—(CH₂)₃—HN),(A0112:HO₂C—(CH₂)₃—HN),(A0113:H₂NOC—(CH₂)₃—HN),(A0114:cyano-(CH₂)₃—HN),(A0115:MeHNOC-(CH₂)₃—HN),(A0116:Me₂NOC—(CH₂)₃—HN),(A0117:F₃C—(CH₂)₃—HN),(A0118:1-HO-cHex-HN),(A0119:1-MeO-cHex-HN),(A0120:1-EtO₂C-cHex-HN),(A0121:1-HO₂C-cHex-HN),(A0122:1-H₂NOC-cHex-HN),(A0123:1-cyano-cHex-HN),(A0124:1-MeHNOC-cHex-HN),(A0125:1-Me₂NOC-cHex-HN),(A0126:1-F₃C-cHex-HN),(A0127:2-HO-cHex-HN),(A0128:2-MeO-cHex-HN),(A0129:2-EtO₂C-cHex-HN),(A0130:2-HO₂C-cHex-HN),(A0131:2-H₂NOC-cHex-HN),(A0132:2-cyano-cHex-HN),(A0133:2-MeHNOC-cHex-HN),(A0134:2-Me₂NOC-cHex-HN),(A0135:2-F₃C-cHex-HN),(A0136:3-HO-cHex-HN),(A0137:3-MeO-cHex-HN),(A0138:3-EtO₂C-cHex-HN),(A0139:3-HO₂C-cHex-HN),(A0140:3-H₂NOC-cHex-HN),(A0141:3-cyano-cHex-HN),(A0142:3-MeHNOC-cHex-HN),(A0143:3-Me₂NOC-cHex-HN),(A0144:3-F₃C-cHex-HN),(A0145:4-HO-cHex-HN),(A0146:4-MeO-cHex-HN),(A0147:4-EtO₂C-cHex-HN),(A0148:4-HO₂C-cHex-HN),(A0149:4-H₂NOC-cHex-HN),(A0150:4-cyano-cHex-HN),(A0151:4-MeHNOC-cHex-HN),(A0152:4-Me₂NOC-cHex-HN),(A0153:4-F₃C-cHex-HN),(A0154:3-HO-cPen-HN),(A0155:3-MeO-cPen-HN),(A0156:3-EtO₂C-cPen-HN),(A0157:3-HO₂C-cPen-HN),(A0158:3-H₂NOC-cPen-HN),(A0159:3-cyano-cPen-HN),(A0160:3-MeHNOC-cPen-HN),(A0161:3-Me₂NOC-cPen-HN),(A0162:3-F₃C-cPen-HN),(A0163:3-HO-cBu-HN),(A0164:3-MeO-cBu-HN),(A0165:3-EtO₂C-cBu-HN),(A0166:3-HO₂C-cBu-HN),(A0167:3-H₂NOC-cBu-HN),(A0168:3-cyano-cBu-HN),(A0169:3-MeHNOC-cBu-HN),(A0170:3-Me₂NOC-cBu-HN),(A0171:3-F₃C-cBu-HN),(A0172:2-HO-cPr-HN),(A0173:2-MeO-cPr-HN),(A0174:2-EtO₂C-cPr-HN),(A0175:2-HO₂C-cPr-HN),(A0176:2-H₂NOC-cPr-HN),(A0177:2-cyano-cPr-HN),(A0178:2-MeHNOC-cPr-HN),(A0179:2-Me₂NOC-CPr-HN),(A0180:2-F₃C-cPr-HN),(A0181:HO—CH₂-MeN),(A0182:MeO-CH₂-MeN),(A0183:EtO₂C-CH₂-MeN),(A0184:HO₂C—CH₂-MeN),(A0185:H₂NOC—CH₂-MeN),(A0186:cyano-CH₂-MeN),(A0187:MeHNOC-CH₂-MeN),(A0188:Me₂NOC-CH₂-MeN),(A0189:F₃C—CH₂-MeN),(A0190:HO—(CH₂)₂-MeN),(A0191:MeO-(CH₂)₂-MeN),(A0192:EtO₂C-(CH₂)₂-MeN),(A0193:HO₂C—(CH₂)₂-MeN),(A0194:H₂NOC—(CH₂)₂-MeN),(A0195:cyano-(CH₂)₂-MeN),(A0196:MeHNOC-(CH₂)₂-MeN),(A0197:Me₂NOC-(CH₂)₂-MeN),(A0198:F₃C—(CH₂)₂-MeN),(A0199:HO—(CH₂)₃-MeN),(A0200:MeO-(CH₂)₃-MeN),(A0201:EtO₂C-(CH₂)₃-MeN),(A0202:HO₂C—(CH₂)₃-MeN),(A0203:H₂NOC—(CH₂)₃-MeN),(A0204:cyano-(CH₂)₃—MeN),(A0205:MeHNOC-(CH₂)₃-MeN),(A0206:Me₂NOC-(CH₂)₃-MeN),(A0207:F₃C—(CH₂)₃-MeN),(A0208:1-HO-cHex-MeN),(A0209:1-MeO-cHex-MeN),(A0210:1-EtO₂C-cHex-MeN),(A0211:1-HO₂C-cHex-MeN),(A0212:1-H₂NOC-cHex-MeN),(A0213:1-cyano-cHex-MeN),(A0214:1-MeHNOC-cHex-MeN),(A0215:1-Me₂NOC-cHex-MeN),(A0216:1-F₃C-cHex-MeN),(A0217:2-HO-cHex-MeN),(A0218:2-MeO-cHex-MeN),(A0219:2-EtO₂C-cHex-MeN),(A0220:2-HO₂C-cHex-MeN),(A0221:2-H₂NOC-cHex-MeN),(A0222:2-cyano-cHex-MeN),(A0223:2-MeHNOC-cHex-MeN),(A0224:2-Me₂NOC-cHex-MeN),(A0225:2-F₃C-cHex-MeN),(A0226:3-HO-cHex-MeN),(A0227:3-MeO-cHex-MeN),(A0228:3-EtO₂C-cHex-MeN),(A0229:3-HO₂C-cHex-MeN),(A0230:3-H₂NOC-cHex-MeN),(A0231:3-cyano-cHex-MeN),(A0232:3-MeHNOC-cHex-MeN),(A0233:3-Me₂NOC-cHex-MeN),(A0234:3-F₃C-cHex-MeN),(A0235:4-HO-cHex-MeN),(A0236:4-MeO-cHex-MeN),(A0237:4-EtO₂C-cHex-MeN),(A0238:4-HO₂C-cHex-MeN),(A0239:4-H₂NOC-cHex-MeN),(A0240:4-cyano-cHex-MeN),(A0241:4-MeHNOC-cHex-MeN),(A0242:4-Me₂NOC-cHex-MeN),(A0243:4-F₃C-cHex-MeN),(A0244:3-HO-cPen-MeN),(A0245:3-MeO-cPen-MeN),(A0246:3-EtO₂C-cPen-MeN),(A0247:3-HO₂C-cPen-MeN),(A0248:3-H₂NOC-cPen-MeN),(A0249:3-cyano-cPen-MeN),(A0250:3-MeHNOC-cPen-MeN),(A0251:3-Me₂NOC-cPen-MeN),(A0252:3-F₃C-cPen-MeN),(A0253:3-HO-cBu-MeN),(A0254:3-MeO-cBu-MeN),(A0255:3-EtO₂C-cBu-MeN),(A0256:3-HO₂C-cBu-MeN),(A0257:3-H₂NOC-cBu-MeN),(A0258:3-cyano-cBu-MeN),(A0259:3-MeHNOC-cBu-MeN),(A0260:3-Me₂NOC-cBu-MeN),(A0261:3-F₃C-cBu-MeN),(A0262:2-HO-cPr-MeN),(A0263:2-MeO-cPr-MeN),(A0264:2-EtO₂C-cPr-MeN),(A0265:2-HO₂C-cPr-MeN),(A0266:2-H₂NOC-cPr-MeN),(A0267:2-cyano-cPr-MeN),(A0268:2-MeHNOC-cPr-MeN),(A0269:2-Me₂NOC-cPr-MeN),(A0270:2-F₃C-cPr-MeN),(A0271:(oxetan-3-yl)-O),(A0272:(tetrahydrofuran-3-yl)-O),(A0273:(tetrahydro-2H-pyran-3-yl)-O),(A0274:(tetrahydro-2H-pyran-4-yl)-O),(A0275:(oxetan-2-yl)-CH₂—O),(A0276:(oxetan-3-yl)-CH₂—O),(A0277:(tetrahydrofuran-2-yl)-CH₂—O),(A0278:(tetrahydrofuran-3-yl)-CH₂—O),(A0279:(tetrahydro-2H-pyran-2-yl)-CH₂—O),(A0280:(tetrahydro-2H-pyran-3-yl)-CH₂—O),(A0281:(tetrahydro-2H-pyran-4-yl)-CH₂—O),(A0282:(morpholin-2-yl)-CH₂—O),(A0283:(morpholin-3-yl)-CH₂—O),(A0284:mor-CH₂—O),(A0285:(1,4-dioxan-2-yl)-CH₂—O),(A0286:(oxetan-2-yl)-(CH₂)₂—O),(A0287:(oxetan-3-yl)-HN),(A0288:(tetrahydrofuran-3-yl)-HN),(A0289:(tetrahydro-2H-pyran-3-yl)-HN),(A0290:(tetrahydro-2H-pyran-4-yl)-HN),(A0291:(oxetan-2-yl)-CH₂—HN),(A0292:(oxetan-3-yl)-CH₂—HN),(A0293:(tetrahydrofuran-2-yl)-CH₂—HN),(A0294:(tetrahydrofuran-3-yl)-CH₂—HN),(A0295:(tetrahydro-2H-pyran-2-yl)-CH₂—HN),(A0296:(tetrahydro-2H-pyran-3-yl)-CH₂—HN),(A0297:(tetrahydro-2H-pyran-4-yl)-CH₂—HN),(A0298:(morpholin-2-yl)-CH₂—HN),(A0299:(morpholin-3-yl)-CH₂—HN),(A0300:mor-CH₂—HN),(A0301:(1,4-dioxan-2-yl)-CH₂—HN),(A0302:(oxetan-3-yl)-MeN),(A0303:(tetrahydrofuran-3-yl)-MeN),(A0304:(tetrahydro-2H-pyran-3-yl)-MeN),(A0305:(tetrahydro-2H-pyran-4-yl)-MeN),(A0306:(oxetan-2-yl)-CH₂-MeN),(A0307:(oxetan-3-yl)-CH₂-MeN),(A0308:(tetrahydrofuran-2-yl)-CH₂-MeN),(A0309:(tetrahydrofuran-3-yl)-CH₂-MeN),(A0310:(tetrahydro-2H-pyran-2-yl)-CH₂-MeN),(A0311:(tetrahydro-2H-pyran-3-yl)-CH₂-MeN),(A0312:(tetrahydro-2H-pyran-4-yl)-CH₂-MeN),(A0313:(morpholin-2-yl)-CH₂-MeN),(A0314:(morpholin-3-yl)-CH₂-MeN),(A0315:mor-CH₂-MeN),(A0316:(1,4-dioxan-2-yl)-CH₂-MeN),(A0317:HO₂C—CH₂CH(OH)—O),(A0318:H₂NOC—CH₂CH(OH)—O),(A0319:cyano-CH₂CH(OH)—O),(A0320:HO₂C—CH₂CH(OMe)-O),(A0321:H₂NOC—CH₂CH(OMe)-O),(A0322:cyano-CH₂CH(OMe)-O),(A0323:HO—CH₂CH(OH)CH₂—O),(A0324:MeO-CH₂CH(OH)CH₂—O),(A0325:HO₂C—CH₂CH(OH)CH₂—O),(A0326:H₂NOC—CH₂CH(OH)CH₂—O),(A0327:cyano-CH₂CH(OH)CH₂—O),(A0328:HO—CH₂CH(OMe)CH₂—O),(A0329:MeO-CH₂CH(OMe)CH₂—O),(A0330:HO₂C—CH₂CH(OMe)CH₂—O),(A0331:H₂NOC—CH₂CH(OMe)CH₂—O),(A0332:cyano-CH₂CH(OMe)CH₂—O),(A0333:HO₂C—CH₂CH(OH)—HN),(A0334:H₂NOC—CH₂CH(OH)—HN),(A0335:cyano-CH₂CH(OH)—HN),(A0336:HO₂C—CH₂CH(OMe)-HN),(A0337:H₂NOC—CH₂CH(OMe)-HN),(A0338:cyano-CH₂CH(OMe)-HN),(A0339:HO—CH₂CH(OH)CH₂—HN),(A0340:MeO-CH₂CH(OH)CH₂—HN),(A0341:HO₂C—CH₂CH(OH)CH₂—HN),(A0342:H₂NOC—CH₂CH(OH)CH₂—HN),(A0343:cyano-CH₂CH(OH)CH₂—HN),(A0344:HO—CH₂CH(OMe)CH₂—HN),(A0345:MeO-CH₂CH(OMe)CH₂—HN),(A0346:HO₂C—CH₂CH(OMe)CH₂—HN),(A0347:H₂NOC—CH₂CH(OMe)CH₂—HN),(A0348:cyano-CH₂CH(OMe)CH₂—HN),(A0349:HO₂C—CH₂CH(OH)-MeN),(A0350:H₂NOC—CH₂CH(OH)-MeN),(A0351:cyano-CH₂CH(OH)-MeN),(A0352:HO₂C—CH₂CH(OMe)-MeN),(A0353:H₂NOC—CH₂CH(OMe)-MeN),(A0354:cyano-CH₂CH(OMe)-MeN),(A0355:HO—CH₂CH(OH)CH₂-MeN),(A0356:MeO-CH₂CH(OH)CH₂-MeN),(A0357:HO₂C—CH₂CH(OH)CH₂-MeN),(A0358:H₂NOC—CH₂CH(OH)CH₂-MeN),(A0359:cyano-CH₂CH(OH)CH₂-MeN),(A0360:HO—CH₂CH(OMe)CH₂-MeN),(A0361:MeO-CH₂CH(OMe)CH₂-MeN),(A0362:HO₂C—CH₂CH(OMe)CH₂-MeN),(A0363:H₂NOC—CH₂CH(OMe)CH₂-MeN),(A0364:cyano-CH₂CH(OMe)CH₂-MeN),(A0365:HO—(CH₂)₂—(HO(CH₂)₂)N),(A0366:MeO-(CH₂)₂—(HO(CH₂)₂)N),(A0367:HO₂C—(CH₂)₂—(HO(CH₂)₂)N),(A0368:H₂NOC—(CH₂)₂—(HO(CH₂)₂)N),(A0369:cyano-(CH₂)₂—(HO(CH₂)₂)N),(A0370:HO—(CH₂)₃—(HO(CH₂)₂)N),(A0371:MeO-(CH₂)₃—(HO(CH₂)₂)N),(A0372:HO₂C—(CH₂)₃—(HO(CH₂)₂)N),(A0373:H₂NOC—(CH₂)₃—(HO(CH₂)₂)N),(A0374:cyano-(CH₂)₃—(HO(CH₂)₂)N),(A0375:HO—(CH₂)₂-(MeO(CH₂)₂)N),(A0376:MeO-(CH₂)₂-(MeO(CH₂)₂)N),(A0377:HO₂C—(CH₂)₂-(MeO(CH₂)₂)N),(A0378:H₂NOC—(CH₂)₂-(MeO(CH₂)₂)N),(A0379:cyano-(CH₂)₂-(MeO(CH₂)₂)N),(A0380:HO—(CH₂)₃-(MeO(CH₂)₂)N),(A0381:MeO-(CH₂)₃-(MeO(CH₂)₂)N),(A0382:HO₂C—(CH₂)₃-(MeO(CH₂)₂)N),(A0383:H₂NOC—(CH₂)₃-(MeO(CH₂)₂)N),(A0384:cyano-(CH₂)₃-(MeO(CH₂)₂)N).

TABLE 24

(No:R^(K)) = (A0385:3-HO-pyrr),(A0386:3-MeO-pyrr),(A0387:3-HO₂C-pyrr),(A0388:3-H₂NOC-pyrr),(A0389:3-cyano-pyrr), (A0390:3-MeHNOC-pyrr),(A0391:3-Me₂NOC-pyrr),(A0392:3-F₃C-pyrr),(A0393:3-F-pyrr),(A0394:3-oxo-pyrr), (A0395:3-H₂NO2S-pyrr), (A0396:3-HO₃S-pyrr),(A0397:3-ttrz-pyrr),(A0398:3-HOCH₂-pyrr),(A0399:3-MeOCH₂-pyrr),(A0400:3-HO₂CCH₂-pyrr),(A0401:3-H₂NOCCH₂-pyrr),(A0402:3-(cyano-CH₂)-pyrr),(A0403:3-HO₂CCH₂O-pyrr),(A0404:3-H₂NOCCH₂O-pyrr),(A0405:3-HO-pipe),(A0406:3-MeO- pipe),(A0407:3-HO₂C-pipe),(A0408:3-H₂NOC-pipe),(A0409:3-cyano-pipe),(A0410:3-MeHNOC-pipe),(A0411:3-Me₂NOC-pipe),(A0412:3-F₃C-pipe),(A0413:3-F-pipe),(A0414:3-oxo-pipe),(A0415:3-H₂NO₂S-pipe),(A0416:3-HO₃S-pipe),(A0417:3-ttrz-pipe),(A0418:3-HOCH₂-pipe),(A0419:3-MeOCH₂-pipe),(A0420:3-HO₂CCH₂-pipe),(A0421:3-H₂NOCCH₂-pipe),(A0422:3-(cyano-CH₂)-pipe),(A0423:3-HO₂CCH₂O-pipe),(A0424:3-H₂NOCCH₂O-pipe),(A0425:4-HO-pipe),(A0426:4-MeO-pipe),(A0427:4-HO₂C-pipe),(A0428:4-H₂NOC-pipe),(A0429:4-cyano-pipe),(A0430:4-MeHNOC-pipe),(A0431:4-Me₂NOC-pipe),(A0432:4-F₃C-pipe),(A0433:4-F-pipe),(A0434:4-oxo-pipe), (A0435:4-H₂NO₂S-pipe),(A0436:4-HO₃S- pipe),(A0437:4-ttrz-pipe),(A0438:4-HOCH₂-pipe),(A0439:4-MeOCH₂-pipe),(A0440:4-HO₂CCH₂-pipe),(A0441:4-H₂NOCCH₂-pipe),(A0442:4-(cyano-CH₂)-pipe),(A0443:4-HO₂CCH₂O-pipe),(A0444:4-H₂NOCCH₂O-pipe).

TABLE 25

(NO:R^(L)) = (A0445:HO—CH₂—O),(A0446:MeO—CH₂—O),(A0447:EtO₂C—CH₂—O),(A0448:HO₂C—CH₂—O),(A0449:H₂NOC—CH₂—O),(A0450:cyano-CH₂—O),(A0451:HO—(CH₂)₂—O),(A0452:MeO—(CH₂)₂—O),(A0453:EtO₂C—(CH₂)₂—O),(A0454:HO₂C—(CH₂)₂—O),(A0455:H₂NOC—(CH₂)₂—O),(A0456:cyano-(CH₂)₂—O),(A0457:HO—(CH₂)₃—O),(A0458:MeO—(CH₂)₃—O),(A0459:EtO₂C—(CH₂)₃—O),(A0460:HO₂C—(CH₂)₃—O),(A0461:H₂NOC—(CH₂)₃—O),(A0462:cyano-(CH₂)₃—O),(A0463:HO—CH₂—HN),(A0464:MeO-CH₂—HN),(A0465:EtO₂C—CH₂—HN),(A0466:HO₂C—CH₂—HN),(A0467:H₂NOC—CH₂—HN),(A0468:cyano-CH₂—HN),(A0469:HO—(CH₂)₂—HN),(A0470:MeO—(CH₂)₂—HN),(A0471:EtO₂C—(CH₂)₂—HN),(A0472:HO₂C—(CH₂)₂—HN),(A0473:H₂NOC—(CH₂)₂—HN),(A0474:cyano-(CH₂)₂—HN),(A0475:HO—(CH₂)₃—HN),(A0476:MeO—(CH₂)₃—HN),(A0477:EtO₂C—(CH₂)₃—HN),(A0478:HO₂C—(CH₂)₃—HN),(A0479:H₂—NOC(CH₂)₃—HN),(A0480:cyano-(CH₂)₃—HN),(A0481:HO—CH₂—MeN),(A0482:MeO—CH₂—MeN),(A0483:EtO₂C—CH₂—MeN),(A0484:HO₂C—CH₂—MeN),(A0485:H₂NOC—CH₂—MeN),(A0486:cyano-CH₂—MeN),(A0487:HO—(CH₂)₂—MeN),(A0488:MeO—(CH₂)₂—MeN),(A0489:EtO₂C—(CH₂)₂—MeN),(A0490:HO₂C—(CH₂)₂—MeN),(A0491:H₂NOC—(CH₂)₂—MeN),(A0492:cyano-(CH₂)₂—MeN),(A0493:HO—(CH₂)₃—MeN),(A0494:MeO—(CH₂)₃—MeN),(A0495:EtO₂C—(CH₂)₃—MeN),(A0496:HO₂C—(CH₂)₃—MeN),(A0497:H₂NOC—(CH₂)₃—MeN),(A0498:cyano-(CH₂)₃—MeN).

TABLE 26

(No:R^(M)) =(A0499:2-HO₂C-azet),(A0500:2-H₂NOC-azet),(A0501:2-cyano-azet),(A0502:2-MeHNOC-azet),(A0503:2-Me₂NOC-azet),(A0504:2-(MeO(CH₂)₂—(HNOC))-azet),(A0505:2-(MeO(CH₂)₃—(HNOC))-azet),(A0506:2-(mor-OC)-azet),(A0507:2-F₃C-azet),(A0508:2-oxo-azet),(A0509:2-H₂NO₂S-azet),(A0510:2-HO₃S-azet),(A0511:2-ttrz-azet),(A0512:2-HOCH₂-azet),(A0513:2-MeOCH₂-azet),(A0514:2-HO₂CCH₂-azet),(A0515:2-H₂NOCCH₂-azet),(A0516:2-(cyano-CH₂)-azet),(A0517:2-HO(CH₂)₂-azet),(A0518:2-MeO(CH₂)₂-azet),(A0519:2-HO₂C(CH₂)₂-azet),(A0520:2-H₂NOC(CH₂)₂-azet),(A0521:2-(cyano-(CH₂)₂)-azet),(A0522:3-HO-azet),(A0523:3-MeO-azet),(A0524:3-HO₂C-azet),(A0525:3-H₂NOC-azet),(A0526:3-cyano-azet),(A0527:3-MeHNOC-azet),(A0528:3-Me₂NOC-azet),(A0529:3-(MeO(CH₂)₂—(HNOC))-azet),(A0530:3-MeO(CH₂)₃—(HNOC))-azet),(A0531:3-(mor-OC)-azet),(A0532:3-F₃C-azet),(A0533:3-F-azet),(A0534:3-oxo-azet),(A0535:3-H₂NO₂S-azet),(A0536:3-HO₃S-azet),(A0537:3-ttrz-azet),(A0538:3-HOCH₂-azet),(A0539:3-MeOCH₂-azet),(A0540:3-HO₂CCH₂-azet),(A0541:3-H₂NOCCH₂-azet),(A0542:3-(cyano-CH₂)-azet),(A0543:3-HO(CH₂)₂-azet),(A0544:3-MeO(CH₂)₂-azet),(A0545:3-HO₂C(CH₂)₂-azet),(A0546:3-H₂NOC(CH₂)₂-azet),(A0547:3-(cyano-(CH₂)₂)-azet),(A0548:3-HO₂CCH₂O-azet),(A0549:3-H₂NOCCH₂O-azet),(A0550:2-HO₂C-pyrr),(A0551:2-H₂NOC-pyrr),(A0552:2-cyano-pyrr),(A0553:2-MeHNOC-pyrr),(A0554:2-Me2NOC-pyrr),(A0555:2-(MeO(CH₂)₂—(HNOC))-pyrr),(A0556:2-(MeO(CH₂)₃—(HNOC))-pyrr),(A0557:2-(mor-OC)-pyrr),(A0558:2-F₃C-pyrr),(A0559:2-oxo-pyrr),(A0560:2-H₂NO₂S-pyrr),(A0561:2-HO₃S-pyrr),(A0562:2-ttrz-pyrr),(A0563:2-HOCH₂-pyrr),(A0564:2-MeOCH₂-pyrr),(A0565:2-HO₂CCH₂-pyrr),(A0566:2-H₂NOCCH₂-pyrr),(A0567:2-(cyano-CH₂)-pyrr),(A0568:3-HO-pyrr),(A0569:3-MeO-pyrr),(A0570:3-HO₂C-pyrr),(A0571:3-H₂NOC-pyrr),(A0572:3-cyano-pyrr),(A0573:3-MeHNOC-pyrr),(A0574:3-Me₂NOC-pyrr),(A0575:3-(MeO(CH₂)₂—(HNOC))-pyrr),(A0576:3-(MeO(CH₂)₃—(HNOC))-pyrr),(A0577:3-(mor-OC)-pyrr),(A0578:3-F₃C-pyrr),(A0579:3-F-pyrr),(A0580:3-oxo-pyrr),(A0581:3-H₂NO₂S-pyrr),(A0582:3-HO₃S-pyrr),(A0583:3-ttrz-pyrr),(A0584:3-HOCH₂-pyrr),(A0585:3-MeOCH₂-pyrr),(A0586:3-HO₂CCH₂-pyrr),(A0587:3-H₂NOCCH₂-pyrr),(A0588:3-(cyano-CH₂)-pyrr),(A0589:3-HO₂CCH₂O-pyrr),(A0590:3-H₂NOCCH₂O-pyrr),(A0591:2-HO₂C-pipe),(A0592:2-H₂NOC-pipe),(A0593:2-cyano-pipe),(A0594:2-MeHNOC-pipe),(A-595:2-Me₂NOC-pipe),(A-596:2-(MeO(CH₂)₂—(HNOC))-pipe),(A0597:2-(MeO(CH₂)₃-(HNOC))-pipe),(A0598:2-(mor-OC)-pipe),(A0599:2-F₃C-pipe),(A0600:2-oxo-pipe),(A0601:2-H₂NO₂S-pipe),(A0602:2-HO₃S-pipe),(A0603:2-ttrz-pipe),(A0604:2-HOCH₂-pipe),(A0605:2-MeOCH₂-pipe),(A0606:2-HO₂CCH₂-pipe),(A0607:2-H₂NOCCH₂-pipe),(A0608:2-(cyano-CH₂)-pipe),(A0609:2-HO(CH₂)₂-pipe),(A0610:3-HO-pipe),(A0611:3-MeO-pipe),(A0612:3-HO₂C-pipe),(A0613:3-H₂NOC-pipe),(A0614:3-cyano-pipe),(A0615:3-MeHNOC-pipe),(A0616:3-Me₂NOC-pipe),(A0617:3-(MeO(CH₂)₂—(HNOC))-pipe),(A0618:3-(MeO(CH₂)₃—(HNOC))-pipe),(A0619:3-(mor-OC)-pipe),(A0620:3-F₃C-pipe),(A0621:3-F-pipe),(A0622:3-oxo-pipe),(A0623:3-H₂NO₂S-pipe),(A0624:3-HO₃S-pipe),(A0625:3-ttrz-pipe),(A0626:3-HOCH₂-pipe),(A0627:3-MeOCH₂-pipe),(A0628:3-HO₂CCH₂-pipe),(A0629:3-H₂NOCCH₂-pipe),(A0630:3-(cyano-CH₂)-pipe),(A0631:3-HO₂CCH₂O-pipe),(A0632:3-H₂NOCCH₂O-pipe),(A0633:4-HO-pipe),(A0634:4-MeO-pipe),(A0635:4-HO₂C-pipe),(A0636:4-H₂NOC-pipe),(A0637:4-cyano-pipe),(A0638:4-MeHNOC-pipe),(A0639:4-Me₂NOC-pipe),(A0640:4-(MeO(CH₂)₂—(HNOC))-pipe),(A0641:4-(MeO(CH₂)₃—(HNOC))-pipe),(A0642:4-(mor-OC)-pipe),(A0643:4-F₃C-pipe),(A0644:4-F-pipe),(A0645:4-oxo-pipe),(A0646:4-H₂NO₂S-pipe),(A0647:4-HO₃S-pipe),(A0648:4-ttrz-pipe),(A0649:4-HOCH₂-pipe),(A0650:4-MeOCH₂-pipe),(A0651:4-HO₂CCH₂-pipe),(A0652:4-H₂NOCCH₂-pipe),(A0653:4-(cyano-CH₂)-pipe),(A0654:4-HO₂CCH₂O-pipe),(A0655:4-H₂NOCCH₂O-pipa),(A0656:2-HO₂C-pipa),(A0657:2-H₂NOC-pipa),(A0658:2-cyano-pipa),(A0659:2-MeHNOC-pipa),(A0660:2-Me₂NOC-pipa),(A0661:2-(MeO(CH₂)₂-(HNOC))-pipa),(A0662:2-(MeO(CH₂)₃—(HNOC))-pipa),(A0663:2-(mor-OC)-pipa),(A0664:2-F₃C-pipa),(A0665:2-oxo-pipa),(A0666:2-H₂NO₂S-pipa),(A0667:2-HO₃S-pipa),(A0668:2-ttrz-pipa),(A0669:2-HOCH₂-pipa),(A0670:2-MeOCH₂-pipa),(A0671:2-HO₂CCH₂-pipa),(A0672:2-H₂NOCCH₂-pipa),(A0673:2-(cyano-CH₂)-pipa),(A0674:3-HO₂C-pipa),(A0675:3-H₂NOC-pipa),(A0676:3-cyano-pipa),(A0677:3-MeHNOC-pipa),(A0678:3-Me₂NOC-pipa),(A0679:3-(MeO(CH₂)₂—(HNOC))-pipa),(A0680:3-(MeO(CH₂)₃—-(HNOC))-pipa),(A0681:3-(mor-OC)-pipa),(A0682:3-F₃C-pipa),(A0683:3-oxo-pipa),(A0684:3-H₂NO₂S-pipa),(A0685:3-HO₃S-pipa),(A0686:3-ttrz-pipa),(A0687:3-HOCH₂-pipa),(A0688:3-MeOCH₂-pipa),(A0689:3-HO₂CCH₂-pipa),(A0690:3-H₂NOCCH₂-pipa),(A0691:3-(cyano-CH₂)-pipa),(A0692:4-H₂NOC-pipa),(A0693:4-MeHNOC-pipa),(A0694:4-Me₂NOC-pipa),(A0695:4-(MeO(CH₂)₂—(HNOC))-pipa),(A0696:4-(MeO(CH₂)₃—(HNOC))-pipa),(A0697:4-(mor-OC)-pipa),(A0698:4-F₃C-pipa),(A0699:4-H₂NO₂S-pipa),(A0700:4-EtO₂C-pipa),(A0701:4-HO₂CCH₂-pipa),(A0702:4-H₂NOCCH₂-pipa),(A0703:4-(cyano-CH₂)-pipa),(A0704:2-HO₂C-mor),(A0705:2-H₂NOC-mor),(A0706:2-cyano-mor),(A0707:2-MeHNOC-mor),(A0708:2-Me₂NOC-mor),(A0709:2-(MeO(CH₂)₂—(HNOC))-mor),(A0710:2-(MeO(CH₂)₃—(HNOC))-mor),(A0711:2-(mor-OC)-mor),(A0712:2-F₃C-mor),(A0713:2-oxo-mor),(A0714:2-H₂NO₂S-mor),(A0715:2-HO₃S-mor),(A0716:2-ttrz-mor),(A0717:2-HOCH₂-mor),(A0718:2-MeOCH₂-mor),(A0719:2-HO₂CCH₂-mor),(A0720:2-H₂NOCCH₂-mor),(A0721:2-(cyano-CH₂)-mor),(A0722:3-HO₂C-mor),(A0723:3-H₂NOC-mor),(A0724:3-cyano-mor),(A0725:3-MeHNOC-mor),(A0726:3-Me₂NOC-mor),(A0727:3-(MeO(CH₂)₂—(HNOC))-mor),(A0728:3-(MeO(CH₂)₃—(HNOC))-mor),(A0729:3-(mor-OC)-mor),(A0730:3-F₃C-mor),(A0731:3-oxo-mor),(A0732:3-H₂NO₂S-mor),(A0733:3-HO₃S-mor),(A0734:3-ttrz-mor),(A0735:3-HOCH₂-mor),(A0736:3-MeOCH₂-mor),(A0737:3-HO₂CCH₂-mor),(A0738:3-H₂NOCCH₂-mor),(A0739:3-(cyano-CH₂)-mor),(A0740:2-HO₂C-tmor),(A0741:2-H₂NOC-tmor),(A0742:2-cyano-tmor),(A0743:2-MeHNOC-tmor),(A0744:2-Me₂NOC-tmor),(A0745:2-(MeO(CH₂)₂—(HNOC))-tmor),(A0746:2-(MeO(CH₂)₃—(HNOC))-tmor),(A0747:2-(mor-OC)-tmor),(A0748:2-F₃C-tmor),(A0749:2-oxo-tmor),(A0750:2-H₂NO₂S-tmor),(A0751:2-HO₃S-tmor),(A0752:2-ttrz-tmor),(A0753:2-HOCH₂-tmor),(A0754:2-MeOCH₂-tmor),(A0755:2-HO₂CCH₂-tmor),(A0756:2-H₂NOCCH₂-tmor),(A0757:2-(cyano-CH₂)-tmor),(A0758:3-HO₂C-tmor),(A0759:3-H₂NOC-tmor),(A0760:3-cyano-tmor),(A0761:3-MeHNOC-tmor),(A0762:3-Me₂NOC-tmor),(A0763:3-(MeO(CH₂)₂—(HNOC))-tmor),(A0764:3-(MeO(CH₂)₃—(HNOC))-tmor),(A0765:3-(mor-OC)-tmor),(A0766:3-F₃C-tmor),(A0767:3-oxo-tmor),(A0768:3-H₂NO₂S-tmor),(A0769:3-HO₃S-tmor),(A0770:3-ttrz-tmor),(A0771:3-HOCH₂-tmor),(A0772:3-MeOCH₂-tmor),(A0773:3-HO₂CCH₂-tmor),(A0774:3-H₂NOCCH₂-tmor),(A0775:3-(cyano-CH₂)-tmor),(A0776:1-oxido-tmor),(A0777:1,1-dioxido-tmor),(A0778:4-HO-cHex),(A0779:4-MeO-cHex),(A0780:4-HO₂C-cHex),(A0781:4-H₂NOC-cHex),(A0782:4-cyano-cHex),(A0783:4-MeHNOC-cHex),(A0784:4-Me₂NOC-cHex),(A0785:4-(MeO(CH₂)₂—(HNOC))-cHex),(A0786:4-(MeO(CH₂)₃—(HNOC))-cHex),(A0787:4-(mor-OC)-cHex),(A0788:4-F₃C-cHex),(A0789:4-F-cHex),(A0790:4-oxo-cHex),(A0791:4-H₂NO₂S-cHex),(A0792:4-HO₂S-cHex),(A0793:4-ttrz-cHex),(A0794:4-HOCH₂-cHex),(A0795:4-MeOCH₂-cHex),(A0796:4-HO₂CCH₂-cHex),(A0797:4-H₂NOCCH₂-cHex),(A0798:4-(cyano-CH₂)-cHex),(A0799:4-HO₂CCH₂O-cHex),(A0800:4-H₂NOCCH₂O-cHex),(A0801:1-H₂NOC-piperidin-4-yl),(A0802:1-MeHNOC-piperidin-4-yl),(A0803:1-Me₂NOC-piperidin-4-yl),(A0804:1-(MeO(CH₂)₂—(HNOC))-piperidin-4-yl),(A0805:1-(MeO(CH₂)₃—(HNOC))-piperidin-4-yl),(A0806:1-(mor-OC)-piperidin-4-yl),(A0807:1-F₃C-piperidin-4-yl),(A0808:1-H₂NO₂S-piperidin-4-yl),(A0809:1-EtO₂C-piperidin-4-yl),(A0810:1-HO₂CCH₂-piperidin-4-yl),(A0811:1-H₂NOCCH₂-piperidin-4-yl),(A0812:1-(cyano-CH₂)-piperidin-4-yl),(A0813:2-HO₂C-4-HO-pipe),(A0814:2-H₂NOC-4-HO-pipe),(A0815:2-cyano-4-HO-pipe),(A0816:2-HOCH₂-4-HO-pipe),(A0817:3-HO-4-HO-pipe),(A0818:3-MeO-4-HO-pipe),(A0819:3-HO₂C-4-HO-pipe),(A0820:3-H₂NOC-4-HO-pipe),(A0821:3-cyano-4-HO-pipe),(A0822:3-HOCH₂-4-HO-pipe),(A0823:4-HO-4-HO-pipe),(A0824:4-MeO-4-HO-pipe),(A0825:4-HO₂C-4-HO-pipe),(A0826:4-H₂NOC-4-HO-pipe),(A0827:4-cyano-4-HO-pipe),(A0828:2-HO₂C-4-MeO-pipe),(A0829:2-H₂NOC-4-MeO-pipe),(A0830:2-cyano-4-MeO-pipe),(A0831:2-HOCH₂-4-MeO-pipe),(A0832:3-HO-4-MeO-pipe),(A0833:3-MeO-4-MeO-pipe),(A0834:3-HO₂C-4-MeO-pipe),(A0835:3-H₂NOC-4-MeO-pipe),(A0836:3-cyano-4-MeO-pipe),(A0837:3-HOCH₂-4-MeO-pipe),(A0838:4-HO-4-MeO-pipe),(A0839:4-MeO-4-MeO-pipe),(A0840:4-HO₂C-4-MeO-pipe),(A0841:4-H₂NOC-4-MeO-pipe),(A0842:4-cyano-4-MeO-pipe),(A0843:2-HO₂C-4-HO₂C-pipe),(A0844:2-H₂NOC-4-HO₂C-pipe),(A0845:2-cyano-4-HO₂C-pipe),(A0846:2-HOCH₂-4-HO₂C-pipe),(A0847:3-HO-4-HO₂C-pipe),(A0848:3-MeO-4-HO₂C-pipe),(A0849:3-HO₂C-4-HO₂C-pipe),(A0850:3-H₂NOC-4-HO₂C-pipe),(A0851:3-cyano-4-HO₂C-pipe),(A0852:3-HOCH₂-4-HO₂C-pipe),(A0853:4-HO-4-HO₂C-pipe),(A0854:4-MeO-4-HO₂C-pipe),(A0855:4-HO₂C-4-HO₂C-pipe),(A0856:4-H₂NOC-4-HO₂C-pipe),(A0857:4-cyano-4-HO₂C-pipe),(A0858:2-HO₂C-4-H₂NOC-pipe),(A0859:2-H₂NOC-4-H₂NOC-pipe),(A0860:2-cyano-4-H₂NOC-pipe),(A0861:2-HOCH₂-4-H₂NOC-pipe),(A0862:3-HO-4-H₂NOC-pipe),(A0863:3-MeO-4-H₂NOC-pipe),(A0864:3-HO₂C-4-H₂NOC-pipe),(A0865:3-H₂NOC-4-H₂NOC-pipe),(A0866:3-cyano-4-H₂NOC-pipe),(A0867:3-HOCH₂-4-H₂NOC-pipe),(A0868:4-HO-4-H₂NOC-pipe),(A0869:4-MeO-4-H₂NOC-pipe),(A0870:4-HO₂C-4-H₂NOC-pipe),(A0871:4-H₂NOC-4-H₂NOC-pipe),(A0872:4-cyano-4-H₂NOC-pipe),(A0873:2-HO₂C-4-cyano-pipe),(A0874:2-H₂NOC-4-cyano-pipe),(A0875:2-cyano-4-cyano-pipe),(A0876:2-HOCH₂-4-cyano-pipe),(A0877:3-HO-4-cyano-pipe),(A0878:3-MeO-4-cyano-pipe),(A0879:3-HO₂C-4-cyano-pipe),(A0880:3-H₂NOC-4-cyano-pipe),(A0881:3-cyano-4-cyano-pipe),(A0882:3-HOCH₂-4-cyano-pipe),(A0883:4-HO-4-cyano-pipe),(A0884:4-MeO-4-cyano-pipe),(A0885:4-HO₂C-4-cyano-pipe),(A0886:4-H₂NOC-4-cyano-pipe),(A0887:4-cyano-4-cyano-pipe),(A0888:2-HO₂C-4-(HOCH₂)-pipe),(A0889:2-H₂NOC-4-(HOCH₂)-pipe),(A0890:2-cyano-4-(HOCH₂)-pipe),(A0891:2-HOCH₂-4-(HOCH₂)-pipe),(A0892:3-HO-4-(HOCH₂)-pipe),(A0893:3-MeO-4-(HOCH₂)-pipe),(A0894:3-HO₂C-4-(HOCH₂)-pipe),(A0895:3-H₂NOC-4-(HOCH₂)-pipe),(A0896:3-cyano-4-(HOCH₂)-pipe),(A0897:3-HOCH₂-4-(HOCH₂)-pipe),(A0898:4-HO-4-(HOCH₂)-pipe),(A0899:4-MeO-4-(HOCH₂)-pipe),(A0900:4-HO₂C-4-(HOCH₂)-pipe),(A0901:4-H₂NOC-4-(HOCH₂)-pipe),(A0902:4-cyano-4-(HOCH₂)-pipe),(A0903:2-HO₂C-4-HO-pyrr),(A0904:2-H₂NOC-4-HO-pyrr),(A0905:2-cyano-4-HO-pyrr),(A0906:2-HOCH₂-4-HO-pyrr),(A0907:3-HO-4-HO-pyrr),(A0908:3-MeO-4-HO-pyrr),(A0909:3-HO₂C-4-HO-pyrr),(A0910:3-H₂NOC-4-HO-pyrr),(A0911:3-cyano-4-HO-pyrr),(A0912:3-HOCH₂-4-HO-pyrr),(A0913:2-HO₂C-4-MeO-pyrr),(A0914:2-H₂NOC-4-MeO-pyrr),(A0915:2-cyano-4-MeO-pyrr),(A0916:2-HOCH₂-4-MeO-pyrr),(A0917:3-HO-4-MeO-pyrr),(A0918:3-MeO-4-MeO-pyrr),(A0919:3-HO₂C-4-MeO-pyrr),(A0920:3-H₂NOC-4-MeO-pyrr),(A0921:3-cyano-4-MeO-pyrr),(A0922:3-HOCH₂-4-MeO-pyrr),(A0923:2-HO₂C-4-HO₂C-pyrr),(A0924:2-H₂NOC-4-HO₂C-pyrr),(A0925:2-cyano-4-HO₂C-pyrr),(A0926:2-HOCH₂-4-HO₂C-pyrr),(A0927:3-HO-4-HO₂C-pyrr),(A0928:3-MeO-4-HO₂C-pyrr),(A0929:3-HO₂C-4-HO₂C-pyrr),(A0930:3-H₂NOC-4-HO₂C-pyrr),(A0931:3-cyano-4-HO₂C-pyrr),(A0932:3-HOCH₂-4-HO₂C-pyrr),(A0933:2-HO₂C-4-H₂NOC-pyrr),(A0934:2-H₂NOC-4-H₂NOC-pyrr),(A0935:2-cyano-4-H₂NOC-pyrr),(A0936:2-HOCH₂-4-H₂NOC-pyrr),(A0937:3-HO-4-H₂NOC-pyrr),(A0938:3-MeO-4-H₂NOC-pyrr),(A0939:3-HO₂C-4-H₂NOC-pyrr),(A0940:3-H₂NOC-4-H₂NOC-pyrr),(A0941:3-cyano-4-H₂NOC-pyrr),(A0942:3-HOCH₂-4-H₂NOC-pyrr),(A0943:2-HO₂C-4-cyano-pyrr),(A0944:2-H₂NOC-4-cyano-pyrr),(A0945:2-cyano-4-cyano-pyrr),(A0946:2-HOCH₂-4-cyano-pyrr),(A0947:3-HO-4-cyano-pyrr),(A0948:3-MeO-4-cyano-pyrr),(A0949:3-HO₂C-4-cyano-pyrr),(A0950:3-H₂NOC-4-cyano-pyrr),(A0951:3-cyano-4-cyano-pyrr),(A0952:3-HOCH₂-4-cyano-pyrr),(A0953:2-HO₂C-4-(HOCH₂)-pyrr),(A0954:2-H₂NOC-4-(HOCH₂)-pyrr),(A0955:2-cyano-4-(HOCH₂)-pyrr),(A0956:2-HOCH₂-4-(HOCH₂)-pyrr),(A0957:3-HO-4-(HOCH₂)-pyrr),(A0958:3-MeO-4-(HOCH₂)-pyrr),(A0959:3-HO₂C-4-(HOCH₂)-pyrr),(A0960:3-H₂NOC-4-(HOCH₂)-pyrr),(A0961:3-cyano-4-(HOCH₂)-pyrr),(A0962:3-HOCH₂-4-(HOCH₂)-pyrr),(A0963:2-HO₂C-3-HO-pyrr),(A0964:2-H₂NOC-3-HO-pyrr),(A0965:2-cyano-3-HO-pyrr),(A0966:2-HOCH₂-3-HO-pyrr),(A0967:3-HO-3-HO-pyrr),(A0968:3-MeO-3-HO-pyrr),(A0969:3-HO₂C-3-HO-pyrr),(A0970:3-H₂NOC-3-HO-pyrr),(A0971:3-cyano-3-HO-pyrr),(A0972:2-HO₂C-3-MeO-pyrr),(A0973:2-H₂NOC-3-MeO-pyrr),(A0974:2-Cyano-3-MeO-pyrr),(A0975:2-HOCH₂-3-MeO-pyrr),(A0976:3-HO-3-MeO-pyrr),(A0977:3-MeO-3-MeO-pyrr),(A0978:3-HO₂C-3-MeO-pyrr),(A0979:3-H₂NOC-3-MeO-pyrr),(A0980:3-cyano-3-MeO-pyrr),(A0981:2-HO₂C-3-HO₂C-pyrr),(A0982:2-H₂NOC-3-HO₂C-pyrr),(A0983:2-cyano-3-HO₂C-pyrr),(A0984:2-HOCH₂-3-HO₂C-pyrr), (A0985:3-HO-3-HO₂C-pyrr),(A0986:3-MeO-3-HO₂C-pyrr),(A0987:3-HO₂C-3-HO₂C-pyrr),(A0988:3-H₂NOC-3-HO₂C-pyrr),(A0989:3-cyano-3-HO₂C-pyrr),(A0990:2-HO₂C-3-H₂NOC-pyrr),(A0991:2-H₂NOC-3-H₂NOC-pyrr),(A0992:2-cyano-3-H₂NOC-pyrr),(A0993:2-HOCH₂-3-H₂NOC-pyrr),(A0994:3-HO-3-H₂NOC-pyrr),(A0995:3-MeO-3-H₂NOC-pyrr),(A0996:3-HO₂C-3-H₂NOC-pyrr),(A0997:3-H₂NOC-3-H₂NOC-pyrr),(A0998:3-cyano-3-H₂NOC-pyrr),(A0999:2-HO₂C-3-cyanopyrr),(A1000:2-H₂NOC-3-cyano-pyrr),(A1001:2-cyano-3-cyano-pyrr),(A1002:2-HOCH₂-3-cyano-pyrr),(A1003:3-HO-3-cyano-pyrr),(A1004:3-MeO-3-cyano-pyrr),(A1005:3-HO₂C-3-cyano-pyrr),(A1006:3-H₂NOC-3-cyano-pyrr),(A1007:3-cyano-3-cyano-pyrr),(A1008:2-HO₂C-3-(HOCH₂)-pyrr),(A1009:2-H₂NOC-3-(HOCH₂)-pyrr),A1010:2-cyano-3-(HOCH₂)-pyrr),(A1001:2-HOCH₂-3-(HOCH₂)-pyrr),(A1012:3-HO-3-(HOCH₂)-pyrr),(A1013:3-MeO-3-(HOCH₂)-pyrr),(A1014:3-HO₂C-3-(HOCH₂)-pyrr),(A1015:3-H₂NOC-3-(HOCH₂)-pyrr),(A1016:3-cyano-3-(HOCH₂)-pyrr),(A1017:8-azaspiro[4.5]dec-8-yl),(A1018:1-oxa-8-azaspiro[4,5]dec-8-yl),(A1019:2′-oxo-(piperidine-4-spiro-3′-pyrrolidine)-1-yl),(A1020:1′-methyl-2′-oxo-(piperidine-4-spiro-3′-pyrrolidine)-1-yl),(A1021:1-phenyl-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl),(A1022:(piperidine-4-spiro-5′-hydantoin)-1-yl),(A1023:(1,3-dihydroisobenzofuran-1-spiro-4′-piperidin)-1′-yl),(A1024:3-oxo-(1,3-dihydroisobenzofuran-1-spiro-4′-piperidin)-1′-yl).

TABLE 27

(No:R^(N),R^(O),R^(P)) =(A1025:H,HO,H),(A1026:H,HO—(CH₂)₂—O,H),(A1027:H,HO—(CH₂)₃—O,H),(A1028:H,4-HO-pipe,H),(A1029:H,3-HO-pyrr,H),(A1030:H,4-HO₂C-pipe,H),(A1031:H,4-(cyano)-pipe,H),(A1032:H,4-Ac-pipa,H),(A1033:H,3-oxo-pipa,H),(A1034:F,HO,H),(A1035:F,HO—(CH₂)₂—O,H),(A1036:F, HO—(CH₂)₃—O,H),(A1037:F,4-HO-pipe,H),(A1038:F,3-HO-pyrr,H),(A1039:F,4-HO₂C-pipe,H),(A1040:F,4-(cyano)-pipe,H),(A1041:F,4-Ac-pipa,H),(A1042:F,3-oxo-pipa,H),(A1043:F,HO,F),(A1044:F,HO-(CH₂)₂—O,F),(A1045:F,HO—(CH₂)₃—O,F),(A1046:F,4-HO-pipe,F),(A1047:F,3-HO-pyrr,F),(A1048:F,4-HO₂C-pipe,F),(A1049:F,4-(cyano)-pipe,F),(A1050:F,4-Ac-pipa,F),(A1051:F,3-oxo-pipa,F),(A1052:F,HO,Cl),(A1053:F,HO—(CH₂)₂—O,Cl),(A1054:F,HO—(CH₂)₃—O,Cl),(A1055:F,4-HO-pipe,Cl),(A1056:F,3-HO-pyrr,Cl),(A1057:F,4-HO₂C-pipe,Cl),(A1058:F,4-(cyano)-pipe,Cl),(A1059:F,4-Ac-pipa,Cl),(A1060:F,3-oxo-pipa,Cl),(A1061:F,HO,Br),(A1062:F,HO—(CH₂)₂—O,Br),(A1063:F,HO—(CH₂)₃—O,Br),(A1064:F,4-HO-pipe,Br),(A1065:F,3-HO-pyrr,Br),(A1066:F,4-HO₂C-pipe,Br),(A1067:F,4-(cyano)-pipe,Br),(A1068:F,4-Ac-pipa,Br),(A1069:F,3-oxo-pipa,Br),(A1070:F,HO,Me),(A1071:F,HO—(CH₂)₂—O,Me),(A1072:F,HO—(CH₂)₃—O,Me),(A1073:F,4-HO-pipe,Me),(A1074:F,3-HO-pyrr,Me),(A1075:F,4-HO₂C-pipe,Me),(A1076:F,4-(cyano)-pipe,Me),(A1077:F,4-Ac-pipa,Me),(A1078:F,3-oxo-pipa,Me),(A1079:F,HO,HO),(A1080:F,HO—(CH₂)₂—O,HO),(A1081:F,HO—(CH₂)₃—O,HO),(A1082:F,4-HO-pipe,HO),(A1083:F,3-HO-pyrr,HO),(A1084:F,4-HO₂C-pipe,HO),(A1085:F,4-(cyano)-pipe,HO),(A1086:F,4-Ac-pipa,HO),(A1087:F,3-oxo-pipa,HO),(A1088:F,HO,MeO),(A1089:F,HO—(CH₂)₂—O,MeO),(A1090:F,HO—(CH₂)₃—O,MeO),(A1091:F,4-HO-pipe,MeO),(A1092:F,3-HO-pyrr,MeO),(A1093:F,4-HO₂C-pipe,MeO),(A1094:F,4-(cyano)-pipe,MeO),(A1095:F,4-Ac-pipa,MeO),(A1096:F,3-oxo-pipa,MeO),(A1097:Cl,HO,Cl),(A1098:Cl,HO—(CH₂)₂—O,Cl),(A1099:Cl,HO—(CH₂)₃—O,Cl),(A1100:Cl,4-HO-pipe,Cl),(A1101:Cl,3-HO-pyrr,Cl),(A1102:Cl,4-HO₂C-pipe,Cl),(A1103:Cl,4-(cyano)-pipe,Cl),(A1104:Cl,4-Ac-pipa,Cl),(A1105:Cl,3-oxo-pipa,Cl),(A1106:Cl,HO,Br),(A1107:Cl,HO—(CH₂)₂—O,Br),(A1108:Cl,HO—(CH₂)₃—O,Br),(A1109:Cl,4-HO-pipe,Br),(A1110:Cl,3-HO-pyrr,Br),(A1111:Cl,4-HO₂C-pipe,Br),(A1112:Cl,4-(cyano)-pipe,Br),(A1113:Cl,4-Ac-pipa,Br),(A1114:1,3-oxo-pipa,Br),(A1115:Cl,HO,Me),(A1116:Cl,HO—(CH₂)₂—O,Me),(A1117:Cl,HO—(CH₂)₃—O,Me),(A1118:Cl,4-HO-pipe,Me),(A1119:Cl,3-HO-pyrr,Me),(A1120:Cl,4-HO₂C-pipe,Me),(A1121:Cl,4-(cyano)-pipe,Me),(A1122:Cl,4-Ac-pipa,Me),(A1123:Cl,3-oxo-pipa,Me),(A1124:Cl,HO,HO),(A1125:Cl,HO—(CH₂)₂—O,HO),(A1126:Cl,HO—(CH₂)₃—O,HO),(A1127:Cl,4-HO-pipe,HO),(A1128:Cl,3-HO-pyrr,HO),(A1129:Cl,4-HO₂C-pipe,HO),(A1130:Cl,4-(cyano)-pipe,HO),(A1131:Cl,4-Ac-pipa,HO),(A1132:Cl,3-oxo-pipa,HO),(A1133:Cl,HO,MeO),(A1134:Cl,HO—(CH₂)₂—O,MeO),(A1135:Cl,HO—(CH₂)₃—O,MeO),(A1136:Cl,4-HO-pipe,MeO),(A1137:Cl,3-HO-pyrr,MeO),(A1138:Cl,4-HO₂C-pipe,MeO),(A1139:Cl,4-(cyano)-pipe,MeO),(A1140:Cl,4-Ac-pipa,MeO),(A1141:Cl,3-oxo-pipa,MeO),(A1142:Br,HO,H),(A1143:Br,HO—(CH₂)₂—O,H),(A1144:Br,HO—(CH₂)₃—O,H),(A1145:Br,4-HO-pipe,H),(A1146:Br,3-HO-pyrr,H),(A1147:Br,4-HO₂C-pipe,H),(A1148:Br,4-(cyano)-pipe,H),(A1149:Br,4-Ac-pipa,H),(A1150:Br,3-oxo-pipa,H),(A1151:Me,HO,H),(A1152:Me,HO—(CH₂)₂—O,H),(A1153:Me,HO—(CH₂)₃—O,H),(A1154:Me,4-HO-pipe,H),(A1155:Me,3-HO-pyrr,H),(A1156:Me,4-HO₂C-pipe,H),(A1157:Me,4-(cyano)-pipe,H),(A1158:Me,4-Ac-pipa,H),(A1159:Me,3-oxo-pipa,H),(A1160:HO,HO,H),(A1161:HO,HO—(CH₂)₂—O,H),(A1162:HO,HO—(CH₂)₃—O,H),(A1163:HO,4-HO-pipe,H),(A1164:HO,3-HO-pyrr,H),(A1165:HO,4-HO₂C-pipe,H),(A1166:HO,4-(cyano)-pipe,H),(A1167:HO,4-Ac-pipa,H),(A1168:HO,3-oxo-pipa,H),(A1169:MeO,HO,H),(A1170:MeO,HO—(CH₂)₂—O,H),(A1171:MeO,HO—(CH₂)₃—O,H),(A1172:MeO,4-HO-pipe,H),(A1173:MeO,3-HO-pyrr,H),(A1174:MeO,4-HO₂C-pipe,H),(A1175:MeO,4-(cyano)-pipe,H),(A1176:MeO,4-Ac-pipa,H),(A1177:MeO,3-oxo-pipa,H),(A1178:H,H,HO),(A1179:H,H,HO—(CH₂)₂—O),(A1180:H,H,HO—(CH₂)₃—O),(A1181:H,H,4-HO-pipe),(A1182:H,H,3-HO-pyrr),(A1183:H,H,4-HO₂C-pipe),(A1184:H,H,4-(cyano)-pipe),(A1185:H,H,4-Ac-pipa),(A1186:H,H,3-oxo-pipa),(A1187:F,H,HO),(A1188:F,H,HO—(CH₂)₂—O),(A1189:F,H,HO—(CH₂)₃—O),(A1190:F,H,4-HO-pipe),(A1191:F,H,3-HO-pyrr),(A1192:F,H,4-HO₂C-pipe),(A1193:F,H,4-(cyano)-pipe),(A1194:F,H,4-Ac-pipa),(A1195:F,H,3-oxo-pipa),(A1196:Cl,H,HO),(A1197:Cl,H,HO—(CH₂)₂—O),(A1198:Cl,H,HO—(CH₂)₃—O),(A1199:Cl,H,4-HO-pipe),(A1200:Cl,H,3-HO-pyrr),(A1201:Cl,H,4-HO₂C-pipe),(A1202:Cl,H,4-(cyano)-pipe),(A1203:Cl,H,4-Ac-pipa),(A1204:Cl,H,3-oxo-pipa),(A1205:Br,H,HO),(A1206:Br,H,HO—(CH₂)₂—O),(A1207:Br,H,HO—(CH₂)₃—O),(A1208:Br,H,4-HO-pipe),(A1209:Br,H,3-HO-pyrr),(A1210:Br,H,4-HO₂C-pipe),(A1211:Br,H,4-(cyano)-pipe),(A1212:Br,H,4-Ac-pipa),(A1213:Br,H,3-oxo-pipa),(A1214:Me,H,HO),(A1215:Me,H,HO—(CH₂)₂—O),(A1216:Me,H,HO—(CH₂)₃—O),(A1217:Me,H,4-HO-pipe),(A1218:Me,H,3-HO-pyrr),(A1219:Me,H,4-HO₂C-pipe),(A1220:Me,H,4-(cyano)-pipe),(A1221:Me,H,4-Ac-pipa),(A1222:Me,H,3-oxo-pipa),(A1223:HO,H,HO),(A1224:HO,H,HO—(CH₂)₂—O),(A1225:HO,H,HO—(CH₂)₃—O),(A1226:HO,H,4-HO-pipe),(A1227:HO,H,3-HO-pyrr),(A1228:HO,H,4-HO₂C-pipe),(A1229:HO,H,4-(cyano)-pipe),(A1230:HO,H,4-Ac-pipa),(A1231:HO,H,3-oxo-pipa),(A1232:MeO,H,HO),(A1233:MeO,H,HO—(CH₂)₂—O),(A1234:MeO,H,HO—(CH₂)₃—O),(A1235:MeO,H,4-HO-pipe),(A1236:MeO,H,3-HO-pyrr),(A1237:MeO,H,4-HO₂C-pipe),(A1238:MeO,H,4-(cyano)-pipe),(A1239:MeO,H,4-Ac-pipa),(A1240:MeO,H,3-oxo-pipa).

TABLE 28

(No:R^(Q),R^(R)) =(A1241:H,HO),(A1242:H,HO—(CH₂)₂—O),(A1243:H,HO—(CH₂)₃—O),(A1244:H,4-HO-pipe),(A1245:H,3-HO-pyrr),(A1246:H,4-HO₂C-pipe),(A1247:H,4-(cyano)-pipe),(A1248:H,4-Ac-pipa),(A1249:H,3-oxo-pipa),(A1250:F,HO),(A1251:F,HO—(CH₂)₂—O),(A1252:F,HO—(CH₂)₃—O),(A1253:F,4-HO-pipe),(A1254:F,3-HO-pyrr),(A1255:F,4-HO₂C-pipe),(A1256:F,4-(cyano)-pipe),(A1257:F,4-Ac-pipa),(A1258:F,3-oxo-pipa),(A1259:Br,HO),(A1260:Br,HO—(CH₂)₂—O),(A1261:Br,HO—(CH₂)₃—O),(A1262:Br,4-HO-pipe),(A1263:Br,3-HO-pyrr),(A1264:Br,4-HO₂O-pipe),(A1265:Br,4-(cyano)-pipe),(A1266:Br,4-Ac-pipa),(A1267:Br,3-oxo-pipa),(A1268:Me,HO),(A1269:Me,HO—(CH₂)₂—O),(A1270:Me,HO—(CH₂)₃—O),(A1271:Me,4-HO-pipe),(A1272:Me,3-HO-pyrr),(A1273:Me,4-HO₂C-pipe),(A1274:Me,4-(cyano)-pipe),(A1275:Me,4-Ac-pipa),(A1276:Me,3-oxo-pipa),(A1277:HO,HO),(A1278:HO,HO—(CH₂)₂—O),(A1279:HO,HO—(CH₂)₃—O),(A1280:HO,4-HO-pipe),(A1281:HO,3-HO-pyrr),(A1282:HO,4-HO₂C-pipe),(A1283:HO,4-(cyano)-pipe),(A1284:HO,4-Ac-pipa),(A1285:HO,3-oxo-pipa),(A1286:MeO,HO),(A1287:MeO,HO—(CH₂)₂—O),(A1288:MeO,HO—(CH₂)₃—O),(A1289:MeO,4-HO-pipe),(A1290:MeO,3-HO-pyrr),(A1291:MeO,4-HO₂C-pipe),(A1292:MeO,4-(cyano)-pipe),(A1293:MeO,4-Ac-pipa),(A1294:MeO,3-oxo-pipa),(A1295:HO,H),(A1296:HO—(CH₂)₂—O,H),(A1297:HO—(CH₂)₃—O,H),(A1298:4-HO-pipe,H),(A1299:3-HO-pyrr,H),(A1300:4-HO₂C-pipe,H),(A1301:4-(cyano)-pipe,H),(A1302:4-Ac-pipa,H),(A1303:3-oxo-pipa,H).

TABLE 29

(No:R^(S),R^(T)) =(A1304:H,H),(A1305:H,HO—(CH₂)₂—O),(A1306:H,HO—(CH₂)₃—O),(A1307:H,4-HO-pipe),(A1308:H,3-HO-pyrr),(A1309:H,4-HO₂C-pipe),(A1310:H,4-(cyano)-pipe),(A1311:H,4-Ac-pipa),(A1312:H,3-oxo-pipa),(A1313:Cl,HO—(CH₂)₂—O),(A1314:Cl,HO—(CH₂)₃—O),(A1315:Cl,4-HO-pipe),(A1316:Cl,3-HO-pyrr),(A1317:Cl,4-HO₂C-pipe),(A1318:Cl,4-(cyano)-pipe),(A1319:Cl,4-Ac-pipa),(A1320:Cl,3-oxo-pipa),(A1321:Me,HO—(CH₂)₂—O),(A1322:Me,HO—(CH₂)₃—O),(A1323:Me,4-HO-pipe),(A1324:Me,3-HO-pyrr),(A1325:Me,4-HO₂C-pipe),(A1326:Me,4-(cyano)-pipe),(A1327:Me,4-Ac-pipa),(A1328:Me,3-oxo-pipa),(A1329:MeO,HO—(CH₂)₂—O),(A1330:MeO,HO—(CH₂)₃—O),(A1331:MeO,4-HO-pipe),(A1332:MeO,3-HO-pyrr),(A1333:MeO,4-HO₂C-pipe),(A1334:MeO,4-(cyano)-pipe),(A1335:MeO,4-Ac-pipa),(A1336:MeO,3-oxo-pipa).

TABLE 30

(No:R^(AA),R^(BB)) =(A1337:H,HO),(A1338:H,HO—(CH₂)₂—O),(A1339:H,HO—(CH₂)₃—O),(A1340:H,4-HO-pipe),(A1341:H,3-HO-pyrr),(A1342:H,4-HO₂C-pipe),(A1343:H,4-(cyano)-pipe),(A1344:H,4-Ac-pipa),(A1345:H,3-oxo-pipa),(A1346:F,HO),(A1347:F,HO—(CH₂)₂—O),(A1348:F,HO—(CH₂)₃—O),(A1349:F,4-HO-pipe),(A1350:F,3-HO-pyrr),(A1351:F,4-HO₂C-pipe),(A1352:F,4-(cyano)-pipe),(A1353:F,4-Ac-pipa),(A1354:F,3-oxo-pipa),(A1355:Cl,HO),(A1356:Cl,HO—(CH₂)₂—O),(A1357:Cl,HO—(CH₂)₃—O),(A1358:Cl,4-HO-pipe),(A1359:Cl,3-HO-pyrr),(A1360:Cl,4-HO₂C-pipe),(A1361:Cl,4-(cyano)-pipe),(A1362:Cl,4-Ac-pipa),(A1363:Cl,3-oxo-pipa),(A1364:Br,HO),(A1365:Br,HO—(CH₂)₂—O),(A1366:Br,HO—(CH₂)₃—O),(A1367:Br,4-HO-pipe),(A1368:Br,3-HO-pyrr),(A1369:Br,4-HO₂C-pipe),(A1370:Br,4-(cyano)-pipe),(A1371:Br,4-Ac-pipa),(A1372:Br,3-oxo-pipa),(A1373:Me,HO),(A1374:Me,HO—(CH₂)₂—O),(A1375:Me,HO—(CH₂)₃—O),(A1376:Me,4-HO-pipe),(A1377:Me,3-HO-pyrr),(A1378:Me,4-HO₂C-pipe),(A1379:Me,4-(cyano)-pipe),(A1380:Me,4-Ac-pipa),(A1381:Me,3-oxo-pipa),(A1382:HO,HO),(A1383:HO,HO—(CH₂)₂—O),(A1384:HO,HO—(CH₂)₃—O),(A1385:HO,4-HO-pipe),(A1386:HO,3-HO-pyrr),(A1387:HO,4-HO₂C-pipe),(A1388:HO,4-(cyano)-pipe),(A1389:HO,4-Ac-pipa),(A1390:HO,3-oxo-pipa),(A1391:MeO,HO),(A1392:MeO,HO—(CH₂)₂—O),(A1393:MeO,HO—(CH₂)₃—O),(A1394:MeO,4-HO-pipe),(A1395:MeO,3-HO-pyrr),(A1396:MeO,4-HO₂C-pipe),(A1397:MeO,4-(cyano)-pipe),(A1398:MeO,4-Ac-pipa),(A1399:MeO,3-oxo-pipa).

TABLE 31

(No:R^(CC),R^(DD)) = (A1400:H₂N,HO),(A1401:H₂N,HO—(CH₂)₂—O),(A1402:H₂N,HO—(CH₂)₃—O),(A1403:H₂N,4-HO-pipe),(A1404:H₂N,3-HO-pyrr),(A1405:H₂N,4-HO₂C-pipe),(A1406:H₂N,4-(cyano)-pipe),(A1407:H₂N,4-Ac-pipa),(A1408:H₂N,3-oxo-pipa),(A1409:MeHN,HO),(A1410:MeHN,HO—(CH₂)₂—O),(A1411:MeHN,HO—(CH₂)₃—O),(A1412:MeHN,4-HO-pipe),(A1413:MeHN,3-HO-pyrr),(A1414:MeHN,4-HO₂C-pipe),(A1415:MeHN,4-(cyano)-pipe),(A1416:MeHN,4-Ac-pipa),(A1417:MeHN,3-oxo-pipa),(A1418:HO,HO),(A1419:HO,HO—(CH₂)₂—O),(A1420:HO,HO—(CH₂)₃—O),(A1421:HO,4-HO-pipe),(A1422:HO,3-HO-pyrr),(A1423:HO,4-HO₂C-pipe),(A1424:HO,4-(cyano)-pipe),(A1425:HO,4-Ac-pipa),(A1426:HO,3-oxo-pipa),(A1427:MeO,HO),(A1428:MeO,HO—(CH₂)₂—O),(A1429:MeO,HO—(CH₂)₃—O),(A1430:MeO,4-HO-pipe),(A1431:MeO,3-HO-pyrr),(A1432:MeO,4-HO₂C-pipe),(A1433:MeO,4-(cyano)-pipe),(A1434:MeO,4-Ac-pipa),(A1435:MeO,3-oxo-pipa),(A1436:Cl,HO),(A1437:Cl,HO—(CH₂)₂—O),(A1438:Cl,HO—(CH₂)₃—O),(A1439:Cl,4-HO-pipe),(A1440:Cl,3-HO-pyrr),(A1441:Cl,4-HO₂O-pipe),(A1442:Cl,4-(cyano)-pipe),(A1443:Cl,4-Ac-pipa),(A1444:Cl,3-oxo-pipa).

TABLE 32

(No:R^(EE),R^(FF)) = (A1445:H,HO—(CH₂)₂),(A1446:H,HO—(CH₂)₃),(A1447:F,HO—(CH₂)₂),(A1448:F,HO—(CH₂)₃),(A1449:Cl,HO—(CH₂)₂),(A1450:Cl,HO—(CH₂)₃),(A1451:Me,HO—(CH₂)₂),(A1452:Me,HO—(CH₂)₃),(A1453:HO,HO—(CH₂)₂),(A1454:HO,HO—(CH₂)₃),(A1455:MeO,HO—(CH₂)₂),(A1456:MeO,HO—(CH₂)₃).

TABLE 33

(No:R^(GG))= (A1457:5-F-2-The),(A1458:5-Cl-2-The),(A1459:5-Br-2-The),(A1460:5-Me-2-The),(A1461:5-F₃C-2-The),(A1462:4-F-2-The),(A1463:4-Cl-2-The),(A1464:4-Br-2-The),(A1465:4-Me-2-The),(A1466:4-F₃C-2-The),(A1467:4-F-5-Cl-2-The),(A1468:4,5-diCl-2-The),(A1469:4-Br-5-Cl-2-The),(A1470:4-Me-5-Cl-2-The),(A1471:4-F₃C-5-Cl-2-The),(A1472:4-F-Ph),(A1473:4-Cl-Ph),(A1474:4-Br-Ph),(A1475:4-Me-Ph),(A1476:4-F₃C-Ph),(A1477:3-F-Ph),(A1478:3-Cl-Ph),(A1479:3-Br-Ph),(A1480:3-Me-Ph),(A1481:3-F₃C-Ph),(A1482:2-F-Ph),(A1483:2-Cl-Ph),(A1484:2-Br-Ph),(A1485:2-Me-Ph),(A1486:2-F₃C-Ph),(A1487:3,4-diF-Ph),(A1488:3-Cl-4-F-Ph),(A1489:3-Br-4-F-Ph),(A1490:3-Me-4-F-Ph),(A1491:3-F₃C-4-F-Ph),(A1492:5-Me-2-Py),(A1493:6-Me-3-Py),(A1494:4-Py),(A1495:2-pyrimidinyl),(A1496:2-Me-4-pyrimidinyl),(A1497:2-Me-5-pyrimidinyl),(A1498:4-pyridazinyl),(A1499:6-Me-3-pyridazinyl),(A1500:5-Me-2-pyrazinyl),(A1501:4-Me-2-Fur),(A1502:1-Me-3-pyrrolyl),(A1503:4-Me-2-thiazolyl),(A1504:4-Cl-2-thiazolyl),(A1505:4-F₃C-2-thiazolyl),(A1506:5-Me-2-thiazolyl),(A1507:2-Me-5-thiazolyl),(A1508:5-Me-2-oxazolyl),(A1509:2-Me-5-oxazolyl),(A1510:4-Me-2-imidazolyl),(A1511:2-Me-4-imidazolyt),(A1512:1-Me-4-imidazolyl),(A1513:5-Me-3-isothiazolyl),(A1514:3-Me-5-isothiazolyl),(A1515:5-Me-3-isoxazolyl),(A1516:3-Me-5-isoxazolyl),(A1517:5-Me-3-pyrazolyl),(A1518:1-Me-4-pyrazolyl),(A1519:1-Me-3-pyrazolyl),(A1520:5-Me-1,3,4-thiadiazol-2-yl),(A1521:5-Me-1,3,4-oxadiazol-2-yl),(A1522:5-Me-1,2,4-triazol-3-yl),(A1523:1-Me-1,2,4-triazol-3-yl),(A1524:5-Me-1,2,4-thiadiazol-3-yl),(A1525:3-Me-1,2,4-thiadiazol-5-yl),(A1526:5-Me-1,2,4-oxadiazol-3-yl),(A1527:3-Me-1,2,4-oxadiazol-5-yl),(A1528:1-Me-1,2,3-triazol-4-yl).

1. A pharmaceutical composition for increasing the number of plateletscomprising a 2-acylaminothiazole derivative represented by the followinggeneral Formula (I) or a pharmaceutically acceptable salt thereof as anactive ingredient:

wherein symbols have the following meanings, Ar¹: optionally substitutedaryl, monocyclic aromatic heterocycle, or bicyclic condensed heterocycle(with the proviso that when R¹ is aryl or pyridyl, each of which may besubstituted with one or more groups selected from the group consistingof lower alkyl, —CO-lower alkyl, —COO-lower alkyl, —OH, —O-lower alkyl,—OCO-lower alkyl, and halogen, and R² is a group represented by thefollowing general Formula (II); Ar¹ is not phenyl or pyridyl, each ofwhich may be substituted with one or more groups selected from the groupconsisting of lower alkyl, —CO-lower alkyl, —COO-lower alkyl, —OH,—O-lower alkyl, —OCO-lower alkyl, and halogen), R¹: aryl or monocyclicaromatic heterocycle, each of which may be substituted, R²: a grouprepresented by the following general Formula (II), (III) or (IV):

wherein symbols have the following meanings, n: an integer of 1 to 3, m:an integer of 1 to 3, (when n or m is an integer of 2 or more, CR²⁰R²¹and CR²²R²³ may be identical or different.) X: O, S, or a grouprepresented by N—R²⁶ or C(—R²⁷)—R²⁸, E, G, J, L: independently N or agroup represented by C—R²⁹, with the proviso that at least one of themis C—R²⁹, R²⁰, R²¹, R²², R²³, R²⁶, R²⁷, R²⁸, R²⁹: which may be identicalor different, —H; —OH; —O-lower alkyl; optionally substituted loweralkyl; optionally substituted cycloalkyl; optionally substituted aryl;optionally substituted arylalkyl; optionally substituted aromaticheterocycle; optionally substituted aromatic heterocyclic alkyl;optionally substituted nonaromatic heterocycle; optionally substitutedlower alkenyl; optionally substituted lower alkylidene; —COOH;—COO-lower alkyl; —COO-lower alkenyl; —COO-lower alkylene-aryl;—COO-lower alkylene-aromatic heterocycle; carbamoyl or amino, each ofwhich may be substituted with one or more groups selected from the groupconsisting of lower alkyl and cycloalkyl, each of which may besubstituted with halogen, —OH, —O-lower alkyl, or —O-aryl; —NHCO-loweralkyl; or oxo. R²⁴, R²⁵: which may be identical or different, —H,optionally substituted lower alkyl, optionally substituted cycloalkyl,or optionally substituted nonaromatic heterocycle.
 2. The pharmaceuticalcomposition according to claim 1, wherein R¹ is phenyl or thienyl, eachof which may be substituted with 1 to 3 halogen atoms (when substitutedwith 2 or 3 halogen atoms, the halogen atoms may be identical ordifferent); R² is a group represented by the general Formula (II)(wherein n is 2, m is 2, X is a group represented by N—R²⁶ orC(—R²⁷)—R²⁸); and Ar¹ is phenyl or pyridyl, each of which may besubstituted.
 3. The pharmaceutical composition according to claim 1 or2, wherein the pharmaceutical composition is used as a therapeutic agentfor thrombocytopenia.
 4. The pharmaceutical composition according toclaim 1 or 2, wherein the pharmaceutical composition is a c-Mpl ligand.5. A 2-acylaminothiazole derivative represented by the following generalFormula (V) or a pharmaceutically acceptable salt thereof

wherein symbols have the following meanings: Ar²: a group represented byAr¹ as described in claim 1, with the proviso that indol-2-yl isexcluded, R³: a group represented by R¹ as described in claim 1, R⁴: agroup represented by R² as described in claim 1, with the proviso that agroup represented by the general Formula (IV) is excluded.
 6. Thecompound according to claim 5, wherein Ar² is phenyl or monocyclicaromatic heterocycle, each of which may be substituted.
 7. The compoundaccording to claim 6, wherein R³ is phenyl or thienyl, each of which maybe substituted; R⁴ is a group represented by the general Formula (II);Ar² is phenyl or pyridyl, each of which may be substituted.
 8. Thecompound according to claim 7, wherein n is 2, m is 2, and X is a grouprepresented by N—R²⁶ or C(—R²⁷)—R²⁸.
 9. The compound according to claim8, wherein R³ is phenyl or thienyl, each of which may be substitutedwith 1 to 3 halogen atoms (when substituted with 2 or 3 halogen atoms,the halogen atoms may be identical or different.).
 10. The compoundaccording to claim 9, wherein R⁴ is 4-(piperidin-1-yl)piperidin-1-yl,4-propylpiperidin-1-yl, 4-cyclohexylpiperazin-1-yl, or4-propylpiperazin-1-yl.
 11. The compound according to claim 10, whereinAr² is phenyl which is unsubstituted at 2- and 6-positions, substitutedwith —H, -F, —Cl, or —Br at 3-position, substituted with -F, —Cl, or —Brat 5-position, and substituted at 4-position; or pyridin-3-yl which isunsubstituted at 2- and 4-positions, substituted with -F, —Cl, or —Br at5-position, and substituted at 6-position.
 12. The compound according toclaim 11, wherein Ar² is phenyl which is substituted at 4-position witha group selected from the group consisting of —O—R^(Y), —NH—R^(Y),optionally substituted piperidin-1-yl and optionally substitutedpiperazin-1-yl; or pyridin-3-yl which is substituted at 6-position witha group selected from the group consisting of —O—R^(Y), —NH—R^(Y),optionally substituted piperidin-1-yl and optionally substitutedpiperazin-1-yl (wherein R^(Y) is lower alkyl which may be substitutedwith one or more groups selected from the group consisting of —OH,—O-lower alkyl, amino which may be substituted with one or two loweralkyl, —CO₂H, —CO-lower alkyl, carbamoyl which may be substituted withone or two lower alkyl, cyano, aryl, aromatic heterocycle, nonaromaticheterocycle and halogen.).
 13. The compound according to any one ofclaims 5 to 12, wherein the compound is selected from the groupconsisting ofN-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide,3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperidino)thiazol-2-yl]-2-methoxyisonicotinamide,N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]isoquinoline-6-carboxamide,3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-hydroxypropoxy)nicotinamide,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(3-hydroxypropyl)amino)]nicotinamide,1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylicacid,1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylicacid,N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-3,5,-difluorobenzamide,1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxylicacid,1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperidin-4-carboxylicacid,1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidin-4-carboxamide,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxymethylpiperidino)nicotinamide,1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylicacid,1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(3-trifluoromethylphenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylicacid,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(2-methoxyethyl)carbamoyl]piperidino}nicotinamide,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-{4-[(3-methoxypropyl)carbamoyl]piperidino}nicotinamide,5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[4-(morpholinocarbonyl)piperidino]nicotinamide,and a pharmaceutically acceptable salt thereof
 14. A pharmaceuticalcomposition comprising the compound of any one of claims 5 to 13 as anactive ingredient.
 15. The pharmaceutical composition according to claim14, wherein the pharmaceutical composition is used as an agent forincreasing the number of platelets.
 16. The pharmaceutical compositionaccording to claim 14, wherein the pharmaceutical composition is use asa therapeutic agent for thrombocytopenia.
 17. The pharmaceuticalcomposition according to claim 14, wherein the pharmaceuticalcomposition is a c-Mpl ligand.